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Abstract
Multiple research studies have demonstrated racial, socioeconomic status (SES), and
neighborhood disparities in first-line treatment of colorectal cancer patients, including
those with metastatic colorectal cancer. However, disparities in adjunct monoclonal
antibody treatment disparities have not been explored. The purpose of this study was to
assess racial, SES, and neighborhood disparities in adjunct monoclonal antibody
treatment of elderly metastatic colorectal cancer patients. The research was rooted in 3
theories: the fundamental cause theory, the diffusion of innovations theory, and theory of
health disparities and medical technology. Data from the SEER-Medicare database and
logistic regression were used to assess the relationship between the variables of interest
and adjunct monoclonal antibody therapy. In this study, race (p = 0.070), SES (p =
0.881), and neighborhood characteristics (p = 0.309) did not significantly predict who
would receive monoclonal antibody therapy. The results demonstrated a potential
improvement in historically documented colorectal cancer treatment disparities.
Specifically, historical treatment disparities may not be relevant to newer therapies
prescribed to patients with severe disease. The difference could be related to improved
access to care or a change in treatment paradigm due to the severity of metastatic
colorectal cancer. Future studies aimed at understanding the causes of this social change
(i.e., reduced treatment disparities) are warranted. Understanding the root cause of the
reduced treatment disparities observed in this study could be used to reduce treatment
disparities in other cancer populations.
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Chapter 1: Introduction to the Study
Introduction
In the United States, colorectal cancer survival rates, including survival rates of
individuals with metastatic colorectal cancer, have been associated with race,
socioeconomic status (SES), and neighborhood characteristics (degree of urbanization;
Hines, Markossian, Johnson, Dong, & Bayakly, 2014; Lian et al., 2011; Simpson, Pagán,
& Chen, 2013). Specifically, Black Americans, individuals of low SES, and individuals
residing in rural neighborhoods have been shown to have increased colorectal cancer
mortality rates (Centers for Disease Control and Prevention [CDC], 2012; Hines et al.,
2014; Lian et al., 2011; Simpson et al., 2013). Differences in colorectal cancer treatment
regimen (surgery, radiation, or chemotherapy) have been shown to contribute to these
survival disparities (Hao et al., 2011; Le, Ziogas, Lipkin, & Zell, 2008; Rane et al., 2014).
In 2004, the first monoclonal antibody therapy for colorectal cancer was approved for
treatment of metastatic colorectal cancer when given in adjunct with chemotherapy
(Scott, Wolchok, & Old, 2012). A review of Phase II-III clinical trials indicated that
monoclonal antibody therapy increases survival in metastatic colorectal cancer patient
populations when added to chemotherapy (Tol & Punt, 2010). It is possible that
disparities in monoclonal antibody treatment could contribute to disparities in the
survival of patients with metastatic colorectal cancer. However, due to the lack of
research, it is unknown if there are racial, SES, or neighborhood disparities in
monoclonal antibody treatment of metastatic colorectal cancer patients.
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This chapter provides an introduction to the research project including a
summarization of items that will be described in detail in Chapters 2 and 3. Specifically,
I open this chapter with a background section summarizing the literature surrounding the
topic, present the research gap, and describe the importance of the study. Following this
brief background, the problem statement and study purpose are presented. Afterward an
overview of the research methodology and the theoretical basis will be provided. Finally,
the scope and limitations of the research project are described.
Background
In this section, I provide a brief summary of literature related to the topic and the
research gap, and I describe the importance of the study. Additional details related to the
literature search and findings are provided in Chapter 2.
Literature Related to the Study Topic
Colorectal cancer survival disparities based on race, SES, and neighborhood
characteristics have been observed in many different studies. Specifically, Black
Americans with colorectal cancer, including metastatic colorectal cancer, have reduced
survival rates compared to White Americans (Simpson et al., 2013; Sineshaw, Robbins,
& Jemal, 2014; Wallace et al., 2013; Wassira, Pinheiro, Symanowski, & Hansen, 2013),
low SES populations have reduced colorectal cancer survival rates compared to higher
SES populations (Hines et al., 2014; Oliphant et al., 2013b; Wassira et al., 2013), and
rural populations have reduced colorectal cancer survival rates compared to urban
populations (Henry, Niu, & Boscoe, 2009; Lian et al., 2011).
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In addition, multiple researchers have associated treatment regimen differences
with these survival disparities, highlighting disparities in both type and aggressiveness of
colorectal cancer therapies (Bakogeorgos et al., 2013; Obeidat et al., 2010; Serra-Rexach
et al., 2012). Le et al. (2008) found significant differences in first-line treatment
(surgery, radiation, and chemotherapy) comparing Black Americans to White Americans.
These racial disparity results were supported in subsequent studies by White et al. (2008),
Hao et al. (2011), and Hines et al. (2012). In addition, Le et al. found significant
differences in first-line treatment (surgery, radiation, and chemotherapy) comparing
higher SES to lower SES areas. Another potential contributor to colorectal cancer
treatment disparities are the characteristics of the neighborhood patients reside within.
Hao et al. (2011) documented urban versus rural disparities in first-line chemotherapy
treatment in colorectal cancer. Specifically, populations with urban or suburban zip
codes were, respectively, 38% and 52% more likely to receive chemotherapy compared
to populations with rural zip codes (Hao et al., 2011).
Research Gap
At highlighted above, multiple studies have provided valuable information on
colorectal cancer treatment disparities. However, they were conducted using patient data
from the 1990s and early 2000, prior to the approval of monoclonal antibodies (Scott et
al., 2012). Currently, there are three monoclonal antibodies (bevacizumab, cetuximab,
and panitumumab) approved for the treatment of metastatic colorectal cancer (Scott et al.,
2012). Of particular importance to this research study, the literature searches performed
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did not uncover any studies addressing racial, SES, or neighborhood (degree of
urbanization) disparities in adjunct monoclonal antibody treatment of colorectal cancer
patients. Adjunct monoclonal antibody therapy has been shown to reduce metastatic
colorectal cancer mortality in multiple populations, including the elderly (Bruera et al.,
2013, Cunningham et al., 2013; Naeim et al., 2013). Therefore, it is possible that
disparities in monoclonal antibody treatment are contributing to disparities in metastatic
colorectal cancer survival. However, given the lack of research, understanding disparities
in monoclonal antibody treatment of metastatic colorectal cancer patients is a clear
research gap.
Study Importance
Determining if racial, SES, or neighborhood disparities in monoclonal antibody
treatment of elderly metastatic colorectal cancer patients exist is a critical first step to
eliminating these social inequalities. This study may provide the basis for positive social
change in one of two ways. First, if treatment disparities are found, this would illuminate
the need for policies that improve access to monoclonal antibodies, thereby helping
reduce social inequalities in colorectal cancer survival. Alternatively, if treatment
disparities are not found, an opportunity exists to understand the root cause of the
reduced treatment disparities, and this knowledge could potentially be used to reduce
treatment disparities in other cancer populations.
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Problem Statement
Multiple research studies have demonstrated racial, SES, and neighborhood
(degree of urbanization) disparities in treatment of colorectal cancer patients with
surgery, radiation, or chemotherapy (Aarts, Lemmens, Louwman, Kunst, & Coebergh,
2010; Hao et al., 2011; Le et al., 2008). These treatment disparities have been associated
with colorectal cancer survival (Le et al., 2008). However, due to the lack of research, it
was unknown if there are racial, SES, or neighborhood disparities in monoclonal
antibody treatment of elderly metastatic colorectal cancer patients.
Purpose of the Study
Disparities in chemotherapy, radiation, and/or surgery have been associated with
disparities in colorectal cancer survival. However, information regarding disparities in
adjunct monoclonal antibody treatment was not found in the literature. Therefore, my
aim was to determine whether these historical colorectal cancer treatment disparities have
persisted into newer monoclonal antibody therapies and the metastatic colorectal cancer
population. The expressed purpose of this study was to determine if there are racial, SES,
or neighborhood (degree of urbanization) disparities in first-line adjunct monoclonal
antibody treatment of elderly metastatic colorectal cancer patients.
Study Methodology and Intent
In this quantitative research study, I used a retrospective cohort study design and
data from the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End
Results (SEER)-Medicare linked database, years 2007 to 2012.
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Study Variables
The independent, dependent, and control variables used in this research project
are described briefly below. Detailed information on each variable, including operational
definitions, the location of the data and data codes, can be found in Chapter 3.
Independent variables. The first research question addresses racial/ethnic
disparities in first-line monoclonal antibody treatment. Therefore, race was the first
independent variable. The second research question addresses SES disparities in firstline monoclonal antibody treatment. The census tract poverty indicator, located in the
NCI’s Patient Entitlement and Diagnosis Summary File (PEDSF), was used as a
surrogate for SES. The final research question addresses neighborhood characteristic
(degree of urbanization) differences in first-line monoclonal antibody treatment. The
2003 Rural/Urban Continuum Codes from the Economic Research Service (ERS), which
categories counties on an urban/rural scale based on population size, degree of
urbanization, and adjacency to a metro or nonmetro area, was used for this purpose (NCI,
2015c).
Dependent variable. The dependent variable for these research questions is
receipt of first-line adjunct (in combination with chemotherapy) monoclonal antibody
therapy, “yes” or “no.”
Covariates. Four covariates were added to the logistic regression analysis to
control for confounding. The first covariate used was gender (male or female). The
second covariate used was age at diagnosis. The third covariate was reason for original
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Medicare entitlement (age or disability). Individuals who qualified for Medicare due to
End Stage Renal Disease were excluded from the study. The fourth covariate was the
registry that reported the data.
Research Questions and Hypotheses
The three research questions (RQ1-RQ3) addressed by this research project are
listed below. In addition, the null and alternative hypotheses have been stated (H01-H03
and Ha1-Ha3 respectively).
RQ1: Within the population of elderly (65 years+) individuals diagnosed with
metastatic colorectal cancer from January 2007 to December 2011, are there racial
disparities in first line adjunct monoclonal antibody treatment?
H01: There is no significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody treatment based on race.
Ha1: There is a significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody treatment based on race.
RQ2: Within the population of elderly (65 years+) individuals diagnosed with
metastatic colorectal cancer from January 2007 to December 2011, are there
socioeconomic disparities in first line adjunct monoclonal antibody treatment?
H02: There is no significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
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monoclonal antibody therapy based on area socioeconomic status (as defined by
the PEDSF census tract poverty indicator).
Ha2: There is a significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on area socioeconomic status (as defined by
the PEDSF census tract poverty indictor).
RQ3: Within the population of elderly (65 years+) individuals diagnosed with
metastatic colorectal cancer from January 2007 to December 2011, are there
neighborhood characteristic (degree of urbanization) disparities in first line adjunct
monoclonal antibody treatment?
H03: There is no significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on neighborhood characteristics.
Ha3: There is a significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on neighborhood characteristics.
Theoretical Framework for the Study
The theoretical framework used for this project was a combination of theories
similar to the theoretical framework proposed by Chang and Lauderdale (2009). The
overarching theory was the fundamental cause theory. However, two additional theories
(the diffusion of innovations theory and the theory of health disparities and medical
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technology) were used to extend the fundamental cause theory for the purpose of this
project. These theories and their relevance to the research topic are described briefly in
the following sections.
Theoretical Propositions
The fundamental cause theory was first proposed by Link and Phelan in 1995.
The theory argues that social states, such as race and SES, contribute to disease
rates/outcomes. Since resources are constantly changing, the authors proposed that it is
the beneficial social connections that serve to protect health regardless of the resource
mechanism (Phelan et al., 2010). In support of the fundamental cause theory, two other
theories were used. First, the diffusion of innovations theory was first proposed by
Rogers (1962) but has subsequently been updated with the most recent version of the
theory published by Rogers in 2010. The theory presents factors that influence whether
or not an individual or population will adopt a new innovation (Rogers, 2010). Second,
the theory of health disparities and medical technology was developed by Goldman and
Lakdawalla in 2005. The theory surrounds the assumption that richer patients
disproportionately use newer therapies.
Theoretical Framework Supports the Study Approach
In line with the fundamental cause theory, individuals of low SES, minority races,
or individuals living in rural areas could have systematically less of a given resource due
to their social connections. Therefore, it is possible that disparities in monoclonal
antibody therapy exist due, in part, to disparities in resource acquisition. Additionally,
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according to the diffusion of innovation theory (Rogers, 2010), some populations (high
SES, urban neighborhoods) might be more likely to obtain newer treatments (such as
monoclonal antibody therapy). Finally, the theory of health disparities and medical
technology supports hypothesizes around higher levels of monoclonal antibody use by
high SES or nonminority populations.
In summary, these three theories work in concert to provide support for the
research questions. The fundamental cause theory attempts to explain disparities based
on resource acquisition, whereas the diffusion of innovation theory takes a temporal
approach to explain uptake of new technologies or treatments and the theory of health
disparities and medical technology proposes that the complexity and quantity of
treatment influences who will receive treatment. All three of these theories provide
rationale for research into disparities in monoclonal antibody treatment of metastatic
colorectal cancer patients, as it is likely that demographics and social status will
contribute to disparities in the use of newer, more complex treatments.
Nature of the Study
The specific aim of this quantitative study was to determine if there are racial,
SES, or neighborhood characteristic (degree of urbanization) disparities in first-line
adjunct monoclonal antibody treatment of elderly metastatic colorectal cancer patients.
In this section, I briefly describe the design selected to address this question including the
key study variables and an overview of the methodology.
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Design Rationale
Quantitative research was the most appropriate research design to answer the
research questions. The most complete dataset available to answer these questions was
archival data from the NCI’s SEER-Medicare database. Therefore, since archival data
were used, this quantitative study is strictly observational and no interventions were be
performed.
Data for all the variables were obtained from five data sources within the SEERMedicare database: the PEDSF file (Patient Entitlement and Diagnosis Summary File)
and four Medicare claims files, the DME file (Durable Medical Equipment File), the
Medicare Part D Event (PDE) file, the Medicare Outpatient Claims file, and the Medicare
Carrier Claims file. The PEDSF dataset was available through 2011, while all the claims
datasets were available through 2012 with the first full year of PDE data in 2007.
Therefore, this project was limited to individuals diagnosed with metastatic colorectal
cancer from January 2007 to December 2011. This allowed for assessment of
chemotherapy and monoclonal antibody treatment into the 2012 claims datasets for
individuals diagnosed in the second half of 2011.
Methodology
Population. The specific population used for this study was elderly (65+)
Medicare enrolled individuals diagnosed with metastatic colorectal cancer between
January 2007 and December 2011 and treated with first-line chemotherapy within 6
months of diagnosis as in Meyerhardt, Sanoff, Carpenter, and Schrag (2012). This
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population was carefully selected for appropriateness in regards to the research question
and to control for confounding.
Sampling. This population was sampled using the NCI’s SEER-Medicare
database. The SEER-Medicare database is a unique research-oriented database resulting
from the linkage of the SEER cancer registries database and the Medicare enrollment and
claims data files (NCI, 2013a; Warren, Klabunde, Schrag, Bach, & Riley, 2002).
Patient data for the study variables (independent, dependent, covariate/control,
and selection variables) from 2007 to 2012 were compiled for all individuals meeting the
inclusion and exclusion criteria using MySQL, Python and SPSS.
Analysis. Logistic regression in SPSS was used to model the dichotomous
dependent variable based on the independent variables as in Burns and Burns (2008).
Specifically, the output of logistic regression predicted which dependent variable group
(monoclonal antibody, “yes” or “no”) a sample should reside in based on the independent
variables (race, SES, neighborhood characteristics; Burns & Burns, 2008). Additional
models were planned to control for potential confounding variables.
Definitions
Study Variables
Concise definitions of the independent variables, dependent variable, and control
variables/covariates are provided in the following sections.
Independent variables. There are three research questions and three total
independent variables included in this research project. Data for all of the independent
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variables were available from the PEDSF (NCI, 2015c). The three independent variables
included in this research project are defined below:
Neighborhood characteristics (degree of urbanization). Neighborhood was
defined using the 2003 Rural/Urban Continuum Codes from the ERS, which categories
counties on an urban/rural scale based on population size, degree of urbanization, and
adjacency to a metro or nonmetro area (NCI, 2015c). This variable categorizes
neighborhoods as Big Metro, Metro, Urban, Less Urban, Rural, or Unknown (NCI,
2015c).
Race. Race used the SEER recode of the patient’s self-reported race to allow for
analysis of Latino individuals. The SEER recode reports race as one of the 11 selections:
Caucasian, Black, American Indian/Alaska Native, Chinese, Japanese, Filipino,
Hawaiian, Other Asian or Pacific Islander, Unknown, Caucasian, Spanish origin or
surname, Other unspecified (NCI, 2015c). Given the low representation of some of the
races in the cohort, American Indian/Alaska Native persons were excluded from the race
analysis and Chinese, Japanese, Filipino, Hawaiian and Other Asian or Pacific Islander
groups were pooled into a single group entitled Asian or Pacific Islander.
Socioeconomic status (SES). As in an article by Schlichting, Soliman, Schairer,
Schottenfeld and Merajver (2012), the Census Tract Poverty Indicator variable was used
as a surrogate measure of SES. This variable uses information from the American
Community Survey that measures and reports census tract poverty levels (Kentucky
Cancer Registry, n.d.).
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Dependent variable. The dependent variable for all three research questions was
receipt of first-line adjunct (in combination with chemotherapy) monoclonal antibody
therapy. As in Meyerhardt et al. (2012), first-line adjunct monoclonal antibody treatment
was defined as at least one claim for a monoclonal antibody (bevacizumab, cetuximab, or
panitumumab) within 1 month of chemotherapy (which must occur within 6 months of
diagnosis). For the purpose of this research project, the dependent variable (first-line
monoclonal antibody treatment) was recorded dichotomized as “yes” or “no.”
Covariates. Four covariates were added to the logistic regression analysis to
control for confounding. These covariates are defined below.
Age at diagnosis. As documented by Medicare.
Gender. Gender was self-reported and defined as male or female.
Reason for original Medicare entitlement. Reason for original Medicare
entitlement; age, disability, End Stage Renal Disease (ESRD), or disability and ESRD.
Age and disability were the only options for this covariate as individuals with ESRD
were excluded from the study.
SEER Registry that reported the data. Which geographically based SEERRegistry reported the data.
Study Terms
Operational definitions for the independent, dependent, and control/covariate
variables are documented in the study variable section above. In this section, I provide
two additional definitions required for sample selection and study execution.
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First-line chemotherapy. Given chemotherapy within 6 months of cancer
diagnosis as in Meyerhardt et al. (2012).
Socioeconomic status (SES). SES is a representation of the social and economic
state of an individual or population.
Assumptions
There is one large assumption necessary to justify this research project:
specifically that monoclonal antibodies improve survival of elderly metastatic colorectal
cancer patients. Clinical studies have shown a survival benefit in elderly metastatic
colorectal cancer patients treated with adjunct monoclonal antibody therapy
(Cunningham et al., 2013). However, real world evidence of improved survival of
elderly metastatic colorectal cancer patients associated with monoclonal antibody therapy
has not been shown using the SEER-Medicare population.
Scope and Delimitations
Scope
The focus of this study is on identifying disparities in first-line adjunct
monoclonal antibody treatment of elderly metastatic colorectal cancer patients. The
natural next question is whether or not any observed monoclonal antibody treatment
disparities correlate with disparities in survival. A robust analysis of survival would
require assessment and controlling for multiple comorbidities both pre- and postdiagnosis. This type of analysis is large, complex, and out of scope for this study.
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However, if disparities in adjunct monoclonal antibody therapy are found, a future study
could address the impact of these findings on colorectal cancer survival.
Delimitations
This study was limited to U.S. elderly (65+ years) Medicare Part B and Part D
enrolled (but with no HMO coverage), SEER registry colorectal cancer patients whose
cancer had metastasized at diagnosis and who received first-line chemotherapy. This
very specific population was selected to reduce validity threats and bias in the study.
However, as a result, it is unclear how these results will generalize to other populations
(e.g., elderly population with different health insurance, individuals in a different region
of the United States, younger individuals, and individuals who are diagnosed with an
earlier stage cancer, and progress to metastatic cancer).
Limitations and Methods to Address Limitations
Design/Methodology Weaknesses
Study design weaknesses. In this study, I employed a retrospective cohort
observational study design. Given the sample selection criteria, loss to follow-up (the
main concern in cohort studies) should be small. Specifically, assessment of monoclonal
antibody therapy (the dependent variable) occurs within 1 month of chemotherapy.
Given that receipt of chemotherapy is a selection criterion, the loss to follow-up time was
only 1 month long, limiting the impact of this concern.
Data source weaknesses. I used archival data from the SEER-Medicare database
to address the research questions. Therefore, the study quality is limited by the validity,
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reliability and completeness of the SEER-Medicare database. Given that hospitals,
clinicians, and pathologists are responsible for accurate reporting and coding of SEER
data, there is the potential for missing or inaccurate data. However, there are published
studies that have documented good reliability, validity, and completeness of different
subsets of the SEER-Medicare data (Du et al., 2008; Mahnken et al., 2008).
As a result of the database used for this study, concerns regarding extrapolation of
the study results do exist. This SEER database includes data from approximately 28% of
the U.S. cancer population. However, this sample comes from specific SEER funded
cancer registries. These registries are geographically dispersed, located in 13 different
states. However, it is unclear whether the data within the SEER database is a true
representation of the greater U.S. cancer population. This threat cannot be avoided and
will be noted in the limitations section of Chapter 5.
Threats to validity. Study validity could be threatened by confounding variables.
Therefore, the logistic regression analysis plans included covariates to test for
independent associations between the independent and dependent variables. However,
the possibility still exists that other variables, not cited in the literature as associating
treatment and thus not included in the models, could confound the analysis.
To increase statistical conclusion validity, great effort was employed to ensure the
study was powered appropriately and that the statistical tests did not violate any
assumptions. In addition, the statistical analysis plan was explicitly laid out and further,
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undocumented analyses were not performed. This effort attempts to limit the type I error
rate.
Biases
Given that this is a cohort study, there is the potential for bias in the outcome
assessment. For example, it is possible that hospitals that treat primarily black patients
are less likely to record treatments compared to hospitals that treat primarily white
patients. However, Mahnken et al. (2008) found that the completeness of the SEERMedicare data did vary nonsignificantly by race and ethnicity. Therefore, if the dataset is
relatively complete (all treatments reported regardless of race, SES, or neighborhood
characteristics), bias in the outcome assessment should be reduced.
Other potential biases include selection bias. In the case of this study, all SEERMedicare colorectal cancer patients were included in the cohort if they met the sample
selection criteria (there was no random selection from the SEER dataset). This reduced
selection bias. Additionally, the SEER sample is large (represents 28% of U.S. cancer
cases), also reducing issues associated with selection.
Significance
In this section, I describe the potential significance of the study results.
Specifically, how the results could advance knowledge of the discipline, impact
practice/policy, and promote positive social change.
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Advance Knowledge of the Discipline
Given the survival benefit associated with adjunct monoclonal antibody therapy
(Tol & Punt, 2010), it is possible that disparities in adjunct monoclonal antibody therapy
are contributing to disparities in metastatic colorectal cancer survival. Increased
understanding of colorectal cancer treatment disparities could advance the knowledge of
the discipline and provide a new hypothesis to explain why colorectal cancer survival
disparities are persisting. If racial, SES, or neighborhood (degree of urbanization)
disparities are found, future studies could determine if these disparities contribute to
disparities in metastatic colorectal cancer survival.
Additionally, given that the elderly have the highest colorectal cancer burden (risk
and survival) of any age group, focusing on this group could potentially increase the
impact of the study results. Additionally, limiting this study to elderly colorectal cancer
patients will also allow this research to build on treatment disparity research already
generated using this population (Le et al., 2008; White et al., 2010).
Potential Practice/Policy Contributions
If racial, SES, or neighborhood (degree of urbanization) disparities are found,
research into why these disparities exist could commence. Understanding of the
reasoning behind treatment disparities could have a direct influence on practice or policy.
For example, it is possible that newer treatment options are less well known to
practitioners at rural hospitals compared to urban hospitals, making them less likely to
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prescribe adjunct monoclonal antibody therapy. If this was determined, policies could be
put in place to educate rural doctors regarding new efficacious treatments.
Potential for Positive Social Change
Determining if racial, SES, or neighborhood disparities in monoclonal antibody
treatment of elderly metastatic colorectal cancer patients exist is a critical first step to
eliminating these social inequalities. This study may provide the basis for positive social
change in one of two ways. First, if treatment disparities are found, this would illuminate
the need for policies that improve access to monoclonal antibodies, thereby helping
reduce social inequalities in colorectal cancer survival. Alternatively, if treatment
disparities are not found, an opportunity exists to understand the root cause of the
reduced treatment disparities, and this knowledge could potentially be used to reduce
treatment disparities in other cancer populations.
Summary
Colorectal cancer survival disparities based on race, SES, and neighborhood
characteristics have been observed in many different studies. Specifically, Black
Americans have reduced colorectal cancer survival rates compared to White Americans
(Simpson et al., 2013; Sineshaw et al., 2014; Wallace et al., 2013; Wassira et al., 2013),
low SES populations have reduced colorectal cancer survival rates compared to higher
SES populations (Hines et al., 2014; Oliphant et al., 2013b; Wassira et al., 2013), and
rural populations have reduced colorectal cancer survival rates compared to urban
populations (Henry et al., 2009; Lian et al., 2011).
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In order to address these survival disparities, it is important to understand the
potential underlying causes of these disparities. Multiple articles have highlighted
disparities in both type and aggressiveness of colorectal cancer therapies (surgery,
radiation, and chemotherapy; Bakogeorgos et al., 2013; Obeidat et al., 2010; SerraRexach et al., 2012). However, this project is unique as it is unknown if these historical
colorectal cancer treatment disparities have extended to the newer monoclonal antibody
therapies and individuals with metastatic colorectal cancer. Therefore, the purpose of this
study was to determine if there are racial, SES, or neighborhood (degree of urbanization)
disparities in first-line adjunct monoclonal antibody treatment of elderly metastatic
colorectal cancer patients.
I used archived colorectal cancer patient data available from the NCI’s (NCI)
SEER-Medicare database. Specifically, a retrospective cohort study was performed,
using the SEER-Medicare database, on patients diagnosed with colorectal cancer from
January 2007 to December 2011. The data were analyzed using logistic regression with
defined covariates.
Determining if racial, SES, or neighborhood disparities in monoclonal antibody
treatment of elderly metastatic colorectal cancer patients exist is a critical first step to
eliminating these social inequalities. This study may provide the basis for positive social
change either through illuminating the need for policies that improve access to
monoclonal antibodies (if disparities are found) or providing rationale to further
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understand the root cause of the reduced treatment disparities (if disparities are not
found).
In this chapter, I provided an introduction to the research project including
summarization of items that will be described in detail in Chapters 2 and 3. In the
following chapter, I describe, in detail, the literature review performed as a basis for this
research study. Within the literature review, the literature gap described briefly in
Chapter 1 will be clearly illuminated. Additionally, the theoretical foundation for the
research and a rationale for the chosen variables are presented.
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Chapter 2: Literature Review
Introduction
In the United States, colorectal cancer accounts for 8.6% of all new cancer cases
and 8.8% of all cancer deaths (NCI, n.d.a). Colorectal cancer risk and mortality rate
increases with age, with the elderly being most affected by the disease (CDC, 2013). In
the United States, elderly individuals (65 years+) account for 60% of all new colorectal
cancer cases and 70.9% of all colorectal cancer deaths (NCI, n.d.a). Colorectal cancer
survival rates in the United States have been shown to be associated with race, SES, and
neighborhood characteristics (degree of urbanization; CDC, 2012; Hao et al., 2011;
Naishadham, Lansdorp-Vogelaar, Siegel, Cokkinides, & Jemal, 2011; White, Vernon,
Franzini, & Du, 2010). Specifically, Black Americans, individuals of low SES, and
individuals residing in rural areas have been shown to have increased colorectal cancer
mortality (CDC, 2012; Naishadham et al., 2011; White et al., 2010). White et al. (2010)
also showed that racial disparities in colorectal cancer survival persisted when the
population was limited to the elderly (65 years+).
Colorectal cancer survival has been shown to be influenced by treatment received.
For example, using a population of elderly colorectal cancer patients, Le et al. (2008)
found significant differences in first-line treatment (surgery, radiation, and
chemotherapy) comparing Black Americans to White Americans and higher SES to
lower SES. Hao et al. (2011) also described disparities in first-line chemotherapy
treatment in colorectal cancer. Specifically, populations with urban or suburban zip
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codes were, respectively, 38% and 52% more likely to receive chemotherapy compared
to populations with rural zip codes (Hao et al., 2011). Additionally, urban Black
American colorectal cancer patients had 24% reduced rates of chemotherapy compared
urban White American colorectal cancer patients (Hao et al., 2011). In a meta-analysis of
studies published from 1995 to 2009, Aarts et al. (2010) found that colorectal cancer
patients of low SES received less aggressive therapies and less adjunct therapies.
Although these studies have provided valuable information on colorectal cancer
treatment disparities, including disparities in elderly populations, they were conducted
using patient data from the 1990s and early 2000. The colorectal therapies employed
during this period included surgery, radiation and chemotherapy. Beginning in 2004,
monoclonal antibody therapies specifically for metastatic colorectal cancer came onto the
market (Scott et al., 2012). Currently, there are three monoclonal antibodies
(bevacizumab, cetuximab, and panitumumab) approved for the treatment of metastatic
colorectal cancer (Scott et al., 2012). A review of clinical trials and observational
studies, included in this chapter, indicated that monoclonal antibodies increased
progression-free survival and overall survival in elderly metastatic colorectal cancer
patients when added to chemotherapy. Therefore, as with chemotherapy, it is possible
that disparities in monoclonal antibody treatment could contribute to disparities in
colorectal cancer survival.
However, due to the lack of research, it is unknown if there are racial, SES, or
neighborhood disparities in monoclonal antibody treatment of elderly metastatic
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colorectal cancer patients. Therefore, the purpose of this study was to determine if there
are racial, SES, or neighborhood disparities in first-line adjunct monoclonal antibody
treatment of U.S. elderly colorectal cancer patients.
This chapter includes three major sections. First, the literature search strategy
will be reviewed in detail, including the rationale behind each combination of search
terms. This section also includes tables highlighting the relevant articles identified by
each combination of search terms. Second, I describe the theoretical foundation
supporting the research question will be outlined. Specifically, one overarching theory
and two supporting theories provide rationale for potential disparities in colorectal cancer
treatment. Third, an in depth review of the literature identified by the literature search
will be provided. This section includes multiple subsections reviewing disparities in
colorectal cancer survival, underlying causes of the disparities, and the utility of
monoclonal antibodies in elderly colorectal cancer patients. Each subsection also
contains rationale for inclusion in this document as well as the relationship to the research
questions. Additionally, in the literature review section, key variables are outlined and
justified. I conclude the chapter with an evaluation of the literature review and a
description of how this study will address the gap and extend knowledge of colorectal
cancer treatment disparities research.
Literature Search Strategy
In this section of the literature review, I discuss databases and search terms used.
Literature searches were conducted to locate articles surrounding colorectal cancer, the
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elderly, drug treatments, and disparities in treatments or care. Search terms and articles
located are provided in table form in this section, and key articles will be reviewed in
Literature Review. As will be described, the reviewed literature informed the design of
the study and methodology discussed in Chapter 3.
Databases and Search Terms
Two databases were searched for literature related to colorectal cancer, the
elderly, drug treatment, and disparities: PubMed and Science Direct. PubMed is a
biomedical literature database developed and maintained by the National Center for
Biotechnology Information. Science Direct is a database with content primarily focused
on medicine, nursing and allied health. These two databases were selected for their
relevance to the research topic. Specifically, they were chosen for their utility in locating
journal articles surrounding colorectal cancer epidemiology, drug treatments, and
disparities in cancer care. Monoclonal antibody therapies for colorectal cancer, the focal
point of the research question, came onto the market in 2004 (Scott et al., 2012).
Therefore, the literature searches were restricted from 2004 to 2015. Only peer-reviewed
primary literature articles were included in the tables below. However, review articles
were read and bibliographies of these sources were also reviewed to ensure the database
searches did not miss any important articles.
Colorectal cancer epidemiology searches. PubMed and Science Direct were
queried using a combination of the following terms to locate articles regarding colorectal
cancer survival disparities in the elderly: colorectal cancer, survival, epidemiology,
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elderly, and disparities. The specific searches are outlined in Table 1. These searches
were restricted from 2004 to 2015 and only peer-reviewed primary journal articles were
included. However, bibliographies of secondary source articles were reviewed to ensure
all important primary articles were captured. Many of these searches produced a
significant number of articles. All articles produced in the queries were reviewed;
however, only potentially relevant articles are listed in Table 1. Potentially relevant
articles met at least one of the following four criteria:
•

Provided U.S. colorectal cancer survival data from after 2004.

•

Discussed treatment or care of elderly colorectal cancer patients.

•

Discussed disparities in colorectal cancer survival, treatment, or care based on
race, socioeconomic status, or geography.

•

Discussed any disparity in colorectal cancer within the population of elderly U.S.
colorectal cancer patients.
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Table 1
Colorectal Cancer Epidemiology Primary Literature From PubMed and Science Direct
Search terms
"Colorectal Cancer"b,
Survivalb,
and Epidemiologya

Primary research articles
Ahmed, Howel & Debrah (2014); Tong et al. (2014); Sineshaw,
Robbins & Jemal (2014); Simpson et al. (2013); Allemani et al.
(2013); Oliphant et al. (2013a); Mitry et al. (2013); Oliphant et
al. (2013b); Wassira, Pinheiro, Symanowski & Hansen (2013);
Chien, Schootman & Pruitt (2013); Wallace et al. (2013); Lam,
Lu, Kouzminova & Lin (2013); Jafri, Gould, El-Serag, Duan &
Davila (2013); Wan, Zhan, Lu & Tiefenbacher (2012);
Lansdorp et al. (2012); Renouf et al. (2011); Lian et al. (2011);
Cueto, Szeja, Wertheim, Ong & Tsikitis (2011); Tsai et al.
(2011); Osterlund et al. (2011); White, Vernon, Franzini & Du
(2010); Lejeune et al. (2010); Koroukian et al. (2010); Henry,
Niu & Boscoe (2009); Ran et al. (2009); Lang et al. (2009);
Kelsall et al. (2009); Le, Ziogas, Lipkin & Zell (2008)
Naeim et al. (2013); Bruera et al. (2013); Fu, Tsai, Marshall &
"Colorectal Cancer"b and
Potosky (2013); Bakogeorgos et al. (2013); Cunningham et al.
Elderlyb
(2013); Serra-Rexach et al. (2012); Singal, Lin, Kuo, Riall &
Goodwin (2013); Abdelwahab, Azmy, Abdel-Aziz, Salim &
Mahmoud (2012); Jehn, Boning, Kroning, Possinger & Luftner
(2012); Price et al. (2012); Wildes et al. (2010); Vrdolijak,
Omrcen, Boban & Hrabar (2011); Kozloff et al. (2010); White
et al. (2008); Wright, Barlow, Green, Baldwin & Taplin (2007)
"Colorectal Cancer"b, Survivalb Sineshaw et al. (2014); Wassira et al. (2013); Wallace et al.
and Disparitiesb
(2013); Lansdorp et al. (2012); Wan, Zhan, Lu & Tiefenbacher
(2012); Cueto et al. (2011); White et al. (2010); Lejeune et al.
(2010); Henry et al. (2009); Le et al. (2008)
a
b
Note. Text Word Search; Title Search

Colorectal cancer disparities search. Additional database queries were
performed to specifically locate any additional articles regarding colorectal cancer
disparities and to exclude any bias searches that could have resulted from including either
“survival” or “elderly” in the previous search. For this purpose, PubMed and Science
Direct were queried using a combination of the following terms: colorectal cancer,
disparities and one of the following: treatment, race or racial, state, rural, geographical
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or geography, or socioeconomic status. Given the importance of treatment disparities to
the research question, the search query that included the terms colorectal cancer,
treatment, and disparities was queried three times, each time moving one of the three
search terms to a text word query instead of a title query. Additionally, given that only
one article was identified with the search colorectal cancer, socioeconomic status, and
disparities, an additional search was performed after eliminating the search term
disparities. The exact search terms are detailed in Table 2.
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Table 2
Colorectal Cancer Disparities Primary Literature From PubMed and Science Direct
Search terms
"Colorectal Cancer"b,
Treatmentb and Disparitiesb
"Colorectal Cancer"b,
Treatmenta and Disparitiesb

"Colorectal Cancer"b,
Treatmentb and Disparitiesa
"Colorectal Cancer"b, "Race or
Racial"b and Disparitiesb

"Colorectal Cancer"b, Stateb
and Disparitiesb
"Colorectal Cancer"b, Ruralb
and Disparitiesb
"Colorectal
Cancer"b,"Geographical or
Geography"b and Disparitiesb
"Colorectal Cancer"b,
"Socioeconomic status"b and
Disparitiesb
"Colorectal Cancer"b and
"Socioeconomic status"b

Primary research articles
Simpson et al. (2013); Wan et al. (2012); Cueto et al. (2011);
Haas et al. (2011); White et al. (2010); Lejeune et al. (2010);
White et al. (2008); Le et al. (2008)
Zullig et al. (2013); Wassira et al. (2013); Wallace et al. (2013);
Cueto et al. (2011); Haas et al. (2011); Crawford, Jones &
Richardson (2010); Obeidat et al. (2010); White et al. (2010);
Lejeune et al. (2010); Hao et al. (2011); White et al. (2008); Le
et al. (2008); McKibbin et al. (2008); Demissie et al. (2004)
Hines & Markossian (2012); Cueto et al. (2011); Haas et al.
(2011); White et al. (2010); Lejeune et al. (2010); White et al.
(2008); Le et al. (2008); Hassan, Arthurs, Sohn & Steele (2009)
Sineshaw et al. (2014); Wassira et al. (2013); Wallace et al.
(2013); Lansdorp-Vogelaar (2012); Stimpson, Pagan & Chen
(2012); Wilkins et al. (2012); Murphy et al. (2011); Laiyemo et
al. (2010); Hao et al. (2011); Robbins, Siegel & Jemal (2012);
White et al. (2010); White et al. (2008)
Rane et al. (2014); Naishadham, Lansdorp-Vogelaar, Siegel,
Cokkinides & Jemal (2011)
Rane et al. (2014); Wilkins et al. (2012); Beyer, Comstock,
Seagren & Rushton (2011); Cole, Jackson & Doescher (2012)
None

Le et al. (2008)

Hines, Markossian, Johnson, Dong & Bayakly (2014); SaldanaRuiz, Rubin, Colen & Link (2013); Steinbrecher et al. (2012);
Kelsall et al. (2009); Le et al. (2008); Gomez, O'Malley,
Stroup, Shema & Satariano (2007)
a
;b
Note. Text Word Search Title Search
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Colorectal cancer monoclonal antibody treatment disparities search. A final
database query was performed to specifically locate any articles regarding colorectal
cancer disparities and monoclonal antibody therapies. For this purpose, PubMed and
Science Direct were queried using a combination of the following terms: colorectal
cancer, disparities and one of the following: antibody, bevacizumab, cetuximab or
panitumumab. Given that very little research has been performed surrounding disparities
in monoclonal antibody treatment of colorectal cancer patients, the search terms were
relaxed. The term colorectal cancer was queried as a title search term; however, the
other two search terms in each case were only listed as text search terms. The exact
search terms are described in detail in Table 3.
Table 3
Colorectal Cancer Monoclonal Antibody Treatment Disparities Primary Literature From
PubMed and Science Direct
Search terms
"Colorectal Cancer"b,
Antibodya and Disparitiesa
"Colorectal Cancer"b,
Bevacizumaba and Disparitiesa
"Colorectal Cancer"b,
Cetuximaba and Disparitiesa
"Colorectal Cancer"b,
Panitumumaba and Disparitiesa

Primary research articles
McKibbin et al. (2008); Wallace et al. (2013)
McKibbin et al. (2008); Wallace et al. (2013)
Wallace et al. (2013)
None

Note. a Text Word Search; b Title Search

It is apparent from this search that very little research has been done surrounding
disparities in monoclonal antibody treatment of colorectal cancer patients. Of the two
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relevant articles located with this search, neither addressed racial, socioeconomic, or
geographical disparities in monoclonal antibody treatment of colorectal cancer patients.
Literature Search Strategy: Summary
The literature search revealed a significant amount of literature surrounding
colorectal cancer survival disparities. The search uncovered disparities in survival in
many populations including the elderly, blacks, Hispanics, Native Americans,
populations with low SES, populations living in rural counties as well as state-to-state
geographical disparities. Additionally, the literature search addressed potential
underlying causes of these disparities including differences in screening, access to care,
and treatment. Of particular relevance to the research topic, the literature search
uncovered documented disparities in colorectal cancer treatment. However, the treatment
disparities explored in these articles are differences in older therapies (chemotherapy and
surgery). The searches did not uncover any articles addressing racial, socioeconomic, or
neighborhood disparities in monoclonal antibody treatment of colorectal cancer patients.
Given that monoclonal antibody treatment has been shown to improve survival in the
elderly, understanding disparities in monoclonal antibody treatment could help explain
the persistence of colorectal cancer survival disparities.
Theoretical Foundation
The theoretical framework for this project is a combination of theories similar to
the theoretical framework proposed by Chang and Lauderdale (2009). The overarching
theory is the fundamental cause theory. However, two additional theories (the diffusion
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of innovations theory and the theory of health disparities and medical technology) are
used to extend the fundamental cause theory for the purpose of this project. I describe
these theories and their relevance to the research topic in detail in the sections below.
Fundamental Cause Theory
The overarching theory for the research questions is the fundamental cause
theory. This theory was originally developed to explain why the association between
SES and mortality persists across multiple diseases and risk factors (Link & Phelan,
1995). This theory proposes that beneficial social connections protect health and reduce
mortality (Link & Phelan, 1995).
Origin and definition of the theory. Link and Phelan (1995) first proposed the
fundamental cause theory in 1995. Link and Phelan (1995) argue that social states, such
as race and SES, contribute to disease rates for two major reasons. First, social states
impact resources available to combat diseases (Link & Phelan, 1995). Second, social
state is tied to multiple other disease risk factors (Link & Phelan). An important
assumption of this theory is that the relationship between social state and disease persists
over time (Phelan et al., 2010). Since resources are constantly changing, it is the
beneficial social connections that serve to protect health regardless of the resource
mechanism (Phelan et al.).
Utilization of the theory. The fundamental cause theory has been used primarily
to address differences in disease and disease mortality rates based on SES. The theory is
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especially useful when attempting to explain SES disparities that persist over time and
across varying resources.
Of particular importance to the research questions, in 2005, Phelan and Link
expanded the theory to help explain why breakthroughs in disease detection or treatment
do not often reduce social disparities. The authors argue that social and economic
inequalities contribute to resource acquisition (Phelan & Link, 2005). Therefore, as new
methods of treating or preventing disease become available, these resources are not
distributed equally (Phelan & Link). Instead they are distributed based on “knowledge,
money, power, prestige, and beneficial social connections” (Phelan & Link, 2005, p.
227). Therefore, even as the ability to combat disease incidence or mortality improves
(as with the introduction of monoclonal antibodies for colorectal cancer) the acquisition
of these new resources is not equal and therefore disparities persist.
These arguments were further supported in an article by Chang and Lauderdale
(2009). In this work the authors address disparities in cholesterol levels in the era of
nongeneric statins (Chang & Lauderdale, 2009). The authors found that in the years
before statin therapy, high SES populations had cholesterol levels higher than low SES
populations (Chang & Lauderdale). However, looking at cholesterol levels through the
statin era, this gradually reversed with the high SES population having lower cholesterol
levels compared to the low SES population (Chang & Lauderdale). The authors propose
that high SES populations had greater access to statins compared to the lower SES
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populations (Chang & Lauderdale). This distribution of resources disparity contributed
to the reversal of cholesterol situation comparing the SES groups.
Relationship to the research questions. Although in recent years (2004-2009)
new colorectal cancer treatments and technologies appear to be contributing to increasing
survival rates in all races, racial disparities in colorectal cancer survival, specifically
comparing Black Americans and White Americans, are increasing (Sineshaw et al.,
2014). Sineshaw et al. (2014) propose that minority populations have not benefited as
greatly from newer treatments or these treatments have not be disseminated into these
populations as greatly (Sineshaw et al.). This hypothesis is supported by Simpson et al.
(2013). In the Simpson et al. (2013) study, black patients with metastatic colorectal
cancer were less likely to receive multimodality therapy compared to White Americans.
In this research project I address disparities in monoclonal antibody treatment of
elderly metastatic colorectal cancer patients. Adjunct monoclonal antibody therapy has
been shown to be highly efficacious in increasing colorectal cancer survival (Bruera et
al., 2013, Cunningham et al., 2013; Naeim et al., 2013). However, monoclonal antibody
therapy is new and expensive. Thus, in accordance with the fundamental cause theory, it
is possible that minority populations or populations of low SES will be less likely to
receive this new resource. These resource acquisition differences could contribute to the
persisting disparities in colorectal cancer survival.
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Diffusion of Innovations Theory
As an extension of the fundamental cause theory, the diffusion of innovation
theory (Rogers, 1962) will be used to help explain why some populations (high SES,
certain geographies) might be more likely to obtain newer treatments. This model is
much older and more widely used compared to the fundamental cause theory. The model
states that widening disparities are influenced by the nature of the new technology and
the uptake/diffusion of the technology (Rogers, 1962).
Origin and definition of the theory. The diffusion of innovations theory was
first proposed by Rogers in1962. The theory has subsequently been updated with the
most recent version of the theory published by Rogers in 2010. The theory proposes five
innovation adopter categories based on how long post availability the innovation is
expected be adopted (Rogers, 2010). The categories use a normal distribution with
innovators (~2.5% of the population) adopting the innovation quickly following
availability, followed by early adopters (13.5%), early majority (34%), late majority
(34%), and 16% laggards (Rogers, 2010). Of particular importance to the model and the
research questions, there are several factors that influence whether or not an individual or
population will adopt a new innovation, and thus which adopter category that individual
or population will reside within (Rogers, 2010). These factors include relative advantage,
compatibility, complexity, triability (ability to “try it out” before committing to adoption)
and observability (observed results) (Rogers, 2010). The requirements needed to meet
each of these factors can differ from one population to another. Therefore, Rogers (2010)
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notes that it is critical to understand the target population and specific social factors that
can contribute to innovation adoption (Rogers, 2010).
Utilization of the theory. Relevant to the research questions, the diffusion of
innovations theory has been used as a model to explain multiple findings including drug
prescribing differences and the uptake of new diagnostic tests. For example, Armstrong,
Weiner, Weber, and Asch (2003) used the diffusion of innovations theory to help
understand early uptake the BRCA1/2 test for breast cancer susceptibility. The authors
found that early adopters of the test were proactive in inquiring about the test and had
heard about the test from sources in addition to their doctor or genetic counselor
(Armstrong et al., 2003). These adoption characteristics, including access to outside
knowledge of the test, could differ based on the social characteristics or demographics of
a population.
Additionally, Makowsky, Guirguis, Hughes, Sadowski, and Yuksel (2013) used
the diffusion of innovations theory to understand the adoption of pharmacist prescribing
behaviors in Alberta, Canada. The authors found that prescribing behaviors varied
greatly and was dependent on the innovation, the adopter, readiness of the system, and
communication/influence (Makowsky et al., 2013). The authors found that patient
focused pharmacists were more likely to prescribe medications compared to disease
focused pharmacists (Makowsky et al.). Additionally, pharmacists commented that
physician relationships influenced their decision to prescribe (Makowsky et al.). Of
importance to this research study, access to patient-centered health care and a
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collaborative healthcare system could influence drug prescribing decisions and uptake of
new innovations (such as monoclonal antibodies).
Relationship to the research questions. In concert with the fundamental cause
theory, the diffusion of innovations theory helps provide support for the research
questions. As noted in the section above, racial disparities in colorectal cancer survival,
specifically comparing Black Americans and White Americans, are increasing (Sineshaw
et al., 2014). Many studies have documented the efficacy of bevacizumab (monoclonal
antibody) in metastatic colorectal cancer. However, the uptake of monoclonal antibody
therapy has not been immediate or complete. According to Renouf et al. (2011), 5.9% of
patients diagnosed with colorectal cancer in 2004 were given bevacizumab compared to
30.6% of colorectal cancer patients diagnosed in 2006. In concert with the diffusion of
innovations theory, it is conceivable that different populations could reside in different
adopter categories based on social factors such as race and SES. Thus, it is possible that
a greater percentage of high SES, nonminority populations fall into innovator or early
adopter categories. This could contribute to the widening colorectal cancer survival
disparities and supports the research questions aimed at addressing disparities in
monoclonal antibody treatment.
Theory of Health Disparities and Medical Technology
As additional support for the fundamental cause theory and the diffusion of
innovations theory, the theory of health disparities and medical technology is used
(Goldman & Lakdawalla, 2005). This theory states that medical advances are linked to
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widening disparities due to disparities in health care utilization (Goldman & Lakdawalla,
2005).
Origin and definition of the theory. The theory of health disparities and
medical technology is a relatively new theory developed by Goldman and Lakdawalla in
2005. The theory itself is very similar to the fundamental cause theory, but focuses on
the quantity and complexity of newly introduced therapies (Goldman & Lakdawalla,
2005). The theory was originally developed to help explain why better-educated people
are healthier (Goldman & Lakdawalla). The authors rooted their theory in basic
consumer theory and argue that new medical technologies disproportionately benefit the
heaviest health care users; richer patients (Goldman & Lakdawalla). They claim that
richer more well-educated patients tend to be the heaviest health care users and use more
complex treatment regimens (Goldman & Lakdawalla). Therefore, richer patients
disproportionately use newer therapies.
Utilization of the theory. Goldman and Lakdawalla (2005) used the theory of
health disparities and medical technology to help explain why the introduction of a
complicated anti-retroviral therapy for HIV patients benefited rich well-educated patients
disproportionately. The authors found that richer patients were more likely to likely to
invest effort into obtaining and adhering to the complex treatment regimen (Goldman &
Lakdawalla, 2005).
Additionally, as noted above, the theory relies on the assumption that the heaviest
healthcare users benefit most from newer, more complex technologies and treatments
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(Goldman & Lakdawalla, 2005). Therefore, Goldman and Lakdawalla (2005) assessed
disparities in survival of chronically ill populations and found the largest survival
disparity was based on education. Specifically, more educated populations had higher
survival rates compared to lower education populations (Goldman & Lakdawalla). This
highly educated population, they argue, is the population expected to be the heaviest
health care utilizers, supporting their theory.
Relationship to the research questions. Treatment for metastatic colorectal
cancer can be multifaceted including surgery (if possible), chemotherapy and monoclonal
antibody therapy. Given that the research questions address disparities in adjunct
monoclonal antibody therapy, a relatively complex treatment regimen, this theory is
appropriate and compliments the other two theories previously presented. Utilizing this
theory, it is possible that richer patients use more health care resources compared to
poorer individuals and are thus more likely to obtain adjunct monoclonal antibody
therapy. This could contribute to disparities in monoclonal antibody treatment based on
social status or demographics.
Theoretical Foundation Summary
Utilization of the three theories noted above in drug uptake and disease outcome
research was first proposed by Chang and Lauderdale (2009). The overarching theory for
this research project is the fundamental cause theory. As commented above, this theory
focuses on disparities in resource distribution and can help explain why breakthroughs in
disease treatment (such as monoclonal antibody therapy) do not reduce social disparities
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in survival. Specifically, as new methods of treating disease become available, these
resources are not distributed equally (Phelan & Link, 2005). Instead they are distributed
based on “knowledge, money, power, prestige, and beneficial social connections” (Phelan
& Link, 2005, p. 227). This theory proposes that beneficial social connections protect
health and reduce mortality (Link & Phelan, 1995). In line with the fundamental cause
theory, it is possible that disparities in monoclonal antibody therapy exist due to
disparities in resource acquisition.
Two additional theories are used to extend the fundamental cause theory for the
purpose of this research project. First, the diffusion of innovation theory (Rogers, 2010)
is used to help explain why some populations (high SES, certain geographies) might be
more likely to obtain newer treatments. This model states that widening disparities are
influenced by the nature of the new technology and the uptake/diffusion of the
technology (Rogers). For monoclonal antibody therapy, this model is supported by
Renouf et al. (2011). The authors found that uptake of monoclonal antibodies for
colorectal cancer treatment was not immediate or complete (Renouf et al.). Early
adopters of monoclonal antibody therapy could have innovator-like characteristics such
as pro-active inquiry into treatment regimens that might contribute to treatment
disparities based on social characteristics or demographics. Second, the theory of health
disparities and medical technology is used (Goldman & Lakdawalla, 2005). This theory
states that medical advances are linked to widening disparities because new medical
technologies disproportionately benefit the heaviest health care users; richer patients
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(Goldman & Lakdawalla). Given that richer more well-educated patients tend to be the
heaviest health care users and use more complex treatment regimens, richer patients
disproportionately use newer therapies (Goldman & Lakdawalla). This could contribute
to higher monoclonal antibody use by high SES or nonminority populations.
In summary, these three theories work in concert to provide support for the
research questions. The fundamental cause theory attempts to explain disparities based
on resource acquisition; whereas the diffusion of innovation theory takes a temporal
approach to explain uptake of new technologies or treatments; and the theory of health
disparities and medical technology proposes that the complexity and quantity of
treatment influences who will receive treatment. All three of these theories provide
rationale for research into disparities in monoclonal antibody treatment of colorectal
cancer patients, as it is likely that demographics and social status will contribute to
disparities in utilization of newer, more complex treatments.
Literature Review
In this literature review I have provided an overview of colorectal cancer
epidemiology, reviews studies related to disparities in colorectal cancer survival, and
examines the potential underlying causes of colorectal cancer survival disparities. I have
also addressed studies related to the safety and efficacy of monoclonal antibodies in
elderly colorectal cancer patients. In addition, I’ve described strengths and weaknesses
of previous approaches and, on this basis, variables and concepts chosen for the study
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were justified. Finally, I provided a review and synthesis of the studies related directly to
the research questions.
Colorectal Cancer Epidemiology
In the United States, colorectal cancer accounts for 8.6% of all new cancer cases
and 8.8% of all cancer deaths (NCI, n.d.b). Colorectal cancer risk and mortality rate
increases with age, with the elderly being most affected by the disease (CDC, 2013). In
the U.S., elderly individuals (65 years+) account for 60% of all new colorectal cancer
cases and 70.9% of all colorectal cancer deaths (NCI, n.d.a). As identified in the
literature search section above, many studies have uncovered disparities in colorectal
cancer survival based on demographics such as race, SES, or neighborhood
characteristics (degree if urbanization). However, the underlying causes of these
disparities, especially in patients with metastatic colorectal cancer, have been only
minimally addressed in the literature.
Review of Studies Related to Constructs and Methods
This research study aims to address disparities in adjunct monoclonal therapy of
elderly metastatic colorectal cancer patients. This topic is important due to previously
observed survival disparities within this population. Therefore, this section will provide
an in-depth review of what is known about survival disparities in colorectal cancer and
will provide the rationale for further research into treatment disparities.
Disparities in colorectal cancer survival. The research topic for the study
addressed disparities in monoclonal antibody therapy based on several demographic
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predictors. This topic is important as it could help explain previously observed and, in
some cases, widening disparities in colorectal cancer survival. Many studies have
addressed disparities in colorectal cancer survival. These studies have uncovered
disparities based on age, race, socioeconomic status, and neighborhood characteristics
(degree of urbanization). These studies also provide the rationale for the research topic
and are described in detail in the sections below.
Disparities in the elderly. Colorectal cancer survival disparities have been
documented in the elderly population. Using data from the SEER-Medicare linked
database, White et al. (2010) found significant survival disparities comparing elderly
black patients to elderly white patients (adjusted Hazard Ratio: 1.24; 95% CI: 1.14-1.35).
Similar results were obtained by Gomez et al. (2007), also using the SEER-Medicare
linked database. Contrarily, Wallace et al. (2013) observed only modest survival
disparities comparing elderly black to elderly white colorectal cancer patients. However,
the population in the Wallace et al. (2013) differed from the other two studies. Namely,
as opposed to using national-level data, Wallace et al. (2013) limited the population
studied to residents of South Carolina and expanded the definition of elderly to include
patients over 50 years of age. The White et al. (2010) and Gomez et al. (2007) studies
defined elderly as over 65 years of age. The source population differences could explain
the discrepancy in results obtained in these studies.
Additionally, Chien et al. (2013) identified spatial disparities in colorectal cancer
survival of elderly patients residing in Atlanta and Detroit. Specifically, their research
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identified geographical areas with excessive risk of colorectal cancer death (Chien et al.,
2013). However, the authors comment that additional research is needed to understand
the moderating pathways driving these disparities (Chien et al., 2013).
Finally, disparities in colorectal cancer mortality based on age were identified in a
study by Ahmed et al. (2014). Specifically, elderly patients over 80 years of age had
higher cancer-specific mortality rates compared to patients 60-80 years of age (Ahmed et
al., 2014). Relevant to the research topic, Ahmed et al. (2014) also identified treatment
disparities associated with advancing age that were correlated with mortality rates.
Similarly, Serra-Rexach et al. (2012) found that a population of colorectal cancer patients
younger than 75 years of age had a better cancer-specific survival rate compared to the
75+ years of age group. These results are documented in detail in Table 4.
The survival disparities observed within the population of elderly colorectal
cancer patients provide some of the rationale for using this population in this research
study. Additionally, many of the key referenced survival disparities studies used data
from the SEER-Medicare database (Chien et al., 2013; Lang et al., 2009; White et al.,
2010). This is the data source used for this research project. Therefore, this research
study builds directly on previous data and methodologies.
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Table 4
Advanced Age-Related Colorectal Cancer Survival Disparities

Source

Chien et al. (2013)

Wallace et al. (2013)

White et al. (2010)

Koroukian et al.
(2010)

Data source

SEER
Database

South Carolina
Central Cancer
Registry

SEER
Database
Ohio Cancer
Incidence
Surveillance
System, Vital
Records,
Medicare
Administrative
Data, Home
Health Care
Outcome and
Assessment
Information
Set (OASIS)

Sample
Elderly (66+
years) US
colorectal
cancer
patients in
two
metropolitan
areas (Detroit
and Atlanta),
1991-2005
Pathologically
documented
colorectal
cancer
patients
diagnosed
from 19962006.

Elderly (66+)
colorectal
cancer
patients
diagnosed
between
1992-2002.
Elderly
colorectal
cancer
patients
diagnosed
between 1999
and 2001 and
admitted to
home health
care 30 days
before or after
diagnosis

Outcome
variable(s)
assessed

Spatial patterns
of survival

Results

Identified geographic
areas with excess risk of
colorectal cancer death.
Spatial patterns varied by
cancer type and stage.

Kaplan-Meier
survival methods

Elderly patients (50+
years) showed only
modest racial disparities
in survival (less than 50
years) (Hazard Ratio:
1.16; 95 % CI 1.01-1.32).
Black patients had worse
survival compared to
white patients (adjusted
Hazard Ratio: 1.24; 95%
CI: 1.14-1.35). Asian
patients had better
survival compared to both
black and white patients
(adjusted Hazard Ratio:
0.80; 95% CI: 0.70-0.92).

Comorbidities
and survival
rates

Two or more geriatric
syndromes were
associated with increased
disease-specific mortality
(Hazard Ratio: 2.71; 95%
CI: 1.80-4.07).

Median survival
time

table continues
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Lang et al. (2009)

Serra-Rexach et al.
(2012)

Gomez et al. (2007)

Ahmed et al. (2014)

SEERMedicare
Linked Data
Hospital
records
(administrative
database) from
a single
institution in
Madrid, Spain

SEERMedicare
Linked Data
Treatment
centers in the
former
Northern
Region of
England
conducted by
the Northern
Region
Colorectal
Cancer Audit
Group
(NORCCAG)

Elderly (66+)
colorectal
cancer
patients
diagnosed
between
1992-2000,
follow-up
through 2005.

5-year survival

Colorectal
cancer
patients
diagnosed or
treated at the
institution

Cancer-specific
survival rate

Colorectal
cancer
patients (65+
years)
diagnosed
between
1992-1996
and followed
through 1999.

Mortality rate

5-year survival improved
temporally, with survival
improving from 43% to
46.3% in colon cancer and
from 39.4% to 42.2% in
rectal cancer from 19922000.
The younger than 75 years
of age group had a better
cancer-specific survival
rate compared to the 75+
years of age group (36.41
months vs. 26.05 months;
hazard ratio: 0.66).
Unadjusted colorectal
cancer mortality rates
were higher in Black
Americans and Hispanic
compared to White
Americans and lower in
Japanese compared to
White Americans.
Adjustments for stage
eliminated the difference
between White Americans
and Hispanics and White
Americans and Japanese.
However, comparing
blacks to White
Americans, cancer stage
and SES only accounted
for half of the observed
mortality difference.

30 day and 6month postoperative
mortality

30-day and 6-month
mortality was the highest
in patients 80+ years.
Association of age with
mortality at 6-months was
the highest in patients
receiving curative surgery
(OR: 3.8, 95% CI: 2.85.2) compared to those
receiving palliative
surgery (OR: 1.5, 95% CI:
1.1-2.1).

Elderly
colorectal
cancer
patients (60+
years) that
had surgery
for their
cancer
between
1998-2003
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Socioeconomic disparities. Socioeconomic disparities in colorectal cancer
survival have been documented in the literature. Specifically, populations with lower
SES often have higher colorectal cancer mortality rates. Oliphant et al. (2013b) found
that both post-operative death and 5-year survival rates were independently predicted by
low SES. Similarly, Lian et al. (2011) and Lejeune et al. (2010) found that lower SES
areas had higher colorectal cancer-specific mortality rates. Interestingly, in several
studies, survival disparities based on race (Le et al., 2008;Wassira et al., 2013; White et
al., 2010; Yan et al., 2009) or urban versus rural geography (Henry et al., 2009; Hines et
al., 2014) were somewhat attenuated when the authors controlled for SES. Therefore,
SES appears to associate with colorectal cancer survival and might even account for
some of the observed racial and geographical disparities in survival. Since this research
study attempts to uncover treatment differences that could contribute to observed
colorectal cancer survival disparities, it is critically important to include SES as a
variable. The results from the referenced papers are documented in detail in Table 5.
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Table 5
Socioeconomic Colorectal Cancer Survival Disparities

Sample

Outcome
variable(s)
assessed

Oliphant
et al.
(2013b)

Regional
audit
database
from West of
Scotland (16
hospitals)

Patients
undergoing
surgery for
colorectal cancer
(2001-2004)

Postoperativ
e mortality
(30 days
postsurgery) and
5-year
relative
survival
rates

Wassira et
al. (2013)

Nevada
Central
Cancer
Registry

Patients
diagnosed with
colorectal cancer
between 19952007.

Survival
rates

Colorectal cancer
patients over 11year time period

5-year
mortality

Colorectal cancer
patients identified
from 1995-2003
and followed
until 2006.

Survival
(Bayesian
multilevel
survival
models)

Source

Lam et al.
(2013)

Lian et al.
(2011)

Data source

Northern
California
urban county
hospital
records and
national
SEER
database
National
Institutes of
Health
AARP Diet
and Health
Study

Results
Low SES was independently
associated with increased
postoperative death (Adjusted
Odds Ratio: 2.26; 95% CI:
1.45-3.53) and lower 5-year
survival rates (Adjusted
Relative Excess Risk: 1.25;
95% CI: 1.03-1.51). However,
when postoperative deaths were
excluded, the relative survival
was similar across SES groups.
Black Americans had a 20.1%
higher risk of colorectal cancer
death compared to White
Americans. This increased risk
persisted when adjusted for
tumor stage, sex, diagnosis
period, tumor sub-location,
marital status, and SES.
5-year survival rate in this
urban underserved population
was worse than the national rate
(52.9% vs. 64.3%). Colorectal
cancer screening was associated
with improved survival.
Advanced age and later stage
cancer was associated with
reduced survival. However,
insurance status of the patients
was not associated with
survival.

Lower SES neighborhoods had
higher colorectal cancerspecific mortality (Hazard
Ratio: 1.2; 95% CI: 1.1-1.5).
table continues
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White et
al. (2010)

SEERMedicare
Linked Data

Elderly (66+)
colorectal cancer
patients
diagnosed
between 19922002.

Lejeune et
al. (2010)

Three UK
cancer
registries
linked to
area-level
socioeconomic
information

Colorectal cancer
patients
diagnosed
between 19972000.

New Jersey
Cancer
Registry

Patients
diagnosed with
colorectal cancer
between 19962003.

Henry et
al. (2009)

Yan et al.
(2009)

Kelsall et
al. (2009)

SEER
Program

Australia
Melbourne
Collaborative
Cohort Study

Patients
diagnosed with
colorectal cancer
between 19881992.
Prospective
Cohort Study
Participants
(recruited
between 19901994; age 40-69)
who were
subsequently
diagnosed with
colorectal cancer

Comorbidities and
socioeconomic status were
associated with a reduction in
Kaplanthe survival difference between
Meier
both blacks and White
survival
Americans and Black
methods
Americans and Asians.
Patients from lower SES areas
Access to
had poorer overall survival and
treatment
were also less likely to receive
(measured
treatment within 6 months of
in time from diagnosis. When limited to
diagnosis to patients receiving treatment
treatment)
within 1 month of diagnosis, no
and 3-year
survival disparity existed based
survival
on area SES.
There were geographical areas
of the state with both higher and
lower survival rates. When
Survival
race/ethnicity and area SES
rates
were controlled, the risk of
evaluated
death was attenuated in several
using spatial areas. However, in some areas,
scan statistic survival disparities persisted.
Black Americans had
significantly higher rates of late
stage disease and were more
likely to reside in lower SES
census tracts. After adjusting
for age, marital status, sex, SES
group, cancer stage, and
treatment, race was no longer a
significant predictor of overall
Survival rate survival.

Even with universal health care,
area-level SES was associated
with reduced survival rates
(Hazard Ratio: 0.73; 95% CI:
0.53-1.00) from colorectal
cancer (after adjustment for age,
Survival rate sex, tumor stage and treatment).
table continues
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Colorectal cancer
patients
diagnosed
between 19942003.

Hines et
al. (2014)

California
Cancer
Registry
Georgia
Comprehensi
ve Cancer
Registry,
Census-tract
level
geographic
residency and
SES.

Steinbrech
er et al.
(2012)

California
Cancer
Registry,
U.S. census
data

Colorectal cancer
patients aged 50+
years

SEERMedicare
Linked Data

Colorectal cancer
patients (65+
years) diagnosed
between 19921996 and
followed through
1999.

Le et al.
(2008)

Gomez et
al. (2007)

Patients
diagnosed with
colorectal cancer
in Georgia (20002007)

KaplanMeier
survival
methods

After adjustment for age, sex,
histology, tumor site, and stage,
Black Americans had increased
cancer-specific death rates
compared to White Americans
(Hazard Ratio: 1.19; 95% CI:
1.14-1.25). However, when
adjusted for area-level SES and
treatment, the disparity was
reduced (Hazard Ratio: 1.08;
95% CI: 1.03-1.13).

Rural residents had a 14%
increased risk of death (Hazard
Ratio: 1.14, 95% CI: 1.07-1.22).
However, when adjusted for
SES level, no differences in
survival between rural and
Survival rate urban tracts were noted.
SES and colorectal cancer
incidence were positively
associated in Hispanics, but
Colorectal
negatively associated in Black
cancer cases Americans and White
(1999-2001) Americans. In White
and
Americans, as SES increased,
colorectal
colorectal cancer mortality
cancer
declined. However, this was
deaths
not observed in Hispanics or
(1999-2001) Black Americans.
Unadjusted colorectal cancer
mortality rates were higher in
Black Americans and Hispanic
compared to White Americans
and lower in Japanese compared
to White Americans.
Adjustments for stage
eliminated the difference
between White Americans and
Hispanics and White Americans
and Japanese. Comparing
Black Americans to White
Americans, cancer stage and
Mortality
SES only accounted for half of
rate
the observed mortality disparity.
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Racial disparities. Many key studies have reported significant racial disparities in
colorectal cancer survival (Hassan et al., 2009; Hines et al., 2012; Le et al., 2008;
Wallace et al., 2013; Wassira et al., 2013; White et al., 2010) . For example, a study by
Wassira et al. (2013) showed that Black Americans had reduced colorectal cancer
survival compared to White Americans. This difference persisted even after adjustment
for tumor stage, sex, age, diagnosis period, tumor sub-location, marital status and SES
(Wassira et al., 2013). However, the role of race has been debated. A study by Yan et al.
(2009) found that after adjusting for age, marital status, sex, SES group, cancer stage, and
treatment, race was no longer a significant predictor of overall survival. Therefore, the
data is somewhat mixed as to whether race or other factors associated with race predict
colorectal cancer survival. However, it is well documented that Black Americans have
higher colorectal cancer mortality rates compared to White Americans. Although the
data sources are minimal, colorectal cancer survival disparities have also been noted in
other minority races including Native Americans (Cuerto et al., 2011) and Hispanics
(Jafri et al., 2013; Wan et al., 2012). Authors from several documented studies comment
that treatment related data are needed to advance the understanding of racial disparities in
colorectal cancer (Wassira et al., 2013; Wallace et al., 2013). This might help explain the
difference in results comparing the Wassira et al. (2013) study to the Yan et al. (2009)
study; as Yan et al. (2009) controlled for treatment regimen. This point is of particular
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importance to this study as disparities in treatment could help explain some of the racial
disparities in colorectal cancer survival.
In recent years (2004-2009), new treatments and technologies appear to be
contributing to increasing survival rates in all races (Sineshaw et al., 2014). However,
these survival increases are greater in White Americans compared to Black Americans
(Sineshaw et al., 2014). Therefore, racial disparities in colorectal cancer survival,
specifically comparing Black Americans and White Americans, are increasing (Sineshaw
et al., 2014). Similar widening disparities were observed in a study by Robbins et al.
(2012). Sineshaw et al. (2014) propose that minority populations have not benefited as
greatly from newer treatments or these treatments have not be disseminated into these
populations as robustly (Sineshaw et al., 2014). This hypothesis is supported by Simpson
et al. (2013). In the Simpson et al. (2013) study, black metastatic colorectal cancer
patients were less likely to receive multimodality therapy compared to White Americans.
When adjusted for differences in treatment, the increased risk of death seen in black
versus white patients disappeared (Simpson et al., 2013).
Given that race has been associated with colorectal cancer survival and the
presence of studies linking racial disparities to treatment disparities, it is critically
important to include race as a variable in this study. It is possible that newer technologies
(monoclonal antibody therapies) are driving the recent widening disparities in colorectal
cancer based on race. Studies describing racial disparities in colorectal cancer survival
are described in detail in Table 6.
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Table 6
Racial Colorectal Cancer Survival Disparities

Source

Data
Source

Sample

Outcome
Variable(s)
Assessed

Sineshaw
et al.
(2014)

SEER
Program

5-year
cause
US colorectal specific
cancer patients survival
(1992-2009)
rates

Simpson
et al.
(2013)

SEERMedicare
Linked
Data

Elderly (66+
years) US
Survival
colorectal
(logistic
cancer patients regression)

Nevada
Central
Cancer
Registry

Patients
diagnosed
with colorectal
cancer
between 1995- Survival
2007.
rates

South
Carolina
Central
Cancer
Registry

Pathologically
documented
colorectal
cancer patients
diagnosed
Median
from 1996survival
2006.
time

Wassira et
al. (2013)

Wallace et
al. (2013)

Results
Comparing 1992-1997 to 2004-2009,
the 5-year
survival rate increased in all races
except nonHispanic Black Americans
(nonHispanic White Americans =
11.4% to 17.7%; nonHispanic Black
Americans = 8.6% to 9.8%).
Black race was associated with a
higher mortality rate (Hazard Ratio:
1.15, 95% CI: 1.08-1.22). When the
data were adjusted for patient, tumor,
and demographic factors, the Hazard
Ratio reduced marginally, but was still
significant. When the data were
adjusted for treatment, there was no
longer a significant different in
survival comparing white to black race.
Black Americans had a 20.1% higher
risk of colorectal cancer death
compared to White Americans. This
increased risk persisted when adjusted
for tumor stage, sex, diagnosis period,
tumor sub location, marital status, and
SES.
Disparities in survival comparing
Black Americans to White Americans
increased over the time period.
Comparing age groups, younger
patients (less than 50 years) showed
the greatest racial disparities in
survival (Hazard Ratio: 1.34, 95% CI:
1.06-1.71). Elderly male patients (50+
years) showed only modest racial
disparities in survival (Hazard Ratio:
1.16, 95% CI: 1.01-1.32). No racial
disparity was observed in elderly
female patients.
table continues
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Jafri et al.
(2013)

SEER
Program

LansdorpVogelaar
et al.
(2012)

MISCANColon
microsimu
lation
model

Cueto et
al. (2011)

White et
al. (2010)

Henry et
al. (2009)

Yan et al.
(2009)

Survival
rates
evaluated
using
spatial scan
statistic

Comparing 1993-1997 to 2003-2007,
there were no significant
improvements in 5-year survival for
Hispanics. There was a modest
increase in 1-year survival for young
Hispanics.
Screening accounted for 19% of the
survival disparity between Black
Americans and White Americans.
36% of the survival disparity was
explained by difference in cancer
stage.
Survival rates from colon cancer were
worse for Native Americans (Hazard
Ratio: 1.20; 95% CI: 1.08-1.34),
however no difference was found in
survival for rectal cancer.
Black patients had worse survival
compared to white patients (adjusted
Hazard Ratio: 1.24; 95% CI: 1.141.35). Asian patients had better
survival compared to black and white
patients (adjusted Hazard Ratio: 0.80;
95% CI: 0.70-0.92).
There were geographical areas of the
state with both higher and lower
survival rates. When race/ethnicity
and area SES were controlled, the risk
of death was attenuated in several
areas. However, in some areas,
survival disparities persisted.

Survival
rate

After adjusting for age, marital status,
sex, SES group, cancer stage, and
treatment, race was no longer a
significant predictor of overall
survival.

1 and 5
Hispanic
year agecolorectal
specific
cancer patients survival
(1993-2007)
rates

SEER
database

Colorectal
cancer patients
(50 years+)
from 19752007
White and
Native
American
colorectal
cancer patients

Survival
rates

SEERMedicare
Linked
Data

Elderly (66+)
colorectal
cancer patients
diagnosed
between 19922002.

KaplanMeier
survival
methods

New
Jersey
Cancer
Registry

SEER
Program

Patients
diagnosed
with colorectal
cancer
between 19962003.
Patients
diagnosed
with colorectal
cancer
between 19881992.

Mortality
rate

table continues
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California
Cancer
Registry

Colorectal
cancer patients
diagnosed
between 19942003.

KaplanMeier
survival
methods

Wan et al.
(2012)

Texas
Cancer
Registry

Colorectal
cancer patients
diagnosed
between 19952003

Survival
and Access
to
Healthcare

After adjustment for age, sex,
histology, tumor site, and stage, Black
Americans had increased cancerspecific death rates compared to White
Americans (Hazard Ratio: 1.19; 95%
CI: 1.14-1.25). However, when
adjusted for area-level SES and
treatment, the disparity was reduced
(Hazard Ratio: 1.08; 95% CI: 1.031.13).
Death rate from Colorectal Cancer was
highest in Hispanics and nonHispanic
Black Americans and in several
geographical regions. Spatial access to
oncologists was significantly
associated with survival in nonurban
areas only. Access to care did not
explain all geographic disparities.

Hines et
al. (2012)

SEER
Cancer
Program
Data
(reporting
from
Atlanta
and Rural
Georgia
Cancer
Registries
only)

Colorectal
Cancer
patients
diagnosed
between 19922007.

Mortality
rate

Black Americans had slightly higher
death rates from both colon and rectal
cancer (Hazard Ratio for colon cancer:
1.11, 95% CI: 1.00-1.24; Hazard Ratio
for rectal cancer: 1.24, 95% CI: 1.141.35).

Hassan et
al. (2009)

Madigan
Army
Medical
Center
medical
records

Colorectal
cancer patients
treated at the
medical center
from 19942004.

Stage of
diagnosis,
Survival
rates

NonWhite Americans were diagnosed
younger and with a greater proportion
of stage III tumors. Age and tumor
stage at diagnosis were the only
predictors of lower survival.

Le et al.
(2008)

table continues
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Robbins et
al. (2012)

Gomez et
al. (2007)

SEER
cancer
program
database

StageColorectal
specific
cancer patients mortality
(1985-2008)
rate

SEERMedicare
Linked
Data

Colorectal
cancer patients
(65+ years)
diagnosed
between 19921996 and
followed
Mortality
through 1999. rate

Over the time period (1985-2008)
mortality rates decreased in both Black
Americans and White Americans.
However, the decreases were smaller
for Black Americans. As a result,
black to white mortality ratios
increased from 1.17 to 1.41 for
localized disease, from 1.03 to 1.30 for
regional disease, and from 1.21 to 1.72
for distant-stage disease.
Unadjusted colorectal cancer mortality
rates were higher in Black Americans
and Hispanic compared to White
Americans and lower in Japanese
compared to White Americans.
Adjustments for stage eliminated the
difference between White Americans
and Hispanics and White Americans
and Japanese. However, comparing
Black Americans to White Americans,
cancer stage and SES only accounted
for half of the observed mortality
difference.

Neighborhood disparities. The presence of neighborhood level disparities
(degree of urbanization) in colorectal cancer survival is controversial. Several studies
have shown that controlling for SES attenuated rural versus urban difference in colorectal
cancer survival. For example, Hines et al. (2014) reported that rural residents in Georgia
had 14% higher risk of colorectal cancer mortality compared to urban residents.
However, when the authors adjusted for SES level, the disparity was attenuated (Hines et
al., 2014). Additionally, Henry et al. (2009) found geographical areas in New Jersey with
higher rates of colorectal cancer death. As in Hines et al. (2014), when the authors
controlled for SES, the increased risk of death was attenuated in many areas (Henry et al.,
2009).
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Lian et al. (2011) took a different approach to the question and directly assessed
neighborhood socioeconomic deprivation as a predictor of colorectal cancer mortality
rates using national-level data. Contrary to the previously listed studies, in the Lian et al.
(2011) article, SES did not explain all the observed geographical variation in mortality.
Therefore, although neighborhood SES appears to contribute to colorectal cancer
mortality, other neighborhood characteristics might also contribute to colorectal cancer
mortality rates. In this study, neighborhood characteristic (degree of urbanization)
disparities in monoclonal antibody treatment will be addressed to assess the possibility
that rural residents have reduced levels of treatment compared to urban residents. Studies
describing neighborhood characteristic disparities in colorectal cancer survival are
described in detail in Table 7.
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Table 7
Neighborhood Characteristics Related to Colorectal Cancer Survival Disparities
Outcome
Variable(s)
Assessed

Source

Data Source

Sample

Hines et
al.
(2014)

Georgia Cancer
Registry,
Census-tract
level geographic
residency and
SES.

Patients
diagnosed with
colorectal
cancer in
Georgia (20002007)

Mortality
rate

Texas Cancer
Registry

Colorectal
cancer patients
diagnosed
between 19952003

Survival
and Access
to
Healthcare

Wan et
al.
(2012)

Henry et
al.
(2009)

New Jersey
Cancer Registry

Chien et
al.
(2013)

SEER ProgramMedicare
Linked Data

Patients
diagnosed with
colorectal
cancer between
1996-2003.
Elderly US
colorectal
cancer patients
(1991-2005)

Lian et
al.
(2011)

National
Institutes of
Health AARP
Diet and Health
Study

Colorectal
cancer patients
identified from
1995-2003 and
followed until
2006.

Survival
rates
evaluated
using
spatial scan
statistic
Spatial
pattern of
survival

Survival
(Bayesian
multilevel
survival
models)

Results
Rural residents had a 14%
increased risk of death (Hazard
Ratio: 1.14, 95% CI: 1.07-1.22).
However, when adjusted for SES
level, no difference in survival
between rural and urban tracts
was noted.
Death rate from Colorectal
Cancer was higher than the state
average in several geographical
regions. Spatial access to
oncologists was significantly
associated with survival in
nonurban areas only. Access to
care did not explain all
geographic disparities.
There were geographical areas of
the state with both higher and
lower survival rates. When
race/ethnicity and area SES were
controlled, the risk of death was
attenuated in several areas.
However, in some areas, survival
disparities persisted.
Identified geographic areas with
excess risk of colorectal cancer
death. Spatial patterns varied by
cancer type and stage.
There was significant
geographical variation in
colorectal cancer-specific
mortality. Lower SES
neighborhoods had higher
colorectal cancer-specific
mortality (Hazard Ratio: 1.2; 95%
CI: 1.1-1.5). . However,
neighborhood SES did not
account for geographical variation
in colorectal cancer deaths.
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Underlying causes of colorectal cancer survival disparities. As documented in
detail in the sections above, there are a multitude of studies describing disparities in
colorectal cancer survival based on many different factors including age, race, SES and
neighborhood characteristics (degree of urbanization). However, in order to reduce these
disparities, it is important to understand the underlying causes of these disparities. This
area of research is less well developed, however the three main areas of exploration
include observed disparities in access to care, screening and treatment.
Access to care disparities. One potential underlying cause of the colorectal
cancer survival disparities are disparities in access to care. Oliphant et al. (2013a) found
that access and utilization of a colorectal cancer specialist for surgery as opposed to a
nonspecialist was associated with a reduced risk of postoperative death and an increased
5-year survival rate. Likewise, Zullig et al. (2013) found that older age was associated
with reduced rate of colorectal cancer specialist referral. Therefore, it is possible that
access to a specialist contributes to the colorectal cancer survival disparity seen in the
elderly. Additionally, Laiyemo et al. (2010) found racial disparities in follow-up to
abnormal colorectal cancer screening results; with Black Americans less likely than
White Americans to obtain follow-up within 1 year of abnormal result. Access to care
was proposed as a reason for this disparity (Laiyemo et al., 2010) However, if access to
care is gauged by healthcare spending, Wright et al. (2007) found that the total cost for
colorectal cancer care was slightly higher in Black Americans compared to White
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Americans. Therefore, the role that access to care disparities play in overall colorectal
cancer survival is still unclear.
Screening disparities. Another potential underlying cause of colorectal cancer
survival disparities are disparities in early detection or screening. Multiple papers have
highlighted racial differences in colorectal cancer screening. For example, Crawford et
al. (2010), Stimpson et al. (2012), and Wilkins et al. (2012) all found that Black
Americans had lower colorectal cancer screening rates compared to White Americans.
The relevance of these results to survival was addressed by Lansdorp-Vogelaar et al.
(2012). In this article, the authors found that 19% of the difference in survival between
elderly Black Americans and White Americans with colorectal cancer could be explained
by differences in screening (Lansdorp-Vogelaar et al., 2012). Therefore, disparities in
early detection via screening do appear to contribute to disparities in colorectal cancer
survival. However, according to Lansdorp-Vogelaar et al. (2012) there are additional
factors contributing to the differences in survival, including potential disparities in
treatment, which need further research. Interestingly, when Stimpson et al. (2012)
adjusted their analysis for SES, no racial screening disparities were found.
Cole et al. (2012) found a modest difference in colorectal screening comparing
rural to urban zip codes. Specifically, after adjustment for demographics and health
characteristics, rural residents had lower screening rates compared to urban residents
(48% vs. 54%, respectively) (Cole et al., 2012). These screening rate disparities could be
reflecting access to care disparities given the geographical nature of the disparity.
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However, this was not address by Cole et al. (2012). Finally, Lang et al. (2009)
performed a temporal study to correlate colorectal cancer screening rates and survival
rates. Across the time period (1992-2005), earlier detection did not appear to impact
survival (Lang et al., 2009). However, the authors did find that technological
improvements (new technologies/treatments or better use of current treatments) and
demographics were responsible for the largest share of the temporal 5-year survival
improvement (Lang et al., 2009).
Treatment disparities. A final potential underlying cause of colorectal cancer
survival disparities are disparities in treatment. This area of disparity research has been
researched to a greater extent compared to access to care or screening disparities.
Multiple papers have found that different demographic variables including age, rural
versus urban geography, SES, and race are associated with different treatment regimens.
For example, although targeted treatments (such as chemotherapy) have been shown to
increase survival rates, Mitry et al. (2013) found that only 10% of elderly received
targeted treatments, compared to 40% of younger populations. These results are
supported in the literature as age-related disparities in colorectal cancer treatment
(surgery, chemotherapy, radiation) have been observed in multiple different studies
including Bakogeorgos et al. (2013), Obeidat et al. (2010) and Serra-Rexach et al. (2012).
Of importance for this study, this age-related treatment disparity has persisted into newer
colorectal cancer therapies. Fu et al. (2013) and Kozloff et al. (2010) observed reduced
adjunct bevacizumab treatment with increasing patient age. Therefore, the literature
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supports an age-related colorectal cancer treatment disparity, where the elderly are less
likely to receive newer treatments.
In addition to age disparities, many articles have addressed racial and SES
disparities in colorectal cancer treatments. Le et al. (2008) found significant differences
in first-line treatment (surgery, radiation, and chemotherapy) comparing Black
Americans to White Americans. These racial disparity results were supported in
subsequent studies by Hao et al. (2011), Hines et al. (2012), and White et al. (2008).
Interestingly, Zullig et al. (2013) found no racial disparities in treatment when the
population was limited to Veteran Affairs (VA) hospitals. In their article, Zullig et al.
(2013) proposed that the racial disparities in treatment observed in the aforementioned
studies could be related to insurance status or access to care differences.
Compared to higher SES areas, Lejeune et al. (2010) found that patients from
lower SES areas were less likely to receive treatment within 6 months of colorectal
cancer diagnosis. Additionally, Le et al. (2008) found significant differences in first-line
treatment (surgery, radiation, and chemotherapy) comparing higher SES to lower SES
areas. Hao et al. (2011) described urban versus rural disparities in first-line
chemotherapy treatment in colorectal cancer. Specifically, populations with urban or
suburban zip codes were, respectively, 38% and 52% more likely to receive
chemotherapy compared to populations with rural zip codes (Hao et al., 2011).
Of particular importance to this study, my literature searches did not uncover any
studies addressing racial, SES, or neighborhood disparities in monoclonal antibody
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treatment of colorectal cancer. Adjunct monoclonal antibody therapy has been shown to
reduce colorectal cancer mortality in multiple populations, including the elderly (as
discussed in the next section). It is possible that disparities in monoclonal antibody
treatment are contributing to disparities in colorectal cancer survival. However, given the
lack of research, disparities in monoclonal antibody treatments are a clear literature gap.
Studies describing access to care, screening and treatment disparities in colorectal
cancer patients are described in Table 8.
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Table 8
Access to Care, Screening and Treatment Disparities
Access to care disparities

Source

Singal et al.
(2013)

Wilkins et al.
(2012)

Zullig et al.
(2013)

Laiyemo et al.
(2010)

Wright et al.
(2007)

Source

Texas
Medicare
Database
(2000-2009)

Telephone
surveys in
two rural
Georgia
counties
Veteran
Affairs (VA)
Health
System
Database
(encompassin
g 128 centers)
Prostate,
Lung,
Colorectal,
and Ovarian
(PLCO)
Cancer
Screening
Trial (10
geographicall
y diverse
sites)

SEERMedicare
Linked Data

Sample

Medicare
beneficiaries (age
66-75)
Individuals 50+
years old living
in the two highest
colorectal cancer
mortality
counties in
Georgia.
Patients
diagnosed with
colorectal cancer
within the VA
system from
2003-2006.
Subjects enrolled
in the study
between 19932001 who
received trialsponsored
flexible
sigmoidoscopy
(FSG) and
obtained an
abnormal result.
Elderly (65+)
colorectal cancer
patients with
stage II-III rectal
or stage III colon
cancer diagnosed
in 1992-1996.

Outcome
Variable(s)
Assessed

Colorectal
cancer
screening
rates

Results
Patients with a primary care
physician (PCP) were more likely
to be screened for colorectal
cancer (OR: 2.05; 95% CI: 2.032.07). Ethnic disparities in
screening were almost eliminated
after accounting for PCP.

Colorectal
cancer
screening
rates

Black Americans were more
likely to report colorectal cancer
screening barriers. Having a
physician recommend screening
was associated with the highest
screening rates regardless of race.

Treatment
patterns

Older age at diagnosis was
associated with reduced odds of
medical oncology referral and
surveillance colonoscopy.

Follow-up
rates

Black Americans were less likely
than White Americans to obtain
follow-up colonoscopy within 1
year of abnormal FSG result
(62.6% vs. 72.4% respectively).

Surgical and
post-surgical
costs for
colorectal
cancer care.

The total colorectal cancer cost
for Black Americans was higher
than White Americans ($44,199
vs. $38,588). However, after
adjusting for covariates, this
difference was insignificant.
table continues
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Regional
audit
database from
Oliphant et al.
West of
(2013a)
Scotland
Screening disparities

Source

LansdorpVogelaar
et al. (2012)

Data Source
Northern
California
urban county
hospital
records and
national
SEER
database
MISCANColon
microsimulati
on model

Crawford et al.
(2010)

Behavioral
Risk Factor
Surveillance
System
(BRFSS)

Stimpson et al.
(2012)

National
Health
Interview
Study and the
linked Area
Resource File

Wilkins et al.
(2012)

Telephone
surveys in
two rural
Georgia
counties

Lam et al.
(2013)

Colorectal cancer
patients
undergoing
surgery during
two time periods
(1991-1994 and
2001-2004)

Postoperative
mortality (30
days post
surgery) and
5-year
relative
survival
rates.

Both postoperative mortality rates
and 5-year survival rates were
improved in patients who
received surgery from a specialist.

Sample

Outcome
Variable(s)
Assessed

Results

Colorectal cancer
patients over 11year time period
Black colorectal
cancer patients
(50 years+) from
1975-2007

Black, white and
Hispanics (age
50+ years)
between 20022004
Subjects with a
personal history
of cancer,
subjects over 50
years old, or
subjects over 40
years old with a
family history of
cancer.
Individuals 50+
years old living
in the two highest
colorectal cancer
mortality
counties in
Georgia.

Colorectal
endoscopy
rates

Colorectal cancer screening was
associated with improved survival
in this urban underserved
population. Insurance status of
the patients was not associated
with survival.
Screening accounted for 19% of
the survival disparity between
Black Americans and White
Americans.
White Americans were more
likely than Black Americans or
Hispanics to have received either
type of colorectal cancer
screening (fecal occult blood
testing or endoscopy). Persons
without insurance or a usual
source of care were less likely to
obtain screening.
White Americans were more
likely to report a colorectal
endoscopy exam (44%), followed
by Black Americans (36%) and
Hispanics (28%). The difference
in screening rates between White
Americans and Black Americans
was eliminated when adjusted for
area socioeconomic status.

Colorectal
cancer
screening
rates

Black respondents had lower
screening rates compared to
White Americans (50.4% and
63.4% respectively).

5-year
mortality

Mortality
rate

Colorectal
cancer
screening
rates

table continues
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Cole et al.
(2012)

Lang et al.
(2009)

Behavioral
Risk Factor
Surveillance
System
(BRFSS)

Individuals (age
50+ years)
between 19982005

Colorectal
cancer
screening
rates

SEER
Database

Elderly (66+)
colorectal cancer
patients
diagnosed
between 19922000, follow-up
through 2005.

5-year
survival

Although the rates in both rural
and urban communities increased
over time, after adjustment for
demographics and health
characteristics, rural residents had
lower screening rates compared to
urban residents (48% vs. 54%
respectively).
Comparing the time periods,
earlier detection did not appear to
impact survival. Technological
improvements (new
technologies/treatments or better
use of current treatments) and
demographics were responsible
for the largest share of the
temporal 5-year survival
improvement.

Treatment disparities

Source

Rane et al.
(2014)

Mitry et al.
(2013)

Cueto et al.
(2011)

Data Source

Sample

West Virginia
Cancer
registry and
the SEER
database

Medicare
beneficiaries
aged 66+ and
diagnosed with
colorectal cancer
from 2003-2006

Outcome
Variable(s)
Assessed
3-year
survival and
Receipt of
minimallyappropriate
colorectal
cancer
treatment

French
populationbased registry

Patients with
nonresectable
metastatic
colorectal cancer
diagnosed from
1976-2009

Treatment
rates and
survival rates

SEER
database

White and Native
American
colorectal cancer
patients

Survival
rates and
Treatment
Regimens

Results
Compared to the national
colorectal cancer sample,
individuals diagnosed in West
Virginia were diagnosed in early
stages, but had poorer survival
rates. The West Virginia cohort
had lower treatment rates.
Comparing the 1997-2004 timeperiod to the earlier time period,
patients receiving chemotherapy
increased from 19% to 57%.
However, from 2005-2009, less
than 10% of the elderly received
targeted treatments, compared to
40% for younger patients.
Native Americans and White
Americans had similar surgery
recommendation rates. Native
Americans were more likely to
receive radiation, but less likely to
receive sphincter-preserving
surgery.
table continues
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Lejeune et al.
(2010)

Fu et al. (2013)

Three UK
cancer
registries
linked to
area-level
socioeconomic
information

SEERMedicare
Linked Data

Access to
treatment
(measured in
time from
diagnosis to
treatment)
and 3-year
survival

Colorectal cancer
patients
diagnosed
between 19972000.
Elderly (65+)
colorectal cancer
patients,
diagnosed from
2005-2009 and
given
chemotherapy
anytime through
2010.

Patient
characteristic
s associated
with adjunct
bevacizumab
use.

Colorectal cancer
patients

Treatment
patterns,
safety,
progressionfree survival,
overall
survival

Stage III
Colorectal cancer
patients (age 6599)

Chemotherap
y treatment
rates, death
rates

Wildes et al.
(2010)

BRiTE
observational
cohort study
BarnesJewish
Hospital
Oncology
Data Services
Registry
(1996-2006)

McKibbin et al.
(2008)

Medical
records from
10 U.S.
community
practices

Patients with
advanced stage
colorectal cancer
(2003-2006).

Treatment
patterns

Bakogeorgos et
al.
(2013)

Single
institution
comparative
study

Colorectal cancer
patients (52.8%
elderly; 70+)

Treatment,
dose,
toxicity,
efficacy

Kozloff et al.
(2010)

Patients from lower SES areas
were less likely to receive
treatment within 6 months of
diagnosis. When limited to
patients receiving treatment
within 1 month of diagnosis, no
survival disparity existed based on
area SES.
57% of newly diagnosed patients
received bevacizumab, compared
to 44% of patients with
progressive disease. Patients aged
80+ were less likely than younger
elderly patients (65-69) to receive
adjunct bevacizumab (OR: 0.64;
CI: 0.57-0.73).
Use of bevacizumab as a first-line
adjunct therapy decreased with
age. Comparing elderly (65+
years) receiving bevacizumab to
elderly not receiving
bevacizumab, there was a
significant increase in median
survival with bevacizumab
Within this group, advancing age
was associated with a reduction
chemotherapy treatment.
Receiving chemotherapy was
associated with lower risk of
death for all stratified elderly age
groups.
Elderly individuals (65+ years)
were less likely to receive firstline doublet chemotherapy
compared to younger (under 65
years) patients (54% vs. 84%).
The use of each of the medicines
studied (irinotecan, oxaliplatin
and bevacizumab) were all lower
in elderly patients.
Elderly patients (70+ years) were
more likely to receive only single
agent chemotherapy, fewer cycles
(6.2 cycles compared to 8.3 for
younger patients), and lower
doses (42.8% of planned dose
compared to 78.4% for younger
patients).
table continues
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Serra-Rexach et
al.
(2012)

Obeidat et al.
(2010)

White et al.
(2008)

Haas et al.
(2011)

Hao et al.
(2011)

Hospital
records
(Administrati
ve database)
from a single
institution in
Madrid,
Spain

SEERMedicare
Linked Data

Colorectal cancer
patients
diagnosed or
treated at the
institution
Elderly (66+
years) stage IV
colorectal cancer
patients
diagnosed
between 20002002 and treated
with first-line
chemotherapy

Irinotecan
treatment
(newest
chemotherap
y option)
based on race
or age

SEERMedicare
Linked Data

White and Black
elderly (65+
years) colorectal
cancer patients
diagnosed
between 19912002.

Treatment
patterns

SEERMedicare
Linked Data

Elderly (65+
years) colorectal
cancer patients
diagnosed
between 19922005.

Treatment
patterns and
mortality

Georgia
Comprehensi
ve Cancer
Registry

Black and white
persons
diagnosed with
stage III colon or
stage II/III rectal
cancer between
2000-2004

Treatment
patterns

Treatment
patterns

The younger than 75 years of age
group was more likely to receive
surgery, radiation, and
chemotherapy and less likely to
receive palliative care compared
to the older group (75+).
Black Americans were less likely
to be treated with the newer
chemotherapy option (Irinotecan)
compared to White Americans
(OR: 0.641; 95% CI: .453-0.907).
Older elderly patients (71+ years)
were less likely to receive
Irinotecan compared to younger
elderly patients (66-70 years).
Receipt of standard of care (stage
specific and defined by the
Physician Data Query guidelines)
increased in both race groups over
time. However, Black Americans
were overall 16% less likely to
receive standard of care compared
to White Americans (OR: 0.85;
95% CI: 0.78-0.90).
Black Americans and Hispanics
were less likely than White
Americans to undergo surgery
(OD: 0.57, 95% CI: 0.52-0.63 and
OR: 0.82, 95% CI: 0.70-0.95
respectively). Similar disparities
were seen for receipt of adjunct
chemotherapy. Adjustment for
area sociodemographics, surgeon
capacity, and medical oncologist
capacity reduced the observed
disparities.
Urban and suburban patients were
more likely than rural patients to
receive chemotherapy (38% and
53% more likely respectively).
Urban black patients were 24%
less likely to receive
chemotherapy compared to urban
white patients. There were no
racial differences within suburban
and rural areas of residence.
table continues
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Hines et al.
(2012)

Hassan et al.
(2009)

Hines et al.
(2014)

Demissie et al.
(2004)

Zullig et al.
(2013)

Koroukian et al.
(2010)

SEER Cancer
Program Data
(reporting
from Atlanta
and Rural
Georgia
Cancer
Registries
only)

Madigan
Army
Medical
Center
medical
records
Georgia
Comprehensi
ve Cancer
Registry,
Census-tract
level
geographic
residency and
SES.

SEER
database
Veteran
Affairs (VA)
Health
System
Database
(encompassin
g 128 centers)
Ohio Cancer
Surveillance
System, Vital
Records,
Medicare
Administrativ
e Data, Home
Health Care
Outcome and
Assessment
Information
Set (OASIS)

Colorectal
Cancer patients
diagnosed
between 19922007.

Surgery rates

Colorectal cancer
patients treated at
the medical
center from 19942004.

Stage of
diagnosis,
treatment
patterns

Black Americans had lower rates
of surgery (50% decreased odds
for colon cancer; 67% decreased
odds for rectal cancer).
NonWhite Americans were
diagnosed younger and with a
greater proportion of stage III
tumors. No disparities in
treatment (surgery, adjunct
therapy, disease recurrence) were
found comparing nonWhite
Americans to White Americans.

Treatment
patterns

Lower SES census tracts had
lower colon cancer surgery rates.
Rural and lower-SES census tracts
also had reduced rates of
chemotherapy.

Treatment
patterns

Black Americans were less likely
than White Americans to receive
standard of care. Black
Americans were also more likely
to refuse recommended treatment.

Treatment
patterns

Black Americans and White
Americans were equally likely to
receive National Comprehensive
Cancer Network guidelineconcordant colorectal cancer care
through the VA system.

Treatment
patterns

Functional limitation and geriatric
syndromes were associated with
lower likelihood of treatment
(surgery-only or surgery +
chemotherapy).

Patients
diagnosed with
colorectal cancer
in Georgia (20002007)
Black and white
persons
diagnosed with
colon or rectal
cancer between
1988-1997.
Patients
diagnosed with
colorectal cancer
within the VA
system from
2003-2006.

Elderly colorectal
cancer patients
diagnosed
between 1999
and 2001 and
admitted to home
health care 30
days before or
after diagnosis
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Safety and efficacy of adjunct monoclonal antibody treatment in elderly
colorectal cancer patients. In this study, I aim to understand a potential underlying
disparity in colorectal cancer survival, namely disparities in adjunct monoclonal antibody
treatment. Therefore, for the validity of the hypothesis, it’s critically important that
monoclonal antibodies extend survival and are safe to use in the study population.
Multiple studies determined that adjunct monoclonal antibody treatment with
either bevacizumab or cetuximab was safe in elderly patients with either manageable side
effects or side effects equivalent to the younger populations of patients (Abdelwahab et
al., 2012; Bruera et al., 2013, Cunningham et al., 2013; Naeim et al., 2013).
Additionally, multiple clinical studies showed improved survival in elderly colorectal
cancer patients treated with adjunct monoclonal antibody therapy. For example, in a
large Phase III study, Cunningham et al. (2013) found that elderly patients that received
bevacizumab plus chemotherapy had a median progression-free survival time of 9.1
months compared to 5.1 months in patients treated with chemotherapy only. Progressionfree survival improvement was also seen with adjunct bevacizumab in a smaller Phase II
study by Vrdoljak et al. (2011). Similar results were obtained with adjunct cetuximab
therapy. Specifically, elderly colorectal cancer patients treated with cetuximab plus
chemotherapy had a progression-free survival time of 8.8 months, compared to 5.8
months for chemotherapy only (Price et al., 2012).
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Several recent population-based observational studies have supported these
clinical findings. Kozloff et al. (2010) and Renouf et al. (2011) both found that adjunct
bevacizumab therapy increased median survival time in elderly colorectal cancer patients.
Additionally, Jehn et al. (2012) found that the efficacy and side effect profile of adjunct
cetuximab therapy was similar comparing elderly patients to younger patients.
Table 9 includes both clinical and observational studies citing the efficacy and/or
safety of monoclonal antibody treatment in the elderly.
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Table 9
Monoclonal Antibody Treatment of Elderly Colorectal Cancer Patients
Clinical Studies with Adjunct Monoclonal Antibody Therapy
Outcome
Variable(s)
Source
Data Source
Sample
Assessed

Naeim et
al. (2013)

Bruera et
al. (2013)

Cunningha
m et al.
(2013)

Vrdoljak et
al. (2011)

Results
Median overall survival was
12.7 months with manageable
side-effects and no new safety
signals for capecitabine
Clinical study
Phase II study
(chemotherapy) and
(capecitabine
in elderly
Survival
bevacizumab (anti-VEGF
plus
colorectal
and Sidemonoclonal antibody)
bevacizumab)
cancer patients Effects
combination.
Clinical study
Drug activity, efficacy, and
(triple
Phase II study
safety of triple chemotherapy +
chemotherapy
fit elderly
Survival
bevacizumab were equivalent to
plus
colorectal
and Sidethe overall colorectal cancer
bevacizumab)
cancer patients Effects
population.
Elderly patients had improved
progression-free survival with
the addition of adjunct
bevacizumab to their
chemotherapy (median survival
Phase III
9.1 months vs. 5.1 months;
Study in
hazard ratio: 0.53, 95% CI:
elderly (70+)
0.41-0.69). Adverse events
previously
were slightly higher in the
Clinical Trial
untreated
Progression combination group, but overall
-free
(capecitabine +/- colorectal
the combination was tolerated
bevacizumab)
cancer patients survival
well.
Median progression-free was
Phase II trial
Progression 11.5 months and overall
Clinical Trial
in elderly (70+ -free
survival was 21.2 months.
(first line
years)
survival,
Side-effects were similar to
capecitabine +/- colorectal
overall
those reported in earlier studies
bevacizumab)
cancer patients survival
with younger age groups.
table continues
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The addition of bevacizumab to
Colorectal
capecitabine to the elderly (75+
cancer patients
years) population increased
given
Progression progression free survival (5.8
MAX trial data
capecitabine
-free
months vs. 8.8 months; Hazard
(international
or
survival
ratio: 0.65). Compared to the
Price et al.
randomized
capecitabine + and
younger age groups, there were
(2012)
controlled trial) bevacizumab
toxicity
no major toxicity differences.
Elderly
colorectal
Median survival time was 7
cancer patients
months and median
(65 years +)
progression-free survival was 4
who
months for irinotecen
progressed
(chemotherapy) + cetuximab
Abdelwaha Clinical Trial
after at least
Survival
(anti-EGFR monoclonal
antibody). Side effects were
b et al.
(irinotecen plus one previous
and Side(2012)
cetuximab)
treatment
Effects
tolerable.
Observational Studies with Adjunct Monoclonal Antibody Therapy
Outcome
Variable(s)
Source
Data Source
Sample
Assessed
Results
Multicenter
Colorectal
Progression Side-effects and efficacy
study in
cancer patients -free
(progression-free survival) of
Germany using
(18 years +)
survival
cetuximab + irinotecan were
electronic
treated with
and side
similar comparing the greater
Jehn et al.
databases (2005- cetuximab +
effect
than 65 age group to the less
(2012)
2007)
irinotecan
assessment than 65 age group.
Treatment
Colorectal
patterns,
Comparing elderly (65+ years)
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Evaluation of Strengths and Weaknesses of Previous Approaches
The vast majority of literature cited in the sections above utilized secondary data
sources (such as the SEER-Medicare database) to address their research questions. In a
broad sense, this has multiple benefits. First, the data is already collected, organized, and
available for use saving both time and cost. Second, using secondary data sources results
in assess a larger or more geographically broad sample. Third, since the data is already
collected, it is possible to retrospectively use several years of collected data; something
that might not have been possible if primary data collection were performed.
Alternatively, data for some of the literature cited above was collected or compiled
specifically for the study in question. These included the utilization of hospital records,
telephone surveys, or clinical trials. The benefit of these approaches is the researchers
were able to address very specific questions; which may not have been answered using
published database sources. However, these approaches can be time consuming and
expensive. Therefore, researchers using these approaches often had smaller sample sizes
or addressed a limited sample (either temporally or geographically). Table 10 describes
the strengths and weakness of multiple data acquisition approaches.
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Table 10
Strengths and Weaknesses of Previous Data Collection Methods Related to the Study
Previous Data
Collection Method

Telephone Surveys

Data Collection
from
Hospital/Medical
Records

Clinical Trials

Database (SEERMedicare Database,
Veteran Affairs
Database, StateLevel Cancer
Surveillance
Systems, BRFSS)

Strengths
Ability to address a very specific
question in a very specific
geographical region. Wilkins et al.
(2012) were able to address the
impact of physician colorectal cancer
screening recommendation on
screening rates and also identify
specific screening barriers.
If present in medical records, this
approach would allow the researchers
to address a specific question.
Hassan et al. (2009) had specific
questions about diagnosis and
survival at a single VA center,
therefore, this approach was
appropriate. This approach also
allows the researcher to address
differences over time.
Clinical trials allow the researcher to
prospectively address questions such
as drug efficacy (Naeim et al., 2013;
Bruera et al., 2013; Cunningham et
al., 2013). These studies are very
well controlled.
Researchers used these databases to
ask a multitude of research questions
including the impact of demographics
on colorectal cancer survival and
treatment without performing any
primary data collection (Naishadham
et al., 2011; White et al., 2010;
Simpson et al., 2013). This method
can save time in data collection and
allows for large, broad data sets.

Weaknesses
Telephone surveys are time
consuming and limited the scope
in Wilkins et al. (2012). This type
of approach is not feasible for
national-level assessments or large
sample sizes. Research is often
limited to a cross-sectional
approach.

This approach also limits the
study scope. Hospital record
research is likely only feasible if
performed at a few hospitals. This
would not be feasible on a large
scale and could be time
consuming.
This approach is very expensive
and time consuming. It is also not
feasible for some types of
questions due to ethical
limitations.

Using secondary databases can
limit the questions that can be
asked. The data in these sources
can be difficult to access and use
if not coded uniformly. The
multitude of data often requires
software for extraction.
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Given the research questions address disparities in monoclonal antibody treatment
based on demographic variables at a national level, some of these approaches are more
feasible than others. For example, telephone surveys are not feasible for this study. It
would be difficult to randomly call enough metastatic colorectal cancer patients to
adequately assess the use of monoclonal antibody therapy. Additionally, clinical trials
would not be feasible due to cost, time, and ethics of the questions asked. Therefore,
since the SEER-Medicare linked database contains all the variables needed to address the
research question in the study, the secondary data collection method using published
databases is appropriate.
The SEER-Medicare database is a large population-based database that contains
matched medical records and demographic information for Medicare beneficiaries who
have been diagnosed with cancer (NCI, 2015a). For this research project, several SEERMedicare datasets containing data from colorectal cancer patients 65+ years in age were
requested and obtained. The first file obtained was the SEER PEDSF; a file containing
demographics and information related to the patient’s cancer diagnosis (i.e. information
on cancer stage, diagnosis date, previous primary tumors) (NCI, 2015b). In addition to
the SEER file, four matched Medicare claims files were obtained. These included the
Part D Event (PDE) dataset, the Outpatient Claims dataset, the Durable Medical
Equipment (DME) dataset and the Carrier Claims dataset from 2007 to 2012. The PDE
dataset includes all drugs prescribed under Medicare Part D; data available only 2007 to
2012 (NCI, 2015b). The remaining datasets contain all Part B claims including diagnosis
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and procedure codes (NCI, 2015b). These five patient matched SEER-Medicare datasets
contain information on all the variables required to answer the research questions.
Justification of Chosen Variables
The independent variables (race, SES, neighborhood characteristics) selected for
the research study were chosen due to their relationship with colorectal cancer survival
(either overall survival or survival specific to the metastatic colorectal cancer population).
This is critical as this study aims to understand disparities in an underlying factor that
could contribute to differences in colorectal cancer survival. The dependent variable,
adjunct monoclonal antibody therapy is a new therapy shown to increase survival in
metastatic colorectal cancer patients. Disparities in treatment of colorectal cancer
patients have been documented, but the findings have not been extended to monoclonal
antibody therapy. If racial, SES, or neighborhood disparities in adjunct monoclonal
antibody treatment are found, future studies could determine if these disparities
contribute to the previously observed disparities in survival.
Review and Synthesis of Studies Related to the Research Questions
The study evaluates racial, SES, and neighborhood (degree of urbanization)
disparities in adjunct monoclonal antibody treatment of elderly colorectal cancer patients.
As outlined in the literature review sections above, there are documented disparities in
colorectal cancer survival based on race, SES, and neighborhood characteristics. The
underlying cause(s) of these disparities is not well researched; although many papers
have suggested treatment disparities as a needed follow-up study. For example,
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Sineshaw et al. (2014) propose that minority populations have not benefited as greatly
from newer treatments or these treatments have not be disseminated into these
populations as greatly (Sineshaw et al., 2014). However, research has not been
performed to determine if disparities in newer colorectal cancer therapies (such as
monoclonal antibodies) exist. Given the documented efficacy of monoclonal antibody
therapy, this study evaluated adjunct monoclonal antibody treatment to determine if any
of the groups exhibiting survival disparities (minority race, low SES, rural neighborhood)
also have disparities in monoclonal antibody treatment.
The dependent variable in the study is rate of adjunct monoclonal antibody
treatment. A review of clinical trials and post-marketing observational studies indicate
that all three available antibodies increase progression-free survival or overall survival
when added to chemotherapy (Bruera et al., 2013, Cunningham et al., 2013; Naeim et al.,
2013). Therefore, as with chemotherapy, it is possible that disparities in monoclonal
antibody treatment could contribute to disparities in colorectal cancer survival.
There are three independent variables in this study. Each independent variable
was selected due to its association with colorectal cancer survival. The first independent
variable is race. There are many key studies that have associated race with increased risk
of colorectal cancer death (Simpson et al., 2013; Sineshaw et al., 2014; Wallace et al.,
2013; Wassira et al., 2013). The second independent variable is SES. As with race,
many studies have associated low SES with increased risk of colorectal cancer death
(Hines et al., 2014; Oliphant et al., 2013b; Wassira et al., 2013). The third independent
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variable is neighborhood characteristics. Although less well researched, two studies have
identified rural neighborhood as a risk factor for reduced colorectal cancer survival
(Henry et al., 2009; Lian et al., 2011).
Summary and Conclusion
As outlined in the literature review above, colorectal cancer survival disparities
based on race, SES, and neighborhood characteristics have been observed in many
different studies. Specifically, Black Americans have reduced colorectal cancer survival
rates compared to White Americans (Simpson et al., 2013; Sineshaw et al., 2014;
Wallace et al., 2013; Wassira et al., 2013), low SES populations have reduced colorectal
cancer survival rates compared to higher SES populations (Hines et al., 2014; Oliphant et
al., 2013b; Wassira et al., 2013), and rural populations have reduced colorectal cancer
survival rates compared to urban populations (Henry et al., 2009; Lian et al., 2011).
In order to address these colorectal cancer survival disparities, it is important to
address the potential underlying causes of these disparities. Historical research into the
underlying causes of colorectal cancer survival disparities can be lumped into three main
categories; access to care disparities, screening disparities, and treatment disparities. This
study aims to fill a gap and expand on potential treatment disparities in colorectal cancer.
Multiple articles have highlighted disparities in both type and aggressiveness of
colorectal cancer therapies (surgery, radiation, and chemotherapy) (Bakogeorgos et al.,
2013; Obeidat et al., 2010; Serra-Rexach et al., 2012). Although these studies have
provided valuable information on colorectal cancer treatment disparities, including
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disparities in elderly populations, they were conducted using patient data from the 1990s
and early 2000. The colorectal therapies employed during this period included surgery,
radiation and chemotherapy. Beginning in 2004, monoclonal antibody therapies for
colorectal cancer came onto the market (Scott et al., 2012). Prior to this research project,
it was unknown if these historical treatment disparities had extended to the newer
monoclonal antibody therapies.
Determining if disparities in monoclonal antibody treatment of elderly metastatic
colorectal cancer patients exist is a critical first step to eliminating these social
inequalities. If racial, SES, or neighborhood disparities are found, future studies could
determine if these disparities contribute to any observed disparities in survival.
Additionally, if treatment disparities are found, this would illuminate the need for policies
that improve access to monoclonal antibodies, thereby helping reduce social inequalities
in colorectal cancer survival. Alternatively, if treatment disparities are not found, an
opportunity exists to understand the root cause of the reduced treatment disparities, and
this knowledge could potentially be used to reduce treatment disparities in other cancer
populations.
The next chapter outlines the specific study design aimed at addressing the
literature gap described above. The study methodology and statistical analysis plans will
also be described in detail.
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Chapter 3: Research Method
Introduction
In this chapter I describe, in detail, the methodology for this research project.
This includes information regarding the design and the rationale behind the chosen
design. Additionally, the archived dataset (SEER-Medicare) that was used is described
and justified. All variables (independent, dependent, and covariate/control) are identified
and operationalized. Detailed information about the coding and location of these
variables is also provided. I also describe the study population and the sample selection
protocol that was used (including inclusion and exclusion criteria and power analysis).
Additionally, within this chapter, the analysis procedure used is outlined. This includes
justification of the software analysis chosen (SPSS) and details on the descriptive and
inferential statistical methods. Finally, information regarding internal, external,
construct, and statistical validity, in addition to ethical practices, is presented.
Research Design and Rationale
In this section, I outline, in detail, the study research design and rationale. This
includes the selected independent, dependent, and control variables and the time/resource
constraints.
Research Design
Study variables. The independent, dependent, and control variables used in this
research project are described in detail below. For each variable, the location of the data
and data codes are listed.
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Independent variables. There were three research questions and three total
independent variables included in this research project. All of the independent variables
are available from the PEDSF (NCI, 2015c). The PEDSF is linked by a 10 digit patient
ID (column #1 in the PEDSF document; patient_id) to the four Medicare claims files
used in this research project.
The first research question addressed racial/ethnic disparities in first-line
monoclonal antibody treatment. Therefore, race was the first independent variable. For
this research project, race was identified using the SEER race recode as listed in column
#101 of the PEDSF (rac_recb); 1 = Caucasian, 2 = Black, 3 = American Indian/Alaska
Native, 4 = Chinese, 5 = Japanese, 6 = Filipino, 7 = Hawaiian, 8 = Other Asian or Pac.
Islander, 9 = Unknown, 11 = Caucasian, Spanish origin or surname, 12 = Other
unspecified (NCI, 2015c). Given the low representation of some of the races in the
cohort, American Indian/Alaska Native persons were excluded from the race analysis,
and Chinese, Japanese, Filipino, Hawaiian and Other Asian or Pacific Islander groups
were pooled into a single group entitled Asian or Pacific Islander.
The second research question addressed SES disparities in first-line monoclonal
antibody treatment. As in an article by Schlichting et al. (2012), the census tract poverty
level was used to estimate of SES. This variable is located in column #146
(census_pov_ind) in the PEDSF document and lists census track poverty as 1 = 0% to <
5% poverty, 2 = 5% to < 10% poverty, 3 = 10% to < 20% poverty, 4 = 20% to 100%
poverty, 9 = unknown (NCI, 2015c).
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The final research question addressed neighborhood (degree of urbanization)
differences in first-line monoclonal antibody treatment. The PEDSF document includes
the 2003 Rural/Urban Continuum Codes from the ERS, which categories counties on an
urban/rural scale based on population size, degree of urbanization, and adjacency to a
metro or nonmetro area (NCI, 2015c). The PEDSF recode of these values was used for
this research project. This is column #97 (urbrur) in the PEDSF document and identifies
county of residence as 1 = Big Metro, 2 = Metro, 3 = Urban, 4 = Less Urban, 5 = Rural,
and 9 = Unknown (NCI, 2015c).
Dependent variable. There were several research questions built into this
research project. However, each research question addressed the independent variable’s
association with the percentage of elderly (65 years+) metastatic colorectal cancer
patients who receive first-line adjunct monoclonal antibody therapy. Therefore, the
dependent variable for these research questions was receipt of first-line adjunct (in
combination with chemotherapy) monoclonal antibody therapy, “yes” or “no.”
There are three monoclonal antibodies (bevacizumab, cetuximab, and
panitumumab) currently approved for first-line treatment of patients with metastatic
colorectal cancer when given in combination with chemotherapy (Amgen, 2014; BristolMyers Squibb & Eli Lilly and Company, 2013; Genentech, 2013). These monoclonal
antibodies can be covered by Medicare Part B (if administered at an outpatient clinic or a
physician’s office) or Medicare Part D (if administered as a prescription drug from a
specialty pharmacy). Therefore, this information was obtained from the Medicare PDE
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dataset, the Medicare Outpatient Claims dataset, and the Medicare Carrier Claims dataset.
The DME dataset was not used for this variable as data for these three drugs is not
present within this dataset.
In the PDE dataset, the brand name for each monoclonal antibody (Avastin,
Erbitux, or Vectibix) is listed in column #90 (BN). In addition the following NDC codes
for the administered drug will be present in column #35 (PROD_SRVC_ID) of the PDE
dataset (NCI, 2015b):
•

Bevacizumab (Avastin): 50242006001 or 50242006101 (293 patients from
2007-2012)

•

Cetuximab (Erbitux): 66733094823 or 66733095823 (59 patients from 20072012)

•

Panitumumab (Vectibix): 55513095401 or 55513095601 (23 patients from
2007-2012)

In the Carrier Claims and Outpatient Claims dataset, receipt of one of the
monoclonal antibodies is listed as a “J” HCPCS code (columns #93 in the Carrier Claims
data set or columns #241 in the Outpatient Claims data set; NCI, 2015b):
•

Bevacizumab: J9035 (25,825 patients from 2007-2012)

•

Cetuximab: J9055 (7,004 patients from 2007-2012)

•

Panitumumab: J9303 (2,026 patients from 2007-2012)

First-line adjunct monoclonal antibody treatment was defined as at least one claim
for a monoclonal antibody (bevacizumab, cetuximab, or panitumumab) in one of the
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three files above within 1 month of first postdiagnosis chemotherapy claim (which must
have occurred within 6 months of diagnosis) as in Meyerhardt et al. (2012). Given the
need to compare claim dates to determine if monoclonal antibody was received within 1
month of chemotherapy, the drug dispense date for each monoclonal antibody claim was
also used. This is listed an MMDDYYYY in PDE dataset column #27 (srvc_mon,
srvc_day, srvc_yr) and in column #32 (from_dtm, from_dtd, from_dty) of the Outpatient
Claims and Carrier Claims datasets. For the purpose of this research project, the
dependent variable (first-line monoclonal antibody treatment) was recorded dichotomized
as “yes” or “no.”
Control variables. Multiple covariates were assessed to control for confounding.
The first covariate assessed was gender. This is column #41 (m_sex) in the PEDSF file:
1 = male, 2 = female. The second covariate was age at diagnosis. This is column #1881
in the PEDSF file. The third covariate was reason for original Medicare entitlement.
This is column #43 in the PEDSF file: 0 = Age, 1 = Disability (individuals with 2 = End
Stage Renal Disease or 3 = Disability/End Stage Renal Disease were excluded from the
study). The final covariate was which registry reported the data. This is indicated by the
first two digits in the patient ID (PEDSF column #1).
Research design. The specific aim of this study was to determine if there are
racial, SES, or neighborhood (degree of urbanization) disparities in first-line adjunct
monoclonal antibody treatment of elderly, Medicare-enrolled, metastatic colorectal
cancer patients. As monoclonal antibody therapy has been shown clinically to improve
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survival, it would be unethical to perform an intervention study to address these
questions. Therefore, the method used was strictly observational, using a retrospective
cohort quantitative research design. Specifically, individuals meeting the selection
criteria were selected from the SEER-Medicare colorectal cancer population as outlined
in the sample selection section of this document. Disparities in monoclonal antibody
treatment were then assessed across different populations (different SES levels, races,
and neighborhood characteristics) using logistic regression.
Rationale. All the research questions can be addressed using numerical values
and/or discrete categories for all variables. Therefore, quantitative research was the most
appropriate research design. Given the utility of the achieved SEER-Medicare database
to answer the research questions, I used only secondary data.
Time and resource constraints. I used data from the NCI’s SEER-Medicare
database. The SEER-Medicare database is a large population-based database that
contains matched medical claim records and demographic information for Medicare
beneficiaries who have been diagnosed with cancer (NCI, 2015a). Data from five files
within this database for years 2007 to 2012 (PEDSF 2007-2011 only) was accessed for a
reasonable fee ($1600). Data access required completion of a dissertation proposal,
International Review Board (IRB) approval, approval of an application by SEERMedicare oversight committee, and dissertation chair approval/completion of a data use
agreement (NCI, 2015e; E. Yanisko, personal communication, February 5, 2013).
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Use of a retrospective research design and archival data reduced the time
constraints associated with data collection. However, time constraints still existed. Upon
completion of a final data application (which required several iterations), approval by the
SEER-Medicare oversight committee took 4 weeks, and data acquisition took an
additional 3 weeks (E. Yanisko, personal communication, February 5, 2013). In all, it
took 4 months from submission of the first draft application to receipt of the final data
set. All the data obtained from SEER-Medicare were received uniformly coded and there
were training courses and support staff available to help with the extraction/compilation
process (E. Yanisko, personal communication, February 5, 2013).
Methodology
In this section, I describe the population used for this study and the procedures
used to sample that population. Since archival data were used and no new data were
collected on study subjects, this section does not contain procedures for new data
collection.
Population
The research questions addressed disparities in monoclonal antibody therapy of
elderly metastatic colorectal cancer patients. The specific population used for this study
was elderly (65+) individuals diagnosed with metastatic colorectal cancer between
January 2007 and December 2011, treated with first-line chemotherapy within 6 months
of diagnosis. Individuals with a previous cancer history and individuals with end stage
renal disease were excluded. Since monoclonal antibodies can be prescribed under
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Medicare Part B or D, to limit the impact of insurance coverage differences, the
population was limited to individuals with evidence of enrollment in Part B and D
Medicare. This population is about 65% of the Medicare population (MedPac, 2013).
Additionally, given that claims billed to Medicare HMOs (Medicare Part C; Medicare
Advantage) would not be included in the SEER-Medicare database, the study cohort was
limited to patient without HMO coverage. Given that metastatic colorectal cancer
patients have high mortality rates and the time from cohort selection (which required a
chemotherapy claim) to assessment of the dependent variable was only 1 month, to limit
unnecessary patient exclusion, continuous Medicare Part B and D enrollment was not
required.
Tumor resection (if possible) followed by chemotherapy (5-Fluorouracil,
Oxaliplatin, or Irinotecan) is the standard of care for metastatic colorectal cancer (NCI,
2015f). Monoclonal antibody therapy is indicated for first-line metastatic colorectal
cancer as an adjunct to chemotherapy. Given this, only individuals who received firstline chemotherapy, as indicated by a chemotherapy claim within 6 months of cancer
diagnosis, as in Meyerhardt et al. (2012), were included in the study population. Finally,
as previously stated, given that adjunct monoclonal antibody therapy is only approved for
metastatic colorectal cancer, the population of interest included only patients with
metastatic colorectal cancer.
In the United States, colorectal cancer accounts for 8.6% of all new cancer cases
and 8.8% of all cancer deaths (NCI, n.d.a). In 2010, 131,607 people in the United States
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were diagnosed with colorectal cancer (CDC, 2013). Colorectal cancer risk and mortality
rate increases with age, with the elderly being most affected by the disease (CDC, 2013).
In the United States, elderly individuals (65 years+) account for 60% of all new
colorectal cancer cases and 70.9% of all colorectal cancer deaths (NCI, n.d.a). In 2010,
approximately 79 thousand elderly (65+) individuals were diagnosed with colorectal
cancer (CDC, 2013). At diagnosis, the tumor in approximately 20% of patients has
already metastasized (Roswell Park Cancer Institute, n.d.a). Therefore, the population of
elderly persons diagnosed per year with metastatic colorectal cancer is approximately
15.8 thousand.
In terms of prevalence, there are approximately 1.16 million people living with
colorectal cancer in the United States (NCI, n.d.a). Of all individuals diagnosed and
being treated for colorectal cancer, it is estimated that 55% of these individuals have
metastasized tumors (Roswell Park Cancer Institute, n.d.). Therefore, the population of
individuals living with metastasized colorectal cancer is approximately 638,000, with the
majority of these individuals over the age of 65.
Sampling and Sampling Procedures
The sampling strategy was carefully designed to eliminate as many confounding
variables as possible. The detailed sampling procedures are described in the following
section.
Sampling procedures. SEER-Medicare datasets for colon and rectal cancer
patients from 2007 to 2011 (PEDSF) and 2007 to 2012 (Outpatient Claims file, DME file,
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Carrier Claims File and PDE file) were received from the NCI. These datasets included
clinical and demographic data from all SEER district reported colorectal cancer cases
(NCI, 2015c). In order to be included in the study, an individual must have met the
following inclusion and exclusion criteria:
•

First colorectal cancer diagnosis at or after 65 years of age (PEDSF column
#1881; Age at Diagnosis).

•

First diagnosis of colorectal cancer occurred between January 2007 and
December 2011 (PEDSF column #1888; Year of Diagnosis).

•

Cancer sequence number (number of primary tumors the individual had been
diagnosed with up to and including their colorectal cancer diagnosis) of 00 or
01 indicating that the colorectal cancer tumor was their first primary tumor
(PEDSF column #1884).

•

Covered by Medicare Part B for at least 1 month during the year of diagnosis
(PEDSF columns #548). Value >/= 1 for diagnosis year. Presence of a
chemotherapy claim in one of the Part B files (DME, Carrier Claims or
Outpatient Claims) was also required for inclusion and demonstrates
coverage.

•

Covered by Medicare Part D for at least 1 month during the year of diagnosis
(PEDSF column #221). Value >/= 1 for diagnosis year.
o Monoclonal antibody therapy can be covered under Medicare Part B or
Medicare Part D. Therefore, this selection criterion is included to help
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ensure complete medical records for all study participants and limit the
impact of insurance coverage on the disparity measures.
•

Not Enrolled in a Medicare managed care plan during the year of diagnosis
(Medicare Part C) (PEDSF column #550; HMO Months). Any number other
than 00 for both the year of diagnosis and the year of treatment will result in
exclusion.
o Managed care plans enrollees have their claims processed by the
managed care entities, not Medicare. Thus, these claims will not be in
the SEER-Medicare data.

•

Colorectal cancer had undergone metastasis at diagnosis (PEDSF column
#1953; CS Mets at Dx). Specifically, individuals with codes 00 (none/no
distant metastasis) or 99 (unknown/distant metastasis not stated) will be
excluded.
o Monoclonal antibodies are only approved for use in metastatic
colorectal cancer patients.

•

Patients that qualified for Medicare due to End Stage Renal Disease were
excluded (PEDSF column #43; rsncd1). Individuals with codes of 2 or 3 were
excluded.

•

Given chemotherapy up to 31 days before or 6 months after of diagnosis as
determined by comparing diagnosis date (PEDSF column #1886 = Month of
Diagnosis; PEDSF column #1888; Year of Diagnosis) to the first
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chemotherapy claim date. Given that no day of the month is listed for
diagnosis, the diagnosis day was set to the last day of the diagnosis month to
ensure all within 6 months of diagnosis chemotherapy claims were captured.
Chemotherapy receipt was defined as receiving any of the following as single
agents or in combination. The “J” HCPCS codes are listed in columns #93 in
the Carrier Claims data set, column #93 in the DME dataset, or columns #241
in the Outpatient Claims data set (NCI, 2015b). The NDC codes are located
in column #409 in the DME dataset (NCI, 2015b). Date of receipt was
defined using the Claim From Date located in column #32 of all three datasets
(NCI, 2015b). Only the earliest chemotherapy claim and claim date for each
individual was recorded.
o 5-fluorouracil (5-FU):
HCPCS = J9190
NDC Codes = 00703301513, 00703301812, 00703301912,
10139006301, 10139006310, 10139006311, 10139006312,
10139006320, 10139006350, 63323011710, 63323011720,
63323011751, 63323011761, 66758004401, 66758004403
o capecitabine:
HCPCS = J8520, J8521
NDC Codes = 00004110020, 54868414300, 54868414301,
54868414302, 00004110150, 00004110175, 54868526000,
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54868526001, 54868526002, 54868526003, 54868526004,
54868526005, 54868526006, 54868526007, 54868526008,
54868526009
o leucovorin:
HCPCS = J0640
NDC Codes = 00703279301, 00703279701, 00703514001,
00703514501, 00703514591, 00904231560, 25021081310,
25021081430, 25021081530, 25021081567, 25021081630,
25021081667, 55390000901, 55390005110, 55390005210,
55390005301, 55390005401, 55390081810, 55390082401,
55390082501, 55390082601, 62701090030, 62701090099,
62701090125, 63323071050, 63323071100
o floxuridine:
HCPCS = J9200
NDC Codes = 55390013501, 63323014507
o oxaliplatin:
HCPCS = J9263
NDC Codes = 00024059010, 00024059120, 00024059240,
00069006701, 00069007001, 00069007401, 00069101001,
00703398501, 00703398601, 25021021120, 25021021250,
41616017640, 41616017840, 47335017640, 47335017840,
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61703036318, 61703036322, 63323017530, 63323017650,
63323065010, 63323065017, 63323065020, 63323065027
o irinotecan
HCPCS = J9206
NDC Codes = 00009111101, 00009111102, 00009752901,
00009752902, 00009752903, 00009752904, 00009752905,
00143970101, 00143970201, 00703443211, 00703443411,
10019093401, 10019093402, 10019093417, 10019093479,
10518010310, 18111000202, 18111000203, 23155017931,
23155017932, 25021020002, 25021020005, 25021021402,
25021021405, 55390029501, 55390029601, 59762752902,
61703034909, 61703034916, 61703034936, 63323019302,
63323019305, 66758004801, 66758004802
Power Analysis
This section describes the G*Power analysis used to estimate sample size required
for each of the three research questions. This section also provides justification for the
effect sizes, alpha level, and power level chosen.
Alpha level. I used an alpha level 0.05 for this study. In social sciences, an alpha
level of 0.05 is often employed (Web Center for Social Research Methods, 2006). This is
because an alpha level of 0.05 represents a compromise between Type I and Type II
error. This alpha level allows for a 5% chance that the null hypothesis will be rejected
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when it is true (i.e. there is no difference between groups; Type I error) (Web Center for
Social Research Methods, 2006). Additionally, being conservative and not setting the
alpha level too low reduces the risk of Type II error or failing to reject the null hypothesis
when it is false (Web Center for Social Research Methods, 2006). Finally, given that the
research questions ask if there is a difference between groups and do not specify
directionality, a two tailed analysis was used.
Effect size and power level. In G*Power version 3.1.9.2 (Faul, Erdfelder,
Buchner, & Lang, 2009) the effect size is represented as an odds ratio, the average
probability of “yes” to the dependent variable (in this case monoclonal antibody
treatment), and a specified power level. Although it’s never been researched, it is
reasonable to hypothesize that the racial, SES, and neighborhood (degree of urbanization)
differences in monoclonal antibody treatment will mimic historical differences in other
colorectal cancer treatments. This hypothesis is in line with the Fundamental Cause
Theory which states that even with changing resources, it is the beneficial social
connections that serve to protect health regardless of the resource mechanism (Phelan et
al., 2010). In other words, groups that showed chemotherapy, radiation, or surgery
treatment disparities might show similar monoclonal antibody treatment disparities.
For SES odds ratio estimation, Lejeune et al. (2010) cites the difference in
adjusted treatment rates (surgery, radiation, or chemotherapy) between high and low SES
districts as 1.15. However, in Hines et al. (2014), the difference in chemotherapy rates
comparing high to low SES districts was greater (OR = 0.83). Given that the degree of
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disparity differs between the two studies, to be conservative, 1.15 was used as the odds
ratio estimate for SES differences. In terms of racial disparities, Obeidat et al. (2010)
determined that Black Americans were less likely than White Americans to receive newer
chemotherapy options (OR = 0.641). However, White (2008) found more modest
differences between Black Americans and White Americans in terms of chemotherapy
receipt (OR = 0.85). Therefore, for this power analysis, a conservative OR of 0.85 was
used. For urban/rural disparity estimation, the Hines et al. (2014) article found that
chemotherapy rates differed comparing urban to rural districts (OR = 0.84). Therefore,
an odds ratio of 0.84 was used for this final power analysis.
In addition to the odds ratios, G*Power also requires the average probability of
receiving treatment. In an observational study conducted using 2006 treatment data,
Renouf et al. (2011) found that 30.6% of metastatic colorectal cancer patients received
adjunct bevacizumab. Therefore, given that this study is assessing 2007 to 2012
treatment data, a conservative probability of 0.306 was used.
Finally, adjunct monoclonal antibody treatment of colorectal patients is
hypothesized to vary by race, SES and neighborhood (degree of urbanization). However,
it is unlikely that any of these variables fully explain differences in treatment. When the
magnitude of the expected outcome is unknown, Cohen (1988) suggests selecting a
medium power level of 0.5. This medium power level (0.5) means that 6% of the
variance in treatment is explained by the independent variable (Cohen, 1988). This
power level was used for the research questions.
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Independent variable association with control variables. For all three research
questions, there are four control variables planned into the logistic model. An R2 for the
relationship between the primary independent variable and the control variables must be
defined for the power analysis. A literature search did not return data on the correlation
between the independent variables (race, SES, neighborhood characteristics) and the
control variables (gender, age at diagnosis, reason for original Medicare entitlement, and
reporting registry) in this elderly metastatic colorectal cancer population. Therefore, for
the purpose of this analysis, a value representing (by convention) a medium correlation
(R = 0.3) was selected. Thus, the R2 value for the relationship between the independent
variable in each research question and the control variables was set at (0.3)2 = 0.09.
Power analysis. This research study has three different research questions and
three different independent variables, all tested as a predictors of a binary outcome
variable (monoclonal antibody treatment; yes or no) using logistic regression. Each
independent variable has a different expected odds ratio. Therefore, three different power
analyses were performed.
Utilizing the information above regarding available alpha level, effect size, power
level and association with control variables, the software program G*Power was used to
estimate required sample size for this logistic regression analysis (Faul, et al., 2009). The
inputs and outputs of this analysis are represented in Appendix C.
Estimated available sample size. According to the NCI (2015d), the number of
newly diagnosed colorectal cancer patients in the SEER dataset was 12,062, 11,489, and
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10,564 in 2007 to 2009 respectively. This is an average of 11,372 new cases per year. In
order to be included in this count the patients had to be enrolled in both Medicare Part A
and Medicare Part B (NCI, 2015d). Since this research study is limited to patients
enrolled in Medicare Part B and D (approximately 65% of the Medicare population), the
number of patients meeting the study selection criteria is approximately 7,392 patients
per year. This study cohort included individuals diagnosed over five years (2007-2011).
Therefore, within the SEER dataset (2007-2011), an estimated 36,960 will be colorectal
cancer patients enrolled in Medicare Part B and D. Approximately 20% of these patients
were expected to be excluded due to enrollment in Medicare managed care/HMO,
leaving approximately 29,568 patients. This sample is further reduced as this study only
addresses treatment in patients diagnosed with metastatic colorectal cancer. If an
estimated 20% of these patients were diagnosed with metastatic colorectal cancer, the
expected available sample size for this study over the years 2007 to 2011 is 5,914. The
sample size will be limited once more by the number of patients receiving first-line
chemotherapy. If an estimated 50% receive first-line chemotherapy, this would result in
a sample size of 2,957.
The actual final sample size was 2,241, slightly lower than estimated. However,
the sample size is still significantly above the size required for all three research
questions (1029, 764, and 666 respectively) with a power of 0.5.
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Procedures for Recruitment, Participation, and Data Collection
As stated above, since archival data were used and no new data were collected on
study subjects, this section does not contain procedures new data collection. However,
this section provides detailed information on the SEER-Medicare database and how the
data were accessed.
Data access. This study used data from the NCI’s SEER-Medicare database.
The SEER-Medicare database is a large population-based database that contains matched
medical claim records and demographic information for Medicare beneficiaries who have
been diagnosed with cancer (NCI, 2015a). The process for requesting the data is outlined
in detail on the SEER Medicare website (NCI, 2015g). Specifically, for this project, an
application form (Appendix A), a SEER-Medicare data use agreement (Appendix B), and
proof of Institutional Review Board (IRB) approval were submitted (NCI, 2015g). Upon
application approval, the data needed for these research questions for years 2007 to 2012
was accessed for a reasonable fee ($1600). The five data files obtained were the Part D
Event (PDE) dataset, the Durable Medical Equipment (DME) dataset, the Carrier Claims
dataset, the Patient Entitlement and Diagnosis Summary File (PEDSF) and the Outpatient
Claims dataset. All colorectal cancer patient data within these five files from 2007 to
2012 (PEDSF 2007-2011 only) was obtained.
SEER-Medicare sample information. The SEER-Medicare database is a unique
research-oriented database resulting from the linkage of the Surveillance, Epidemiology,
and End Results (SEER) cancer registries database and the Medicare enrollment and
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claims data files (NCI, 2015a; Warren et al., 2002). The cancer diagnosis and
demographic information within the SEER-Medicare database comes from the SEER
program. The SEER program includes NCI contracted registries in Connecticut, Iowa,
New Mexico, Utah, Hawaii, Georgia, Louisiana, New Jersey, Puerto Rico, Kentucky and
California (NCI, n.d.a). These registries represent approximately 28% of the U.S. cancer
population (NCI, 2013). When the SEER database is linked to the Medicare claims
databases, such as in the SEER-Medicare dataset, researchers have access to data that
includes incidence, cancer site, stage, histology, demographics, medical procedures,
initial treatments, and vital status (NCI, n.d.a). Starting in 2007, SEER began linking the
Medicare Part D (PDE) file which allows researchers to perform prescription drug
research (NCI, 2013). In total, there are 1.6 million persons with cancer included in the
dataset and over 900 publications using the dataset (NCI, 2013).
Instrumentation. Given that archived data were used, no instrumentation was
used for the current study. All the data within the SEER-Medicare linked database comes
from either cancer registry documents or Medicare claim forms. In the case of the SEER
program (cancer registry documents), data collection is both passive and active. After
hospitals, clinicians and pathologists collect the data, SEER registry personnel actively
perform follow-ups to collect data or passively collect data through state databases (NCI,
2011). Once data is compiled by the registries, they incorporate mortality data from the
National Center of Health Statistics, Medicare claims records, and information from the
U.S. Census Bureau (NCI, 2011). Subsequently quality checks are implemented to
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ensure all the data has been linked appropriately and the data is then de-identified (NCI,
2011).
Given that hospitals, clinicians, and pathologists are responsible for accurate
reporting and coding of SEER data, there is the potential for missing or inaccurate data.
There are multiple published studies that have assessed the reliability and the validity of
different subsets of the SEER-Medicare data. Du et al. (2008) assessed the validity and
reliability of the SEER report on breast cancer chemotherapy. In this assessment, the
authors reviewed medical charts from 1228 women diagnosed with breast cancer and
compared these results to the SEER-Medicare reports (Du et al., 2008). For patients who
did not receive chemotherapy, the SEER-Medicare data agreed with the chart review over
99% of the time (Du et al., 2008). For the women listed as receiving chemotherapy in the
SEER-Medicare dataset, the authors were able to find strong evidence for chemotherapy
in the chart review for 97% of the cases, indicating strong validity (Du et al., 2008). In a
separate analysis, Du et al. (2008) list the overall reliability (kappa) of the SEERMedicare breast cancer chemotherapy data as 0.69 (95% confidence interval = 0.630.76).
Mahnken et al. (2008) assessed the completeness of the SEER-Medicare database
for Oral and Pharyngeal Cancer. When comparing to the SEER limited-use dataset, the
authors found that 6.4% of the incident cases were missing from the larger SEERMedicare linked database (Mahnken et al., 2008). The completeness of the data did vary
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nonsignificantly by race and ethnicity and could be partly explained by differences in
Medicare coverage (Mahnken et al., 2008).
Operationalization of constructs. All of the variables used in this research
project are available within the PEDSF (Patient Entitlement and Diagnosis Summary
File), the Outpatient Claims dataset, the DME (Durable Medical Equipment) dataset, the
Carrier Claims dataset or the Part D Event (PDE) dataset (NCI, 2015c). The independent
and dependent variables are operationalized below. The control/covariate and selection
variables have been described in detail in the previous sections.
•

Race: Identified as listed in column #101 of the PEDSF (rac_recb);
1=Caucasian, 2=Black, 3=American Indian/Alaska Native, 4=Chinese,
5=Japanese, 6=Filipino, 7=Hawaiian, 8=Other Asian or Pac. Islander,
9=Unknown, 11=Caucasian, Spanish origin or surname, 12=Other unspecified
(NCI, 2015c).

•

Socioeconomic Status: The PEDSF Census Tract Poverty Indicator will be
used as an estimation of SES. This is column #146 (census_pov_ind) in the
PEDSF document and uses data from the 2010 Census (NCI, 2015c).

•

Neighborhood characteristics (degree of urbanization): This will be defined
using the 2003 Rural/Urban Continuum Codes from the Economic Research
Service (ERS), which categories counties on an urban/rural scale based on
population size, degree of urbanization and adjacency to a metro or nonmetro
area (NCI, 2015c). The PEDSF re-code of these values will be used for this

104
research project. This is column #91 (urbrur) and identifies county of
residence as 1=Big Metro, 2=Metro, 3=Urban, 4=Less Urban, 5=Rural,
9=Unknown (NCI, 2015c).
•

Monoclonal antibody therapy (yes/no): Receipt of bevacizumab, cetuximab
or panitumumab (as identified by a claim in the PDE, Carrier Claims, or
Outpatient dataset) within 1 month of first post-diagnosis chemotherapy
claim. Location and codes for each file are described below.
o PDE dataset: The brand names for the three monoclonal antibodies
(Avastin, Erbitux, Vectibix) will be listed in column #90 (BN). In
addition, the following NDC codes for the administered drug will be
present in column #35 (PROD_SRVC_ID): bevacizumab
(50242006001 or 50242006101), cetuximab (66733094823 or
66733095823), panitumumab (55513095401 or 55513095601).
o Outpatient Claims dataset: Receipt of one of the monoclonal
antibodies will be listed as a “J” HCPCS code in column #241 (hcpcs):
bevacizumab (J9035), cetuximab (J9055), panitumumab (J9303).
o Carrier Claims dataset: Receipt of one of the monoclonal antibodies
will be listed as an HCPCS code (above) in column #93.
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Research Questions and Hypothesizes
RQ1: Within the population of elderly (65 years+) individuals diagnosed with
metastatic colorectal cancer from January 2007 to December 2011, are there racial
disparities in first line adjunct monoclonal antibody treatment?
H01: There is no significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody treatment based on race.
Ha1: There is a significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody treatment based on race.
RQ2: Within the population of elderly (65 years+) individuals diagnosed with
metastatic colorectal cancer from January 2007 to December 2011, are there
socioeconomic disparities in first line adjunct monoclonal antibody treatment?
H02: There is no significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on area socioeconomic status (as defined by
the PEDSF census tract poverty indicator).
Ha2: There is a significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on area socioeconomic status (as defined by
the PEDSF census tract poverty indictor).
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RQ3: Within the population of elderly (65 years+) individuals diagnosed with
metastatic colorectal cancer from January 2007 to December 2011, are there
neighborhood characteristic (degree of urbanization) disparities in first line adjunct
monoclonal antibody treatment?
H03: There is no significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on neighborhood characteristics.
Ha3: There is a significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on neighborhood characteristics.
Data Analysis Plan
In this section, I describe, in detail, the analysis plan used for this research project.
This includes the software packages that were used for data compilation, management
and analysis, how sample selection occurred, and the statistical methods that were
employed.
Hardware
The SEER-Medicare datasets and all raw analysis files were stored on a server
leased from Hivelocity and accessed remotely over a secure firewall using VPN. The
Hivelocity server had a 2 x 1000GB Hard Drive with 2 x 2.26GHz Quad-Core L5520
Nehalem Xeon Processor and 72GB DDR3 Memory. The operating system was
CentOS7.
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Software
Python 2.7.5, MySQL 5.6.24 Community Server, MySQL Workbench 6.3.3.0 and
BASH (BourneAgain SHell) were employed to create a database to allow access to the
data, compile needed variables into tables and select the study cohort based on the listed
inclusion and exclusion variables. Data for the selected cohort was then imported into
IBM SPSS Statistics 21 and SPSS was used for subsequent descriptive and inferential
statistical analyses (IBM, n.d.). For this research project, it was necessary to compile,
sort and select data from ~100,000 total cases. Therefore, a high capacity, effective data
management program such as MySQL and Python with the ability to query, select and
split datasets was critical. Additionally, SPSS was capable of performing logistic
regression analyses (IBM, n.d.), as was required by this project.
Data Preparation
Prior to analysis, the data needed to be organized and the cohort needed to be
selected. A pictorial representation of the methods followed during the cohort selection
process can be found in Figure 1 and the step by step details can be found in Appendix D.
Additionally, the exact code used for each step is documented in Appendix D.
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Figure 1. Pictorial representation of the software used and files generated during the
cohort selection process.
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After the data were compiled and the preliminary cohort was selected using the
steps outlined above, the all variables needed for the selected cohort will be imported into
SPSS. The variables transferred to SPSS, including several computed variables are
documented in Appendix E.
At this point, the cohort in SPSS had already been selected on the following
variables:
1. Cases with diagnosis dates from January 2007 to December 2011.
2. Cases with an age at diagnosis of 65 or over.
3. Cases with a sequence number of 00 or 01 (first primary tumor).
4. Cases with cancer metastasis at diagnosis.
5. Evidence (at least 1 month in the diagnosis year) of Medicare Part B and
Medicare Part D enrollment.
6. No HMO coverage in the year of diagnosis.
7. Chemotherapy received within 6 months of diagnosis.
Once the data were in SPSS, individuals with Medicare entitlement due to End
Stage Renal disease (Reason for original Medicare entitlement codes 2 or 3) were
excluded. Additionally, any patient with a chemotherapy claim more than 31 days before
diagnosis were excluded. Using the computed column “days” (6a in Appendix D –
indicates days from first post diagnosis chemotherapy claim to first monoclonal antibody
claim), individuals with a monoclonal antibody within 1 month (31 days) of their
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chemotherapy claim date were coded as “yes” in the “Monoclonal antibody” column, all
others were coded as “no”.
As a final step in data preparation, codes for each variable were defined (e.g., 1 =
male, 2 = female) in the variable view section of SPSS. In addition variable type
(categorical or continuous) was defined in the variable view. Once all variables were
defined, data analysis (descriptive and inferential) began.
Statistical Tests
This section will describe, in detail, the statistical tests that employed to answer
the research questions. Statistical assumptions and interpretation of outputs will also be
discussed.
Descriptive statistics. Descriptive statistics in SPSS were used to understand
sample distribution. Specifically tables and/or figures were generated to document
distribution of the sample in terms of race, gender, age at diagnosis, SES, neighborhood
characteristics (degree of urbanization), reporting registry, and reason for original
Medicare entitlement over the study period (2007-2011) and by diagnosis year.
Additionally, also using SPSS, frequency tables were generated to relate the
independent/control variables to the dependent variable as outlined below:
•

Frequency of monoclonal antibody therapy by gender.

•

Frequency of monoclonal antibody therapy stratified by reporting registry.

•

Frequency of monoclonal antibody stratified by reason for original Medicare
entitlement (age or disability).
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•

Frequency of monoclonal antibody therapy stratified by age at diagnosis.

•

Frequency of monoclonal antibody therapy by year of diagnosis.

•

Frequency of monoclonal antibody therapy by race.

•

Frequency of monoclonal antibody therapy across SES ranges (as defined
using the Census Tract Poverty Indicator)

•

Frequency of monoclonal antibody therapy stratified on neighborhood
characteristics (degree of urbanization as defined using the 2003 Rural/Urban
Continuum code)

Inferential statistics. Logistic regression is used to model a dichotomous
outcome variable (in this case receipt of monoclonal antibody, “yes” or “no”) based on
other predictor variable(s) (Burns & Burns, 2008). The output of logistic regression
predicts which dependent variable group a sample should reside in based on the
independent variable(s) (Burns & Burns, 2008). For example, in this study, using a
simple ANOVA, it is possible that race would predict (to a certain extent) the chance of
monoclonal antibody receipt. However, in this example, in order to determine if the
independent variable (race) is independently associated with the dependent variable
(monoclonal antibody receipt), the model will need to control for differences in these
covariates. In other words, is the association between the independent and dependent
variable still significant after adding the covariates to the model? Logistic regression
methods will allow this to be accomplished.
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There are two main assumptions that must be met in order use logistic regression.
First, the dependent variable must be dichotomous (Burns & Burns, 2008). The
dependent variable (monoclonal antibody therapy) is dichotomous, meeting this
assumption. Second, the categories must be mutually exclusive and exhaustive, because
a sample must only be in one group and every sample must be assigned to a group (Burns
& Burns, 2008). This assumption is also met with this data set. For all independent,
dependent and control variables every sample will fall within one (and only one) of the
categories. Burns and Burns (2008) also note that larger samples are often needed for
logistic regression and recommend at least 50 cases per predictor. For the analyses
described in Table 12, the maximum number of predictor variables will be seven. As
noted in the power section above, the sample size (2,241) exceeds this minimum number.
Logistic regression does not assume linear relationships between dependent and
independent variables, nor does it assume equal variance within groups or normal
distribution (Burns & Burns, 2008). Therefore, these conditions do not need to be tested
prior to analysis.
There are multiple logistic regression analyses performed on the study data given
the different research questions. All logistic regression analyses performed described in
Table 11. Covariate analyses to test for independent associations (analyses 4, 5 and 6 in
Table 11) were planned to be performed only if a significant association was found
between the independent variable and the dependent variable for that research question.
For example, if race is found to not associate with monoclonal antibody treatment in
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analysis 1, analyses 4 will not be performed as there will be no need to test for variables
confounding the relationship (as a relationship does not exist). For analysis 7, a final
logistic regression models was generated with any variable (independent or covariate)
that was determined to be significantly associated with monoclonal antibody treatment.
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Table 11
Logistic Regression Analyses
Analysis
#

Dependent
Variable

Analysis
1

Monoclonal
Antibody
Therapy
(yes/no)

Analysis
2

Monoclonal
Antibody
Therapy
(yes/no)

Analysis
3

Monoclonal
Antibody
Therapy
(yes/no)

Analysis
4

Analysis
5

Monoclonal
Antibody
Therapy
(yes/no)

Monoclonal
Antibody
Therapy
(yes/no)

Independent
Variable(s)

Covariates

Race (9
categories)
None
Neighborho
od
Characteristi
cs (5
categories)
None
SES; Census
Tract
Poverty
Indicator (4
categories)
None
Age at
diagnosis,
Gender,
Original
reason for
Medicare
entitlement,
Reporting
Race (9
registry,
Gender
categories)
Age at
diagnosis,
Gender,
Original
reason for
Medicare
Neighborho entitlement,
od: Rural/
Reporting
Urban (5
registry,
categories)
Gender

Sample exclusion
Patients with Race
Unknown or
Other/Unspecified
will be excluded
Patients with
neighborhood
characteristics
Unknown
will be excluded
Patients with
Census Tract
Poverty Indictor
Unknown will be
excluded

Rationale
Test association
between
race and
monoclonal
antibody receipt
Test association
between
neighborhood and
monoclonal
antibody receipt
Test association
between
area SES and
monoclonal
antibody receipt

Patients with Race
Unknown or
Other/Unspecified
will be excluded

Test for an
independent
association
between
race and
monoclonal
antibody receipt

Patients with
neighborhood
characteristics
Unknown
will be excluded

Test for an
independent
association
between
neighborhood and
monoclonal
antibody receipt
table continues
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Analysis
6

Analysis
7

Monoclonal
Antibody
Therapy
(yes/no)

Monoclonal
Antibody
Therapy
(yes/no)

Age at
diagnosis,
Gender,
Original
reason for
SES; Census Medicare
Tract
entitlement,
Poverty
Reporting
Indicator (4 registry,
categories)
Gender
Age at
diagnosis,
Gender,
Original
reason for
Race,
Medicare
Neighborho entitlement,
od
Reporting
Characteristi registry,
cs, SES
Gender

Patients with
Census Tract
Poverty Indictor
Unknown will be
excluded

Test for an
independent
association
between
area SES and
monoclonal
antibody receipt

Samples with
Unknown/Unspeci
fied independent
values will be
excluded

Generate a model
of association
using all
significant
variables
(independent and
covariate).

Covariates and Confounding Variables
Any control variable found to significantly associate with monoclonal antibody
treatment during covariate analysis in Chapter 4 was added to the logistic regression
analyses to control for confounding. There are four control variables/covariates being
controlled for in this research project. The first control variable was gender. Oliver et al.
(2013) cites weak correlations between receipt of chemotherapy or surgery and gender.
Specifically, women were slightly more likely than men to receive surgery (95.5% vs.
92.2%) and men were slightly more likely than women to receive chemotherapy (38.6%
vs. 45.2%) (Oliver et al., 2013). These treatment differences might extend to monoclonal
antibody therapy and it is therefore important to control for gender in the statistical
model.
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The second control variable was age at diagnosis. This study was limited to
individuals over 65 years of age. However, even in the over 65 age group, increasing age
has been correlated with treatment disparities. Fu et al. (2013) and Kozloff et al. (2010)
observed reduced adjunct bevacizumab treatment with increasing patient age. Therefore,
it was important to control for age at diagnosis in the model.
The third control variable was reason for original Medicare entitlement (age or
disability). Individuals with End Stage Renal Disease (ESRD) or disability + End Stage
Renal Disease were excluded. However, underlying disability has the potential to impact
treatment prescribed/received and needed to be included in the model.
The final control variable was which registry reported the data. Naishadham et al.
(2011) found state to state differences in progress toward reducing colorectal cancer
mortality from 1990-2007. Specifically, the southern states showed little to no
improvement, whereas the north-eastern states showed improvement often in excess of a
33% reduction in mortality (Naishadham et al., 2011). Therefore, it is possible that
geographic region (as indicated by reporting district) could impact treatment received.
Results Interpretation
Descriptive statistics. The planned descriptive statistical analyses were
presented in the statistical tests section of this chapter and are reported in frequency
tables in Chapter 4. These frequency tables stratify the cohort by each
independent/control variable and the dependent variable (monoclonal antibody
treatment).

117
Inferential statistics. The outputs of the logistic regression analyses described in
the statistical tests section of this chapter are log odds (b coefficients – slope values),
odds ratio (Exp(B)) and p-values. These values are located in the “Variables in the
Equation” table in the logistic regression SPSS output (Burns & Burns, 2008). The log
odds values (“b”) ranges from 0 to infinity and estimates the likelihood of the
membership in the target group (monoclonal antibody receipt = yes) versus the other
group (monoclonal antibody receipt = no) (Burns & Burns, 2008). For example, if “b”
was 0.04 for the independent variable SES (% below poverty level), then for every one
unit increase (percentage point) increase in SES, the increase in log odds of receipt of
monoclonal antibody receipt increases by 0.04. Negative log odds values mean the
relationship is negative (reduces likelihood of monoclonal antibody receipt) instead of
positive. Additionally, the Exp(b) has been reported. These are the odds ratios for the
predictors (independent variables). The odds ratios indicate the increased (or reduced)
chance of monoclonal antibody receipt based on the model of independent
variables/covariates. 95% confidence intervals for the odds ratios have also be generated
in SPSS. Odds ratios for each research question (race, SES, neighborhood
characteristics) were compared with and without covariate inclusion (if necessary) to
determine if the independent variable is independently associated with the dependent
variable (monoclonal antibody receipt).
A p-value (Sig.) for each logistic regression model has also been reported (Burns
& Burns, 2008). This value informs whether or not the model was significant for the
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independent variable and dependent variable in question. A p-value of less than 0.05 has
been considered significant.
Finally, two pseudo R Square values (Cox & Snell and Nagelkerke) have been
reported for each model. These variables are measures of model fit (values close to 0.0
are a poor fit; values close to 1.0 are a good fit).
Threats to Validity
Threats to External Validity
The external validity of this study could be threatened by population validity or
the ability to extrapolate the data to the larger U.S. elderly population. The SEER
database includes data from approximately 28% of the U.S. cancer population. However,
this sample comes from specific SEER funded cancer registries. These registries are
geographically dispersed, located in 13 different states. However, it is possible that the
ability to extrapolate the data obtained will be limited. It is unclear whether the data
within the SEER database is a true representation of the greater U.S. cancer population.
This threat cannot be avoided and will be noted in the limitations section of Chapter 5.
Given that this research is observation (nonexperimental) and used nonsubjective
medical record data, many of the other threats to external validity are avoided. For
example, ecological validity issues, interaction effect of testing issues, interaction effects
of selection biases and the experiment treatment, and reactive effects of experimental
arrangements are avoided due to the study design.
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Threats to Internal Validity
Internal validity could be threatened by confounding variables. To address this
potential issue, research into potential alternative causes of treatment disparities was
performed. Historical treatment associations with gender, age at diagnosis, and
geographical region (i.e. reporting registry) were found in the literature review.
Therefore, the logistic regression analysis included these three variables as covariates to
test for independent associations between the independent and dependent variables. In
addition, other health issues such as serious disability could influence treatment.
Therefore, in addition, the original reason for Medicare entitlement (age or disability)
was included as a covariate in the logistic regression model. Individuals who qualified
for Medicare due to end stage renal disease (ESRD) and individuals with a previous
cancer history were excluded from the study.
The internal validity of this study could also be threatened by maturation.
Maturation occurs when changes in the dependent variable occur over time. This study
used data over five years of cancer diagnoses and treatments. Therefore, it is possible
that the year of diagnosis could impact prescribed treatment. In other words, if fewer
individuals diagnosed in 2007 were prescribed a monoclonal antibody compared to
diagnosed in 2011, there could be higher levels of disparity in 2007 compared to 2011 (in
line with the Diffusions of Innovations Theory). To address this, monoclonal antibody
treatment rates have been analyzed by diagnosis year in Chapter 4. If a significant
difference exists, Chapter 5 will document a potential for maturation issues in the cohort.
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An additional threat to internal validity is sample selection. In the case of this
study, all SEER-Medicare colorectal cancer patients were included if they met the sample
selection criteria (there was no random selection from the SEER dataset). This reduces
selection bias threats. Additionally, the SEER sample is large (represents 28% of U.S.
cancer cases) also reducing issues associated with selection.
Experimental mortality is another potential threat to internal validity. This is
reduced through sample selection. Since treatment information is reported through the
Medicare claims datasets, only samples with evidence of Medicare Part B and Part D
enrollment in the year of diagnosis (as indicated by at least 1 month of coverage) were
included in the sample. In addition, individuals with any evidence of HMO plan
enrollment in the year of diagnosis were excluded as these individuals could have claims
not reported in the Medicare data files. Finally, presence of a chemotherapy claim was
also required for cohort selection, demonstrating coverage. This should reduce the
incidence of missing treatment data after diagnosis. Additionally, the timeframe from
cohort selection to measurement of the dependent variable (monoclonal antibody
treatment) was only 1 month. This short timeframe should also reduce experimental
mortality concerns.
Threats to Construct or Statistical Conclusion Validity
All of the variables used in this research study were explicitly operationalized to
reduce threats to construct validity. Many of the other threats to construct validity are
reduced due to the observational nature of this study. For example, there should be no
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interaction of different treatments, interaction of testing and treatment, evaluation
apprehension, or experimenter expectancy issues.
To increase statistical conclusion validity, great effort has been employed to
ensure the study was powered appropriately and that the statistical tests have not violated
any assumptions. In addition, the statistical analysis plan was explicitly laid out and
further analyses were not performed. This will ensure that the type I error rate is not
unnecessarily inflated.
Ethical Procedures
Given that this research utilized anonymized medical records and demographic
data, human and data ethnic concerns are minimized. However, the efforts to further
minimize human and data ethic concerns are described in the following sections.
Ethical treatment of humans. The ethical concerns surrounding this research
study are substantially minimized due to the use of anonymized archival data. No new
data collections were performed. Therefore, there are no ethical concerns surrounding
recruitment materials, data collection, or intervention activities. In addition, zip codes
were not requested, minimizing the chance that any data could be accidently unblinded.
All of the SEER-Medicare patient files received from the NCI were anonymized and no
attempt was made to de-anonymize the data. Finally, an approved IRB application was
completed prior to requesting the data.
Ethical treatment of data. All data received from the SEER-Medicare database
was pre-anonymized. The raw data were not shared with anyone not associated with this
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project (chair, co-chair, statistic support, etc.) and all researchers ensured that attempts to
de-anonymize data did not occur. The data were stored securely on a leased Hivelocity
server and accessed through a VPN firewall. All the data reported within this dissertation
document were aggregate data only; no individual or raw data has been shared publically.
There are no conflicts of interest associated with this study.
Agreements to gain access to data. In order to gain access to the SEERMedicare database, a proposal consisting of a data application, a data use agreement
(submitted documents in Appendix A and B) and proof of IRB approval was submitted to
the SEER-Medicare liaisons. The Walden University IRB approval (approval #12-11-140086341) was utilized to satisfy the IRB requirement. The data use agreement (DUA)
was required to be signed by the PhD scientist overseeing the research; in this case, Dr.
Raymond Panas (chair). This data application package was approved by the SEERMedicare (NCI) committee (Appendix F).
Summary
As outlined in the methodology plan above, this study was observational and used
archived colorectal cancer patient data available from the NCI’s (NCI) SEER-Medicare
database. This data within this database contains all information needed to answer the
three research questions regarding disparities in monoclonal antibody treatment.
A retrospective cohort study was performed using individuals diagnosed with
metastatic colorectal cancer between January 2007 and December 2011. The data were
compiled using MySql, Python and SPSS. The outlined sampling procedure limited the
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sample to elderly patients eligible for first-line adjunct monoclonal antibody therapy
(individuals with metastatic colorectal cancer given first line chemotherapy).
Additionally, the sampling procedure aimed to reduce the impact of insurance coverage
on claim availability in the dataset by excluding patient covered by managed care
organizations/HMOs (as their claims would not be billed through Medicare and would
not be represented in the SEER-Medicare dataset).
I present the results in Chapter 4 using descriptive statistics, frequency tables, and
logistic regression. Logistic regression is the appropriate inferential statistic due to the
dichotomous nature of the dependent variable (monoclonal antibody therapy, “yes” or
“no”). Covariate analyses were employed when necessary to determine whether or not
the independent variables are independently associated with the dependent variable.
Finally, validity and ethical concerns have been explicitly addressed.
Specifically, threats to internal, external, construct, and statistical validity have been
addressed and efforts have been taken to minimize threats and maximize the impact of
the data. Additionally, human and data ethical concerns have been discussed. The use of
archived, anonymized data reduces ethical concerns. However, steps were still taken to
protect the data and ensure the anonymized data remains anonymized and secure.
In the following chapter, I describe selection of the study cohort including
attrition at each inclusion/exclusion variable. Additionally, I present demographics of the
cohort, and descriptive statistics of the independent, control and dependent variables.
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Finally, logistic regression modeling is used to test the three research questions
surrounding disparities in adjunct monoclonal antibody treatment.
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Chapter 4: Results
Introduction
The purpose of this research study is to assess disparities (based on race, SES, and
neighborhood characteristics) in adjunct monoclonal antibody treatment of elderly
metastatic colorectal cancer patients. In this chapter, I will first outline the selection of
the study cohort, present the demographics of the study cohort, and use descriptive
statistics to relate the independent variables and the covariates to the dependent variable
(monoclonal antibody treatment). Subsequently, using the selected cohort and logistic
regression, the three research questions will be tested. The research questions along with
null and alternative hypotheses are outlined below:
RQ1: Within the population of elderly (65 years+) individuals diagnosed with
metastatic colorectal cancer from January 2007 to December 2011, are there racial
disparities in first line adjunct monoclonal antibody treatment?
H01: There is no significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody treatment based on race.
Ha1: There is a significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody treatment based on race.
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RQ2: Within the population of elderly (65 years+) individuals diagnosed with
metastatic colorectal cancer from January 2007 to December 2011, are there
socioeconomic disparities in first line adjunct monoclonal antibody treatment?
H02: There is no significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on area socioeconomic status (as defined by
the PEDSF census tract poverty indicator).
Ha2: There is a significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on area socioeconomic status (as defined by
the PEDSF census tract poverty indictor).
RQ3: Within the population of elderly (65 years+) individuals diagnosed with
metastatic colorectal cancer from January 2007 to December 2011, are there
neighborhood characteristic (degree of urbanization) disparities in first line adjunct
monoclonal antibody treatment?
H03: There is no significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on neighborhood characteristics.
Ha3: There is a significant association between the percentage of elderly (65
years+) metastatic colorectal cancer patients who receive first line adjunct
monoclonal antibody therapy based on neighborhood characteristics.
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Data Collection
In this research, I used secondary data from the NCI’s SEER-Medicare database
and thus was strictly retrospective and observational. Therefore, no treatments or
interventions were administered and no adverse events were identified. Additionally, all
of the data remained anonymized and no attempt was made to identify patients. As
requested by the NCI, to conserve anonymity, all data cells with less than 11 counts have
been masked.
The SEER-Medicare database is a large population-based database that contains
matched medical records and demographic information for Medicare beneficiaries who
have been diagnosed with cancer (NCI, 2015a). For this research project, a request was
made for five linked SEER-Medicare datasets containing data from colorectal cancer
patients for the years 2007 to 2012 (with the exception of the PEDSF with years 20072011 only). The first dataset, the PEDSF, is the primary SEER file and contains
demographics and information related to the patient’s cancer diagnosis (i.e., information
on cancer stage, diagnosis date, previous primary tumors; NCI, 2015b). The other four
datasets are all Medicare claims datasets. This included the PDE dataset, the Outpatient
Claims dataset, the DME dataset, and the Carrier Claims dataset. The PDE dataset
includes all drugs prescribed under Medicare Part D and the other three datasets
(Outpatient Claims dataset, the DME and the Carrier Claims dataset) contain all Part B
claims including diagnosis and procedure codes (NCI, 2015b). These five patients
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matched SEER-Medicare datasets contain information on all the variables required to
answer the research questions described above.
The data request/application process began in December, 2014 and required
several revisions and reviews. The specific concern from the NCI was in regard to data
security and storage. The original proposed plan (storage on a home server) and the
secondary plan (storage on the Walden server with access via sFTP) were unacceptable to
the protocol reviewers. The final approved application included plans to lease a secure
server at Hivelocity and access the data via VPN. The raw data files and the analysis
files were stored securely on a Hivelocity server throughout the data compilation/analysis
process. Only the final summary tables enclosed in this chapter were saved and shared
outside the secure server. The entire application process took 4.5 months and data were
received and uploaded to the server in April, 2015. Copies of the application and data
use agreement can be found in Appendix A and B.
Given that secondary data were used, there were no discrepancies in data
collection. However, during the application process, several study design
recommendations were received from the NCI. Specifically, the NCI recommended the
addition of NDC codes to the DME dataset query, the exclusion of patients with HMO
coverage, the exclusion of individuals with a history of other primary tumors, and the
exclusion of individuals with end stage renal disease. These changes were all made to the
study protocol and Chapter 3 was modified prior to cohort selection/data analysis.
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Cohort Selection
The study cohort was selected from a pool of 119,712 patients in the SEERMedicare database diagnosed with colorectal cancer from January 2007 to December
2012 using MySQL, Python, and SPSS. The methods for this process can be found in
Appendix D. A pictorial representation of cohort selection, including the number of
eliminated patients at each step in the selection process, is described in Figure 2. All
subsequent descriptive and inferential analyses are performed using the 2241 patients in
the cohort.
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Figure 2. Flow chart showing the selection of the study cohort based on multiple
different inclusion and exclusion criteria. The number of individuals excluded at each
step in the process is listed.

131
Demographics of the Study Cohort
The study cohort, as outlined in the cohort selection figure above, includes elderly
(65+) patients diagnosed with metastatic colorectal cancer between January 2007 and
December 2011 and given chemotherapy within 6 months of diagnosis (as evident by a
Medicare claim). Individuals included in the cohort had to have evidence of Part B
Medicare coverage (at least 1 month in the year of diagnosis), evidence of Part D
Medicare coverage (at least 1 month in the year of diagnosis), but no HMO coverage in
diagnosis year. Additionally, they could have no history of a previous primary tumor and
could not have been entitled to receive Medicare due to ESRD. The demographics of this
cohort are described in detail in Tables 14 through 20.
As described in Table 12, the cohort is 72% white with an additional 8.7% white
with Spanish origin or surname. The next most prevalent race is black, which makes up
10.7% of the cohort. For the purpose of this research question, due to low patient
numbers in some groups, all Asian and Pacific Islander races (Chinese, Japanese,
Hawaiian, Filipino and Other Pacific Islander) were combined into the group called
Asian or Pacific Islander. Three other SEER reported race categories, American
Indian/Alaska Native, Unknown, and Other Unclassified were excluded from the table
and subsequent analyses due to having a total of 11 patients or less over the years 2007 to
2011. Looking at the cohort over diagnosis years 2007 to 2011, the percentage of White
Americans and White Americans with Spanish origin or surname remains fairly
consistent; however, the percentage of Black Americans in the cohort almost doubles
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(from 7.4% to 13.8%) over the timeframe. The incidence of colorectal cancer in Black
Americans is known to be slightly higher than in White Americans and Black Americans
make up 13.5% of the United States population (NCI, n.d.b). Therefore, the percent of
Black Americans in the cohort could be low. However, given that the chemotherapy
rates in Black Americans in the general population over the years 2007 to 2011 is
unknown and chemotherapy is a selection variable for the cohort, it is difficult to estimate
if this racial breakdown is representative of the larger population.
Table 12
Demographics of the Study Cohort by Year - Race

Study cohort (n)
Race (n/%)
White (nonHispanic)
Black
Asian or Pacific Islander
White (Spanish origin
or surname)

2007

2008

2009

2010

2011

407

450

439

488

457

All
Years
(20072011)
2241

300
(73.7%)
30
(7.4%)
33
(8.1%)
42
(10.3%)

339
(75.3%)
38
(8.4%)
38
(8.4%)
31
(6.9%)

310
(70.6%)
51
(11.6%)
40
(9.1%)
36
(8.2%)

349
(71.5%)
57
(11.7%)
31
(6.4%)
47
(9.6%)

315
(68.9%)
63
(13.8%)
38
(8.3%)
39
(8.5%)

1613
(72%)
239
(10.7%)
180
(8.0%)
195
(8.7%)

The cohort is distributed equally by gender (48.3% male and 51.7% female) as
described in Table 13. Additionally, the gender distribution is fairly constant over the
2007 to 2011 timeframe (with slightly fewer males than females in 2009 and 2010).
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Table 13
Demographics of the Study Cohort by Year - Gender

Study cohort (n)
Gender (n/%)
Male
Female

2007

2008

2009

2010

2011

407

450

439

488

457

All Years
(20072011)
2241

201
(49.4%)
206
(50.6%)

232
(51.6%)
218
(48.4%)

195
(44.4%)
244
(55.6%)

227
(46.5%)
261
(53.5%)

228
(49.9%)
229
(50.1%)

1083
(48.3%)
1158
(51.7%)

As described in Table 14, the average age of diagnosis of the cohort is 74.09 (+/6.51) years. This is consistent over the study time frame with the lowest age at diagnosis
of 73.53 (+/- 6.07 years) in 2007 and the highest age at diagnosis of 74.48 (+/- 6.61) in
2009. This average age at diagnosis in this cohort is consistent with the average
diagnosis age in the general colorectal cancer population given that this study only
includes individuals 65 years and older (NCI, n.d.b).
Table 14
Demographics of the Study Cohort by Year – Age at Diagnosis

Age at diagnosis
(Average +/- SD)

2007

2008

2009

2010

2011

73.53 (+/6.07)

74.23 (+/6.47)

74.48 (+/6.61)

73.82 (+/6.77)

74.35 (+/6.51)

All Years
(20072011)
74.09 (+/6.51)

The study cohort is also fairly evenly distributed across the four SES levels as
described in Table 15. The highest percentage (28.7%) of individuals in the cohort
resided in a census tract with 10% to less than 20% poverty, while the lowest percentage
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(21.3%) of individuals in the cohort resided in a census tract with 0% to less than 5%
poverty. The distribution is fairly consistent over the 2007 to 2011 timeframe with a
slight reduction (25.8% in 2007 to 21.4% in 2011) in the number of individuals residing
in the lowest SES areas (20% to 100% poverty).
Table 15
Demographics of the Study Cohort by Year – Socioeconomic Status

Study cohort (n)
Census tract poverty
indicator (SES) (n/%)
0% - <5% poverty
(highest SES)
5% - <10% poverty
10% - <20% poverty
20% - 100% poverty
(lowest SES)
Unknown

2007

2008

2009

2010

2011

407

450

439

488

457

All
Years
(20072011)
2241

85
(20.9%)
96
(23.6%)
117
(28.7%)
105
(25.8%)
*

104
(23.1%)
104
(23.1%)
132
(29.3%)
104
(23.1%)
*

103
(23.5%)
119
(27.1%)
114
(26.0%)
100
(22.8%)
*

99
(20.3%)
128
(26.2%)
145
(29.7%)
111
(22.7%)
*

87
(19.0%)
93
(20.4%)
135
(29.5%)
98
(21.4%)
44
(9.6%)

478
(21.3%)
540
(24.1%)
643
(28.7%)
518
(23.1%)
62
(2.8%)

Note. *Less than 11 patients in group. Value masked for privacy purposes.

The breakdown of reporting registry for the patients in the cohort is described in
Table 16. The highest percentage of individuals in the cohort (34.3%) had data reported
from California. This is followed by 13.5% in New Jersey and 11.1% in Georgia with
the lowest percentage being reported from Utah (1.5%). Frequency of patients within the
other reporting registries is described in detail in Table 16. Distribution of the cohort
across reporting registry is fairly consistent across the timeframe 2007 to 2011. Given
that the SEER-Medicare database relies on data from 13 registries in district geographies,
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this geographical breakdown is not representative of the larger U.S. metastatic colorectal
cancer population.
Table 16
Demographics of the Study Cohort by Year – Reporting Registry
Reporting registry

2007
(n/%)

2008
(n/%)

2009
(n/%)

2010
(n/%)

2011
(n/%)

Study cohort (n)
Reporting registry
(n/%)
Hawaii
Iowa

407

450

439

488

457

*
33 (8.1%)

*
39 (8.7%)

*
29 (6.6%)

*
39 (8.0%)

*
30 (6.6%)

New Mexico
Seattle

*
20 (4.9%)

*
27 (6.0%)

12 (2.7%)
15 (3.4%)

*
23 (4.7%)

11 (2.4%)
21 (4.6%)

Utah
Kentucky

*
31 (7.6%)

*
37 (8.2%)

*
38 (8.7%)

*
28 (5.7%)

*
27 (5.9%)

Louisiana

18 (4.4%)

22 (4.9%)

28 (6.4%)

42 (8.6%)

43 (9.4%)

New Jersey

44
61
63
71
63
(10.8%)
(13.6%)
(14.4%)
(14.5%)
(13.8%)
Georgia
48
50
51
47 (9.6%)
52
(11.8%)
(11.1%)
(11.6%)
(11.4%)
California
150
147
149
174
149
(36.9%)
(32.7%)
(33.9%)
(35.7%)
(32.6%)
Note. *Less than 11 patients in group. Value masked for privacy purposes.

All Years
(20072011)
(n/%)
2241

35 (1.6%)
170
(7.6%)
49 (2.2%)
106
(4.7%)
34 (1.5%)
161
(7.2%)
153
(6.8%)
302
(13.5%)
248
(11.1%)
769
(34.3%)

Neighborhood characteristics (degree of urbanization) for patients within the
study cohort are described in Table 17. The cohort is primarily from Big Metro areas
(52.7%) with the least number of patients from Rural areas (2.5%). This is fairly
consistent across the 2007 to 2011 timeframe.
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Table 17
Demographics of the Study Cohort by Year – Neighborhood Characteristics

Study Cohort (n)
Neighborhood
Characteristics (n/%)
Big Metro

2007

2008

2009

2010

2011

407

450

439

487

457

All
Years
(20072011)
2240a

238
(52.1%)
131
(28.7%)
35
(7.7%)
39
(8.5%)
14
(3.1%)

1181
(52.7%)
632
(28.2%)
141
(6.3%)
229
(10.2%)
57
(2.5%)

234
243
260
(52.0%)
(55.4%)
(53.4%)
Metro
121
117
139
(26.9%)
(26.7%)
(28.4%)
Urban
30
21
29
(6.7%)
(4.8%)
(5.9%)
Less Urban
49
47
52
(10.9%)
(10.7%)
(10.7%)
Rural
16
11
*
(3.6%)
(2.5%)
Note.*Less than 11 patients in group. Value masked for privacy purposes.
a

206
(50.6%)
124
(30.5%)
26
(6.4%)
42
(10.3%)
*

One missing value
Table 18 describes the cohort based on the reason for original Medicare

entitlement (why they first gained access to Medicare). As described in the cohort
selection section, individuals who gained Medicare entitlement due to ESRD were
excluded from this study. Therefore, individuals in the cohort were only entitled due to
Age or Disability. Individuals in the cohort were primarily entitled due to age (90.6%).
This is fairly consistent over the time frame with slightly fewer (7.1%) begin entitled due
to disability in 2009 and slightly more being entitled due to disability (12.1%) in 2010.
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Table 18
Demographics of the Study Cohort by Year – Reason for Original Medicare Entitlement

Study Cohort (n)
Reason for Original
Medicare Entitlementa
Age

2007

2008

2009

2010

2011

407

450

439

488

457

All
Years
(20072011)
2241

413
(90.4%)
44
(9.6%)

2030
(90.6%)
211
(9.4%)

372
408
408
429
(91.4%)
(90.7%)
(92.9%)
(87.9%)
Disability
35
42
31
59
(8.6%)
(9.3%)
(7.1%)
(12.1%)
a
Entitlement due to End Stage Renal Disease Excluded from Cohort

Analysis of Covariates
Four covariates were assessed to determine if they need to be added to the logistic
regression model to control for confounding. The first covariate assessed was gender
(male or female). The second covariate was age at diagnosis. The third covariate was
reason for original Medicare entitlement (Age or Disability only; Individuals that
qualified for Medicare due to End Stage Renal Disease were excluded from the study
cohort). The fourth covariate was reporting registry.
Distribution of these covariates is described in the following tables and figures.
In addition, univariate analysis describing the association of each of the covariates with
the dependent variable (monoclonal antibody treatment) is presented. Covariates with
significant association with the dependent variable will be carried into the logistic
regression model to test for independent association of the dependent and independent
variables (if an association was found).
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Gender
The first covariate to be analyzed for association with monoclonal antibody
treatment rate is gender. Table 19 describes the frequency of the adjunct monoclonal
antibody receipt based on gender in the cohort. The frequency is fairly equivalent with
slightly fewer women (percentage-wise) receiving adjunct monoclonal antibody therapy.
Table 19
Monoclonal Antibody Treatment Rate by Gender
Gender
Male
Female
Total

Patients (n)
1083
1158
2241

Received Monoclonal Antibody
Treatment (n (%))
460 (42.5%)
470 (40.6%)
930 (41.5%)

Table 20 describes the Chi-Square statistic comparing monoclonal antibody
treatment rate to gender. Gender is not associated with monoclonal antibody treatment
(Pearson’s Chi-Square p-value = .365). Therefore, gender will not be included in the
logistic regression models.
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Table 20
Differences in Gender-Based on Monoclonal Antibody Treatment Rate
Value

df

Asymp. Sig. Exact Sig. (2- Exact Sig. (1(2-sided)
sided)
sided)
.365
.388
.365
.368
.194
.365

Pearson Chi-Square
.821a
1
b
Continuity Correction
.745
1
Likelihood Ratio
.821
1
Fisher's Exact Test
Linear-by-Linear
.821
1
Association
N of Valid Cases
2241
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 449.44.
b. Computed only for a 2x2 table

Reporting Registry
The second covariate to be analyzed for association with monoclonal antibody
treatment is reporting registry. Table 21 describes the frequency of adjunct monoclonal
antibody receipt based on reporting registry within the cohort. There are some registries
with higher than average rates and some with lower than average rates. For example,
Utah, Hawaii, and Seattle have relatively high treatment rates (61.8%, 57.1% and 53.8%
respectively) while Connecticut, California, and New Jersey have lower treatment rates
(33.1%, 37.7% and 38.4%).
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Table 21
Monoclonal Antibody Treatment Rate by Reporting Registry
Reporting Registry
Connecticut
Detroit
Hawaii
Iowa
New Mexico
Seattle
Utah
Kentucky
Louisiana
New Jersey
Georgia
California
Total

Patients (n)
121
93
35
170
49
106
34
161
153
302
248
769
2241

Received Monoclonal Antibody
Treatment (n (%))
40 (33.1%)
48 (51.6%)
20 (57.1%)
70 (41.2%)
23 (46.9%)
57 (53.8%)
21 (61.8%)
69 (42.9%)
61 (39.9%)
116 (38.4%)
115 (46.4%)
290 (37.7%)
930 (41.5%)

Table 22 describes the Chi-Square statistic comparing monoclonal antibody
treatment rate to reporting registry. Reporting registry is associated with monoclonal
antibody treatment (Pearson’s Chi-Square p-value = .001). Therefore, reporting registry
will be included in the logistic regression models to control for confounding.
Table 22
Differences in Reporting Registry Based on Monoclonal Antibody Treatment Rate
Value
df
Asymp. Sig. (2-sided)
Pearson Chi-Square
32.378a
11
.001
Likelihood Ratio
32.138
11
.001
Linear-by-Linear Association
2.470
1
.116
N of Valid Cases
2241
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 14.11.
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Medicare Entitlement Characteristics
The third covariate to be analyzed for association with monoclonal antibody
treatment is original Medicare entitlement characteristics (age or disability). Table 23
describes the frequency of adjunct monoclonal antibody receipt based on entitlement
characteristics. Within the cohort, there are slightly higher rates of monoclonal antibody
receipt in patients entitled due to age compared to patients entitled due to disability.
Table 23
Monoclonal Antibody Treatment by Medicare Entitlement Characteristics
Entitlement Characteristicsa

Patients (n)

Received Monoclonal Antibody
Treatment (n (%))
Age
2030
854 (42.1%)
Disability
211
76 (36.0%)
Total
2141
930 (41.5%)
a
Patients entitled due to End Stage Renal Disease were excluded from both Cohort

Table 24 describes the Chi-Square statistic comparing monoclonal antibody
treatment rate to original Medicare entitlement characteristics. Medicare Entitlement
Characteristics are not associated with monoclonal antibody treatment (Pearson’s ChiSquare p-value = .090). Therefore, entitlement characteristics will not be included in the
logistic regression models.

142
Table 24
Differences in Medicare Entitlement Characteristics Based on Monoclonal Antibody
Treatment Status

Value
df
Asymp. Sig. (2-sided)
Pearson Chi-Square
2.882a
1
.090
Likelihood Ratio
2.921
1
.087
Linear-by-Linear Association
2.880
1
.090
N of Valid Cases
2241
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 87.56.

Age at Diagnosis
The final covariate to be analyzed for association with monoclonal antibody
treatment rate is age at diagnosis. Table 25 describes the mean age of diagnosis for
individuals in the cohort who received and did not receive adjunct monoclonal antibody
treatment. The mean age of diagnosis is higher for individuals who did not receive
adjunct monoclonal antibody therapy.

Table 25
Monoclonal Antibody Treatment by Age at Diagnosis
Monoclonal
Antibody Treatment
Yes
No

N

Mean Age at
Diagnosis
930
73.03
1311
74.84

Std. Deviation

Std. Error Mean

6.002
6.742

.197
.186

Figure 3 graphically represents the distribution of age at diagnosis for those who
received and did not receive monoclonal antibody therapy. The percentage of individuals
who received monoclonal antibody declines with increasing diagnosis age.
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Figure 3. Bar graph showing the distribution of monoclonal antibody treatment by age at
diagnosis.
Table 26 presents the results from an independent samples t-test comparing
monoclonal antibody treatment to age at diagnosis for the cohort. As shown, age at
diagnosis is significantly associated with monoclonal antibody treatment (p-value =
.000). Therefore, age at diagnosis will be included in the logistic regression models to
control for confounding.
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Table 26
Differences in Average Age at Diagnosis Based on Monoclonal Antibody Treatment
Status

Levene's
Test for
Equality of
Variances
F
Sig.

t-test for Equality of Means

t

df

Sig.
Mean
Std. Error
95%
(2- Difference Difference Confidence
tailed)
Interval of
the
Difference
2239 .000
-1.803
.276
(-2.345,
-1.261)

Equal
18.087 .000
variances
6.525
assumed
Age at
Equal
- 2127.67
Diagnosis
variances
6.655
not
assumed

.000

-1.803

.271

(-2.334,
-1.272)

As presented in the sections above, two of the covariates are significantly
associated with monoclonal antibody receipt. Therefore, to control for confounding,
reporting registry and age at diagnosis will be included in the logistic regression models.
Specifically, if a significant association is found between any of the independent
variables (race, SES, neighborhood characteristics) and monoclonal antibody treatment,
an additional model will be run to include these three covariates as potential confounders.
Including the covariates will test for an independent association between the independent
and dependent variables.
Descriptive Statistics
The results for the three research questions presented in this paper are outlined
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and presented here. This section first uses descriptive statistics to present the distribution
of adjunct monoclonal antibody therapy based on race, SES, and neighborhood
characteristics. Specifically, this section describes the overall rate of adjunct monoclonal
antibody treatment and the relationship between monoclonal antibody treatment rate and
the three independent variables. These relationships were also stratified on diagnosis
year to test for maturation issues.
Overall Rate of Adjunct Monoclonal Antibody Treatment
As presented in Table 27, the average adjunct monoclonal antibody treatment rate
was 41.5%. The monoclonal antibody treatment rate declines slightly from 2007 to 2011.
As shown in Table 28, this decrease in treatment rate from 2007 to 2011 approaches
significance (Pearson Chi-Square p-value = .067). Given that the difference in
monoclonal antibody treatment is nonsignificant over the study timeframe, concerns
described in Chapter 3 regarding maturation are minimized.
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Table 27
Monoclonal Antibody Receipt by Diagnosis Year
Total in Study
Cohort (n)
Monoclonal
Antibody Receipt
(n (%))

2007
407

2008
450

2009
439

2010
488

2011
457

Total
2241

181
(44.5%)

192
(42.7%)

196
(44.6%)

194
(39.8%)

167
(36.5%)

960
(41.5%)

Table 28
Differences in Diagnosis Year Based on Monoclonal Antibody Treatment Status
Value
df
Asymp. Sig. (2-sided)
a
Pearson Chi-Square
8.762
4
.067
Likelihood Ratio
8.806
4
.066
Linear-by-Linear Association
6.510
1
.011
N of Valid Cases
2241
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 168.90.

Monoclonal Antibody Treatment Rate by Race
The first research question in this project addresses disparities in adjunct
monoclonal antibody treatment by race. Table 29 presents the monoclonal antibody
treatment rates in the cohort by race. The White (nonHispanic) group had the highest
rates of monoclonal antibody treatment (43.1%). The other three race groups (Black
Americans, Asian or Pacific Islander, and White (Spanish origin or surname)) had
monoclonal antibody treatment rates that were 4.8%-7.2% lower.
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Table 29
Monoclonal Antibody Treatment Rate by Race
Race
White (nonHispanic)
Black
Asian or Pacific Islander
White (Spanish origin or surname)

Total in Study Cohort (n)

Monoclonal Antibody
Treatment Rate (n (%))

1613
239
180
195

695 (43.1%)
88 (36.8%)
69 (38.3%)
70 (35.9%)

Monoclonal Antibody Treatment Rate by SES
The second research question in this project addresses disparities in adjunct
monoclonal antibody treatment by SES. Table 30 presents the monoclonal antibody
treatment rates in the cohort by SES (using the census tract poverty indicator). The rate
of monoclonal antibody treatment is fairly consistent across SES groups.
Table 30
Monoclonal Antibody Treatment Rate by SES Group
Census Tract Poverty Indicator (SES)

0% - <5% (highest SES)
5% - <10%
10% - <20%
20% - 100% (lowest SES)

Total in Study Cohort
(n)
478
540
643
518

Monoclonal
Antibody Treatment
Rate (n (%))
199 (41.6%)
218 (40.4%)
273 (42.5%)
220 (42.5%)

Monoclonal Antibody Treatment Rate by Neighborhood Characteristics
The third research question in this project addresses disparities in adjunct
monoclonal antibody treatment based on neighborhood characteristics (degree of
urbanization). Table 31 presents the monoclonal antibody treatment rates in the cohort
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by Neighborhood (i.e. Big Metro, Metro, Urban, Less Urban or Rural). The rate of
monoclonal antibody is lowest in the rural neighborhood group (31.6%).
Table 31
Monoclonal Antibody Treatment Rate by Neighborhood Characteristics
Total in Study Cohort (n)
Big Metro
Metro
Urban
Less Urban
Rural

1181
632
141
229
57

Monoclonal Antibody Treatment
Rate (n (%))
484 (41.0%)
261 (41.3%)
67 (47.5%)
99 (43.2%)
18 (31.6%)

Statistical Assumptions
Logistic regression will be used in the subsequent sections to test for associations
between the independent and dependent variables. There are two main assumptions that
must be met in order use logistic regression. First, the dependent variable must be
dichotomous (Burns & Burns, 2008). The dependent variable in this case (monoclonal
antibody therapy; “yes” or “no”) is dichotomous, meeting this assumption. Second, the
categories must be mutually exclusive and exhaustive, meaning that a sample must only
be in one group and every sample must be assigned to a group (Burns & Burns, 2008).
This assumption is also met with this data set. For all independent and dependent
variables every sample falls within one (and only one) of the categories. Burns and
Burns (2008) also note that larger samples are often needed for logistic regression and
recommend at least 50 cases per predictor. When all independent variables and
covariates are included, the maximum number of predictor variables will is six (three
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significant covariates and three independent variables). Therefore, for these analyses,
Burns and Burns would recommend at least 300 cases. The total sample size exceeds this
number since the cohort has 2,241 patients. Logistic regression does not assume linear
relationships between dependent and independent variables, nor does it assume equal
variance within groups or normal distribution (Burns & Burns, 2008). Therefore, these
conditions do not need to be tested prior to analysis.
Statistical Analysis of Research Questions
In previous sections in this chapter, cohort demographics were presented,
covariates were assessed and descriptive statistics comparing the independent and
dependent variables were introduced. This section uses logistic modeling to test for
significant and independent associations between the independent and dependent
variables. Specifically, this section will answer the three research questions presented in
the project and determine whether or not, in these two cohorts, there are disparities in
adjunct monoclonal antibody therapy based on race, SES, or neighborhood
characteristics.
Monoclonal Antibody Disparities by Race
Prior to analysis, individuals with race American Indian/Alaska Native, unknown,
or other unspecified (there were 11 patients or less in the cohort in each of these groups)
were excluded. This eliminated a total of 14 patients. Race was coded as a categorical
variable for dummy coding and White (nonHispanic) was listed as the reference variable.

150
Black American was dummy coded as (1), Asian/Pacific Islander was dummy coded as
(2) and White (Spanish origin or surname) was dummy coded as (3).
A binary logistic regression model was then executed using SPSS to determine if
race predicts monoclonal antibody treatment. The syntax for this analysis can be found
in Appendix G. Table 32 shows the result of the logistic regression analysis including a
model summary and statistics for the association between race and monoclonal antibody
treatment. The pseudo R Square values (0.003 for the Cox & Snell and 0.004 for
Nagelkerke) signify a poor model fit for race and monoclonal antibody treatment.
The odds ratios for race versus monoclonal antibody treatment can be found in the
Exp(B) column in the Table 32. The odds ratios are all compared back to the reference
group, in this case White (nonHispanic). The odds ratio for White (nonHispanic) vs.
Black American is 1.299 (95% CI: 0.981, 1.720), the odds ratio for White (nonHispanic)
vs. Asian/Pacific Islander vs. is 1.218 (95% CI: 0.888, 1.671), and the odds ratio for
White (nonHispanic) vs. White (Spanish origin or surname) is 1.352 (95% CI: 0.993,
1.841). Given that the overall model significance was 0.070 and all confidence intervals
overlap 1.0, race is not a significant predictor of monoclonal antibody treatment.
However, Black Amerian and White (Spanish origin or surname) do approach
significance with a p-values of 0.068 and 0.056 respectively.
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Table 32
Logistic Regression Analysis – Race and Monoclonal Antibody Treatment

Model Summary
-2 Log likelihood
3013.928a

Cox & Snell R Square
.003

Nagelkerke R Square
.004

Variables in the Equation
Race (dummy code)

White (nonHispanic)
(reference)
Black (1)
Asian/Pacific Islander (2)
White (Spanish origin or
surname) (3)
Constant

B

S.E.

Wald

df

Sig. Exp(B)

7.071

3

.070

.262
.197
.302

.143
.161
.158

3.337
1.493
3.664

1
1
1

.068
.222
.056

1.299
1.218
1.352

.278

.050 30.632

1

.000

1.321

95% C.I.for
EXP(B)
Lower Upper

.981
.888
.993

1.720
1.671
1.841

a. Estimation terminated at iteration number 3 because parameter estimates changed by less than
.001.

The logistic regression model shows that race is not a significant predictor of
adjunct monoclonal antibody treatment in this cohort. Therefore, the null hypothesis
should be accepted for the first research question relating race to monoclonal antibody
treatment. Additionally, given the lack of association between race and monoclonal
antibody therapy, no covariates need to be added to the models to control for
confounding.
Monoclonal Antibody Disparities by SES
Prior to analysis, individuals with a census tract poverty indicator value of
“unknown” were excluded from the cohort (the census tract poverty indicator variable is
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the measure of SES for this research project). This eliminated a total of 44 patients. SES
was coded as a categorical variable for dummy coding and the 0% to <5% poverty group
was listed as the reference variable. The 5% to <10% poverty group was dummy coded
as (1), the 10% to <20% poverty group was dummy coded as (2) and the 20% to 100%
poverty group was dummy coded as (3).
A binary logistic regression model was then executed using SPSS to determine if
SES predicts monoclonal antibody treatment. The syntax for this analysis can be found
in Appendix H. Table 33 shows the result of the logistic regression analysis including a
model summary and statistics for the association between SES and monoclonal antibody
treatment. The pseudo R Square values (0.000 for the Cox & Snell and 0.000 for
Nagelkerke) signify no model fit for SES and monoclonal antibody treatment.
The odds ratios for SES level versus monoclonal antibody treatment can be found
in the Exp(B) column in the Table 33. The odds ratios are all compared back to the
reference group, in this case 0% to <5% poverty. Therefore, the odds ratio for 0% to
<5% poverty vs. 5% to <10% poverty is 1.054 (95% CI: 0.820, 1.353), the odds ratio for
0% to <5% poverty vs. 10% to <20% poverty is 0.967 (95% CI: 0.761, 1.229), and the
odds ratio for 0% to <5% poverty vs. 20% to 100% poverty is 0.966 (95% CI: 0.751,
1.243). Given that the overall model significance was p = 0.881 and all confidence
intervals overlap 1.0, SES (as measured using the census tract poverty indicator variable)
is not a significant predictor of monoclonal antibody treatment.
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Table 33
Logistic Regression Analysis – SES and Monoclonal Antibody Treatment

Model Summary
-2 Log likelihood
2960.649a

Cox & Snell R Square
.000

Nagelkerke R Square
.000

Variables in the Equation
SES (dummy code)

0% to <5% poverty
(reference)
5% to <10% poverty (1)
10% to <20% poverty (2)
20% to 100% poverty (3)
Constant

B

.052
-.034
-.034
.338

S.E.

Wald

df

Sig.

.668

3

.881

.128
.167
.122
.077
.128
.072
.093 13.262

1
1
1
1

.683
.782
.789
.000

Exp(B)

1.054
0.967
0.966
1.402

95% C.I.for
EXP(B)
Lower Upper

.820
.761
.751

1.353
1.229
1.243

a. Estimation terminated at iteration number 3 because parameter estimates changed by less than
.001.

The logistic regression model shows that SES is not a significant predictor of
adjunct monoclonal antibody treatment. Therefore, the null hypothesis should be
accepted for the second research question relating SES to monoclonal antibody treatment.
Additionally, given the lack of association between SES and monoclonal antibody
therapy, no covariates need to be added to the models to control for confounding.
Monoclonal Antibody Disparities by Neighborhood Characteristics
Prior to analysis, one individual with a missing Rural/Urban Continuum code was
eliminated. The 2003 Rural/Urban Continuum code groups were coded as categorical
variables for dummy coding and the Big Metro group was listed as the reference variable.
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Metro was dummy coded as (1), Urban was dummy coded as (2), Less Urban was
dummy coded as (3) and Rural was dummy coded as (4).
A binary logistic regression model was then executed using SPSS to determine if
Neighborhood Characteristics (degree of urbanization) predicts monoclonal antibody
treatment. The syntax for this analysis can be found in Appendix I. Table 34 shows the
result of the logistic regression analysis including a model summary and statistics for the
association between neighborhood characteristics and monoclonal antibody treatment.
The pseudo R Square values (0.002 for the Cox & Snell and 0.003 for Nagelkerke)
signify a poor model fit for neighborhood characteristics and monoclonal antibody
treatment.
The odds ratios for neighborhood characteristics versus monoclonal antibody
treatment can be found in the Exp(B) column in the Table 34. The odds ratios are all
compared back to the reference group, in this case Big Metro. Therefore, the odds ratio
for Big Metro vs. Metro is 0.987 (95% CI: 0.811, 1.201), the odds ratio for Big Metro vs.
Urban is 0.767 (95% CI: 0.540, 1.089), and the odds ratio for Big Metro vs. Less Urban
is 0.912 (95% CI: 0.685, 1.214) and the odds ratio for Big Metro vs. Rural is 1.505 (95%
CI: 0.851, 2.662). Given that the overall model significance was p = 0.309 and all
confidence intervals overlap 1.0, neighborhood characteristics are not a significant
predictor of monoclonal antibody treatment.
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Table 34
Logistic Regression Analysis – Neighborhood Characteristics and Monoclonal Antibody
Treatment

Model Summary
-2 Log likelihood
3034.950a

Cox & Snell R Square
.002

Nagelkerke R Square
.003

Variables in the Equation
Neighborhood
Characteristics (dummy
code)
Big Metro (reference)
Metro (1)
Urban (2)
Less Urban (3)
Rural (4)
Constant

B

-.013
-.265
-.092
.408
.365

S.E.

.100
.179
.146
.291
.059

Wald

4.792
.017
2.204
.400
1.970
37.993

df

Sig.

4
1
1
1
1
1

.309
.897
.138
.527
.160
.000

Exp(B)

95% C.I.for
EXP(B)
Lower Upper

0.987
0.767
0.912
1.505
1.440

.811
.540
.685
.851

1.201
1.089
1.214
2.662

a. Estimation terminated at iteration number 3 because parameter estimates changed by less than
.001.

The logistic regression model shows that neighborhood characteristics are not a
significant predictor of adjunct monoclonal antibody treatment. Therefore, the null
hypothesis should be accepted for the third research question relating neighborhood
characteristics (degree of urbanization) to monoclonal antibody treatment. Additionally,
given the lack of association between neighborhood characteristics and monoclonal
antibody therapy, no covariates need to be added to the models to control for
confounding.
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Final Logistic Regression Model
The three independent variables tested (race, SES, neighborhood characteristics)
did not significantly predict the dependent variable group (monoclonal antibody therapy;
yes or no) in the logistic regression models above. However, two of the covariates
(diagnosis age and reporting registry) did significantly associate with monoclonal
antibody receipt in the covariate analysis section of this chapter. Therefore, as a final
analysis, a logistic regression model has been generated using these two significant
variables to determine how well these variables fit the model and if they are both
independently associated with monoclonal antibody treatment.
Prior to analysis, the categorical variables reporting registry was coded as a
categorical variable for dummy coding. Binary logistic regression models were executed
using SPSS to determine if the model predicts monoclonal antibody treatment. The
Syntax for these queries can be found in Appendix J. Table 35 shows the result of the
logistic regression analysis including a model summary and statistics for the association
between the two variables (age at diagnosis, reporting registry) and monoclonal antibody
treatment. The pseudo R Square values (0.032 for the Cox & Snell and 0.042 for
Nagelkerke) signify a weak model fit.
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Table 35
Logistic Regression Analysis – Final Model With Diagnosis Age and Reporting Registry

-2 Log likelihood
2969.819a
Variable (dummy code)

Model Summary
Cox & Snell R Square
.032
Variables in the Equation
B
S.E. Wald df Sig.

Nagelkerke R Square
.042
Exp
(B)

95% CI for
EXP(B)
Lower Upper

Reporting Registry = Connecticut
28.953 11 .002
Reporting Registry = Detroit (1)
-.721 .286 6.331
1 .012 .486
.277
.853
Reporting Registry = Hawaii (2)
-.870 .396 4.816
1 .028 .419
.193
.911
Reporting Registry = Iowa (3)
-.293 .251 1.368
1 .242 .746
.456 1.219
Reporting Registry = New Mexico -.497 .348 2.038
1 .153 .608
.307 1.204
(4)
Reporting Registry = Seattle (5)
-.807 .277 8.466
1 .004 .446
.259
.769
Reporting Registry = Utah (6)
-1.017 .406 6.279
1 .012 .362
.163
.801
Reporting Registry = Kentucky (7) -.298 .253 1.389
1 .239 .742
.452 1.219
Reporting Registry = Louisiana (8) -.160 .257
.387
1 .534 .852
.515 1.411
Reporting Registry = New Jersey
-.186 .229
.662
1 .416 .830
.530 1.300
(9)
Reporting Registry = Georgia (10) -.464 .234 3.932
1 .047 .629
.397
.995
Reporting Registry = California
-.124 .209
.350
1 .554 .883
.586 1.332
(11)
Age at Diagnosis
.043 .007 38.437
1 .000 1.044 1.030 1.058
Constant
-2.549 .558 20.892
1 .000 .078
a. Estimation terminated at iteration number 3 because parameter estimates changed by less than
.001.

Although the pseudo R Square values indicate that this is a weak model, the
model does significantly predict monoclonal antibody therapy (0.002 for reporting
registry and 0.000 for age at diagnosis). Additionally, given that both variables
maintained significance in the model, reporting registry and age at diagnosis are
independently associated with monoclonal antibody treatment.
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Summary
In this research project, I explored disparities in adjunct monoclonal antibody
treatment of elderly metastatic colorectal cancer patients. The three independent
variables tested for association with monoclonal antibody treatment were race, SES, and
neighborhood characteristics (degree of urbanization). There were also four covariates
assessed for association with monoclonal antibody treatment; gender, age at diagnosis,
reporting registry and reason for Medicare entitlement. Two of the covariates (age at
diagnosis and reporting registry) were found to significantly associate with monoclonal
antibody therapy. Logistic regression modeling of the three independent variables (race,
SES and neighborhood characteristics) showed that none of the variables significantly
predicted who would receive monoclonal antibody therapy. These data support accepting
the null hypotheses for all three research questions (H01, H02 and H03 listed at the
beginning of this chapter). A final logistic regression model was then executed with all
variables shown to associate with monoclonal antibody therapy (age at diagnosis and
reporting registry). These two variables independently associated with monoclonal
antibody therapy in the logistic regression model.
In the next chapter I will interpret the finding presented in this chapter. Namely, I
will compare the results to what was previously found in the literature and to the
theoretical framework this study was based on. Additionally, limitations of the research,
recommendations for future research and implications of the study will be presented.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Colorectal cancer survival disparities based on race, SES, and neighborhood
characteristics (degree of urbanization) have been documented in the literature.
Disparities in treatment regimen have been associated with these survival disparities.
However, assessments of disparities in adjunct monoclonal antibody treatment (a newer
treatment specifically for metastatic colorectal cancer) were not found in the literature.
Therefore, in this study, my aim was to determine whether these historical colorectal
cancer treatment disparities, observed with surgery, radiation, and chemotherapy,
extended into the newest class of treatments, monoclonal antibody therapies. The
specific aim of this quantitative study was to assess racial, SES, or neighborhood
characteristic (degree of urbanization) disparities in first-line adjunct monoclonal
antibody treatment of elderly metastatic colorectal cancer patients.
To answer these research questions, a retrospective cohort study was performed
using secondary data from the NCI’s SEER-Medicare database. From this database,
2,241 patient records that met the inclusion and exclusion criteria were selected for the
study. The demographics of this cohort including any differences across diagnosis year
were described in Chapter 4 (Tables 12-18). Generally, the cohort was stable over
diagnosis years 2007 to 2011 with a few exceptions including a linear increase in the
number of Black American patients in the cohort from diagnosis year 2007 to diagnosis
year 2011 (7.4% of the cohort to 13.8% of the cohort over the timeframe). Adjunct
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monoclonal antibody treatment rate did not significantly change over the 2007 to 2011
timeframe although a steady decline was observed that almost reached significance (p =
0.067). The covariates age at diagnosis and reporting registry were significantly
associated with adjunct monoclonal antibody therapy, while the covariates gender and
reason for original Medicare entitlement (age or disability) were not. Logistic regression
was then used to model the independent variables as predictors of the dependent variable.
None of the three independent variables (race, SES, and neighborhood characteristics)
predicted monoclonal antibody therapy. As a result, the null hypothesis was accepted for
all three research questions. However, of note, the race vs. monoclonal antibody model
did approach significance (overall model p = 0.070), with black race (p = 0.068) and
White, Spanish origin or surname (p = 0.056) being almost significantly different than the
reference group, White American race. As a final analysis, a model was generated with
the two variables that did significantly associate with monoclonal antibody therapy (age
at diagnosis and reporting registry). This final model was significant and both variables
were independently associated with adjunct monoclonal antibody therapy.
Interpretation of the Findings
The results of this study were outlined in length in Chapter 4 and summarized
above. In this section, I will interpret the findings as they relate to the literature review
and the theoretical foundation of this study.
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Results as They Relate to the Literature
Multiple studies outlined in the literature review found disparities in either the
type of aggressiveness of colorectal cancer treatment based on race, SES, and
neighborhood characteristics (degree of urbanization; Bakogeorgos et al., 2013; Obeidat
et al., 2010; Serra-Rexach et al., 2012). This study is unique in that I examined a
population of newly diagnosed metastatic colorectal cancer patients for disparities in
treatment with adjunct monoclonal antibody treatment (a newer therapy specifically for
metastatic colorectal cancer). Unlike the vast majority of the literature, in this research, I
did not identify significant treatment disparities based on race, SES, or neighborhood
characteristics. Therefore, the historically observed treatment disparities may not be
relevant to newer therapies (monoclonal antibodies) prescribed to patients with severe
disease (metastatic colorectal cancer). The difference could be related to improved
access to care or a change in treatment paradigm due specifically to the severity of
metastatic colorectal cancer.
Although the null hypothesis was accepted for all three research questions
(monoclonal antibody therapy disparities based on race, SES, or neighborhood
characteristics), a few literature reported findings were confirmed. First, age at diagnosis
was selected as a covariate due to previous literature documentation of an association
between diagnosis age and adjunct monoclonal antibody therapy. Specifically, Fu et al.
(2013) and Kozloff et al. (2010) observed reduced adjunct bevacizumab treatment with
increasing patient age. These results were confirmed in this study. Age at diagnosis was
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independently and significantly associated with adjunct monoclonal antibody therapy (p
= 0.000). In addition, another covariate, reporting registry was significantly associated
with monoclonal antibody treatment. SEER reporting registries are geographically
dispersed across regions of the United States. Previous research has shown marked
differences in colorectal cancer survival improvements across geographical regions of the
United States. Specifically, over the timeframe 1990 to 2007, the southern states showed
little to no improvement, whereas the north-eastern states showed improvement often in
excess of a 33% reduction in mortality (Naishadham et al., 2011). It is possible that
regional treatment disparities influence these mortality rates. This was not addressed as a
primary question in this study due to the incomplete coverage of U.S. regions by the
SEER registry data, but could be explored in future studies.
Theoretical Framing of the Results
The overarching theory for this research project was the fundamental cause
theory. According to this theory, as new methods of treating diseases become available,
these resources are not distributed equally (Phelan & Link, 2005). Instead they are
distributed based on “knowledge, money, power, prestige, and beneficial social
connections” (Phelan & Link, 2005, p. 227). Based on this theory and the literature
review documenting disparities in older colorectal cancer therapies, disparities in
monoclonal antibody treatment based on race, SES, or neighborhood characteristics
(degree of urbanization) would have been expected. However, disparities in race, SES,
and neighborhood characteristics were not observed in this study. Therefore, the findings
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are seemly inconsistent with this theory. However, most of the previous research into
colorectal cancer treatment disparities was performed with the general colorectal cancer
population. This study is addressing disparities in patients with advanced disease,
specifically colorectal cancer that had metastasized at diagnosis. Therefore, it is possible,
given the severity of the disease and the high mortality rate, that some of the social
barriers to treatment were eliminated. For example, maybe patients with metastatic
colorectal cancer are more likely to see a specialist or have a doctor advocate on their
behalf. These are questions that could be explored in future studies. Alternatively, given
that monoclonal antibodies were approved in 2004 and I assessed patients diagnosed
between 2007 and 2011, it is possible that the fundamental cause theory (which would
support disparities in new treatments) is no longer applicable. For example, if by 2007,
uptake of monoclonal antibodies was already at a maximum level, monoclonal antibodies
would no longer be considered a new method of treatment and their use may not be
subject to unequal distribution.
Two additional theories were used to extend the fundamental cause theory for the
purpose of this research project: the diffusion of innovations theory and the theory of
health disparities and medical technology. The diffusion of innovation theory states that
widening disparities are influenced by the nature of the new technology and the
uptake/diffusion of the technology (Rogers, 2010). Individuals who were treated with
monoclonal antibody shortly after approval would be expected to have innovator-like
characteristics such as proactive inquiry into treatment regimens that might contribute to
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treatment disparities based on social characteristics or demographics. Renouf et al. (2011)
found that 5.9% of patients diagnosed with colorectal cancer in 2004 were given the
VEGF monoclonal antibody bevacizumab compared to 30.6% of colorectal cancer
patients diagnosed in 2006. In the Renouf et al. study, according to the diffusion of
innovations theory, higher disparities in treatment would have been expected in 2004
compared to 2006 given that treatment was in an uptake phase. However, monoclonal
antibodies were newly approved in 2004, likely accounting for this sharp increase in
treatment rate between 2004 and 2006. In this study, the rate of monoclonal antibody
treatment was 44.5%, 42.7%, 44.6%, 39.8%, and 36.5% in diagnosis years 2007, 2008,
2009, 2010, and 2011 respectively. Therefore, in the years examined in this study (20072011), the overall rate of monoclonal antibody therapy had reached a plateau. Given this,
the diffusion of innovations theory, which is most useful in explaining a disparity during
the uptake of a technology, is likely not valid for this research study.
As additional support for the fundamental cause theory, the theory of health
disparities and medical technology was used (Goldman & Lakdawalla, 2005). This
theory states that medical advances are linked to widening disparities because new
medical technologies disproportionately benefit the heaviest health care users, richer
patients (Goldman & Lakdawalla, 2005). Given that richer more well-educated patients
tend to be the heaviest health care users and use more complex treatment regimens, richer
patients disproportionately use newer therapies (Goldman & Lakdawalla, 2005). This
theory was used to hypothesize that there might be higher monoclonal antibody use by
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high SES or nonminority populations. This study did not demonstrate a social inequality
in receipt of monoclonal antibody as would be expected based on this theory. However,
it is possible, given the severity of the disease and the high mortality rate, that some of
the social/economic barriers to treatment in poorer populations were eliminated.
In summary, the lack of disparity in treatment of metastatic colorectal cancer
patients with monoclonal antibodies is seemly inconsistent with the three theories used to
provide rationale for the research questions. Possible reasons for this include the extreme
severity of disease studied and plateau in the uptake of monoclonal antibody therapy
during the study period.
Limitations of the Study
This study has multiple limitations. First, due to the nature of the data, this study
used a very specific population of elderly individuals enrolled in Medicare Part B and D,
but with no HMO (Medicare Part C; Medicare Advantage) plan. This population does
differ systematically from the general Medicare population and from the population of
Medicare enrollees with an HMO plan. For example, the population sampled for this
study has a higher average income rate compared to the general Medicare population
(America’s Health Insurance Plans, 2015). Additionally, lower frequencies of racial
populations including Black Americans, Asians, and individuals with Hispanic origin are
observed in the population sampled for this study compared to the general Medicare
population (America’s Health Insurance Plans, 2015). Therefore, the sample used in this
study may not be completely representative of the overall Medicare population.
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However, given the potential for missing data with HMO plan enrollees, this limitation
was unavoidable.
Second, all individuals selected for inclusion in the study had colorectal cancer
that had metastasized at diagnosis. This was necessary as the SEER registry data only
identifies metastasis state at diagnosis. There is no way using the SEER registry data to
identify patients that progress to metastasis. Likewise, the Medicare claims files cannot
provide information about metastasis. Claims data are generated for the purpose of
payment (billed items) and not for the purpose of research. Cancer stage and progression
cannot be determined using claims data. Therefore, the sample selected for this study is
entire composed of individuals who were diagnosed with severe metastasized colorectal
cancer tumors. As such, it is unclear how well these results would extrapolate back to
individuals diagnosed in an earlier stage that subsequently progress to metastasis.
Third, the study sample was limited to individuals with a cancer sequence number
of 00 or 01 indicating that the colorectal cancer tumor was their first tumor. Given the
potential implications to treatment for individuals with a history of other cancers, this
exclusion criterion was necessary. However, it is unclear how the results of this study
would extrapolate to individuals with a history of other primary tumors.
Fourth, given the nature of the data used (Medicare claims) in this study, I used
only included Medicare enrolled individuals aged 65+ at diagnosis. As such is it unclear
if these results can be extrapolated to the population of metastatic colorectal cancer
patients under the age of 65 and with different insurance coverages.
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The fifth limitation is the ability to assess survival. In order to assess survival
relative to monoclonal antibody therapy, it would have been necessary to assess and
control for any comorbidities. This comorbidity analysis would have required research
into ICD-9 codes present in the claims files during the pre- and post-diagnosis period for
each patient. This would have been a significant undertaking and was determined to be
out of scope for this research study. Therefore, death dates were not collected, and
survival was not assessed in this study.
Sixth, the population sampled came from the 13 geographically dispersed SEER
registries. The ability to extrapolate the results to the larger U.S. wide population of
metastatic colorectal cancer patients is limited by the representativeness of the SEER
database. This SEER database includes data from approximately 28% of the U.S. cancer
population. However, it is unclear whether the data within the SEER database are a true
representation of the greater U.S. cancer population.
Seventh, I used archival data from the SEER-Medicare database to address the
research questions. Therefore, the study quality is limited by the validity, reliability, and
completeness of the SEER-Medicare database. Given that hospitals, clinicians, and
pathologists are responsible for accurate reporting and coding of SEER data, there is the
potential for missing or inaccurate data. However, there are published studies that have
documented good reliability, validity, and completeness of different subsets of the SEERMedicare data (Du et al., 2008; Mahnken et al., 2008).
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Finally, adjunct monoclonal antibody treatment in this study was defined as being
given any approved monoclonal antibody (Avastin, Erbitux, and Vectibix) in
combination with first line chemotherapy. The different antibodies were not separated
out during the analysis. Of importance, Erbitux and Vectibix (both EGFR antibodies) are
only indicated for adjunct therapy after testing for a specific KRAS genetic mutation.
Thus, there is an additional variable influencing whether or not a person is prescribed an
EGFR antibody. In this study, of the individuals that received adjunct monoclonal
antibody therapy, there were only 72 individuals that received an EGFR antibody; the
remaining 858 individuals received Avastin, a VEGF antibody. Given this, it is unclear
how the study results would extrapolate to a study looking at only adjunct EGFR
antibody therapy.
In summary, as a result of the database used for this study and the necessary
inclusion and exclusion criteria, concerns regarding extrapolation of the study results do
exist. These limitations will be taken into account in the recommendations and
implications sections below.
Recommendations
Multiple previous reports have documented colorectal cancer treatment disparities
based on race, SES, and neighborhood. Given that treatment disparities were not
observed in this study, these historical treatment disparities may not be relevant to newer
therapies (adjunct monoclonal antibodies) prescribed to patients with severe disease
(metastatic colorectal cancer). The difference could be related to improved access to care
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or a change in treatment paradigm due specifically to the severity of metastatic colorectal
cancer. Future studies aimed at understanding the causes of this observed difference is
warranted. Understanding the root cause of the reduced treatment disparities observed in
this study could potentially be used to reduce treatment disparities in other cancer
populations. For example, given the severity of metastatic colorectal cancer, is it possible
that patients are more likely to see a specialist or have a doctor advocate on their behalf,
thus reducing the disparities in treatment? These are questions that could be explored in
future research studies.
As commented previously, race did approach significance in predicting
monoclonal antibody treatment (overall model p = 0.070), with Black American race (p =
0.068) and White, Spanish origin or surname (p = 0.056) being almost significantly
different than the reference group, White American race. Therefore, future confirmatory
studies to confirm (or reject) the lack of racial disparities in monoclonal antibody
treatment of metastatic colorectal cancer patients are needed.
Reporting registry was a significant predictor of adjunct monoclonal antibody
therapy. Given the reported U.S. regional differences in colorectal cancer survival, future
studies could follow-up on regional disparities in adjunct monoclonal antibody treatment
and potentially the influence of treatment on survival. A GIS study to overlay treatment
regimen and survival rate of metastatic colorectal cancer patients could be especially
powerful.
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An additional variable that almost reached significance was reason for original
Medicare entitlement (age or disability). Rates of monoclonal antibody treatment were
lower in individuals entitled to Medicare due to disability compared to those entitled due
to age (p = 0.090). Given the marginal association, future studies assessing disparities in
monoclonal antibody treatment of metastatic colorectal cancer patients based on
disability are warranted.
When assessing the demographics of the study cohort, the number of Black
Americans in the cohort increased linearly and doubled from 2007 to 2011. Given that
the cohort selection criteria required first line chemotherapy, it is possible that this
increase is due to increased first line chemotherapy treatment rates in elderly Black
Americans with metastatic colorectal cancer. Exploring this was out of scope for this
study. However, it is an interesting finding that could be addressed in future studies.
The overall adjunct monoclonal antibody treatment rate in the cohort declined by
8% from diagnosis year 2007 to diagnosis year 2011. This difference in monoclonal
antibody treatment rate based on diagnosis year was almost significant (p = 0.067).
Given the reported efficacy of adjunct monoclonal antibody treatment, this decline is
unexpected. One possible explanation for the low and declining treatment rate is the cost
of monoclonal antibody therapies and the cost-effectiveness of adding monoclonal
antibody treatment to first-line chemotherapy. Although monoclonal antibodies have
been shown to improve survival rates in individuals with metastatic colorectal cancer, a
low perceived cost-effectiveness of adding monoclonal antibodies to chemotherapy could
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be driving down their use (Lange et al., 2014). Prospective studies designed to illicit the
rationale for prescribing behavior or qualitative studies to assess provider/patient feelings
about adjunct monoclonal antibody therapy and their benefit versus their high cost might
be the next logical step.
Implications
The results demonstrate a potential improvement in historically documented
colorectal cancer treatment disparities. Specifically, historical treatment disparities may
not be relevant to newer therapies (adjunct monoclonal antibodies) prescribed to patients
with severe disease (metastatic colorectal cancer). The difference could be related to
improved access to care or a change in treatment paradigm due specifically to the severity
of metastatic colorectal cancer. Future studies aimed at understanding the causes of this
observed social change (i.e. reduced treatment disparities) are warranted. Understanding
the root cause of the reduced treatment disparities observed in this study could potentially
be used to reduce treatment disparities in other cancer populations.
Although disparities in treatment based on race, SES, and neighborhood were not
observed, I did demonstrate, in this study, differences in adjunct monoclonal antibody
treatment rate based on reporting registry and age at diagnosis. The age at diagnosis
disparity replicates results found in two other studies and highlights the need for
interventions (at the policy or practice level) to improve access to monoclonal antibody
therapy for those of advanced age. Additionally, the regional differences in monoclonal
antibody treatment rate demonstrated by the reporting registry differences highlight the
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need to understand treatment patterns at a regional level across the United States.
Remediation in the form of policies to improve access could help increase monoclonal
antibody treatment rates in low treatment rate regions.
Finally, the study uncovered an overall decline in the percent of elderly metastatic
colorectal cancer patients given first line chemotherapy who received adjunct monoclonal
antibody therapy (8% decline from 2007 to 2011). Monoclonal antibodies are efficacious
and safe. Therefore, this study highlights the need for additional research into adjunct
monoclonal antibody treatment patterns and prescribing habits. Understanding this
unexpected decline in adjunct monoclonal antibody treatment rates could illicit social
change by improving antibody treatment rates and, in turn, colorectal cancer survival.
Conclusion
Previous research highlighted social disparities in colorectal cancer treatment that,
in part, explained disparities in colorectal cancer survival. However, all previous
research looked at conventional therapies (chemotherapy, radiation, surgery) in the
general colorectal cancer population. This research project was unique in that it explored
disparities in adjunct monoclonal antibody treatment within a specific population of
elderly metastatic colorectal cancer patients. In this study, race, SES, and neighborhood
characteristics were not associated with adjunct monoclonal antibody therapy. The
results demonstrate a potential improvement in historically documented colorectal cancer
treatment disparities. Specifically, historical treatment disparities may not be relevant to
newer therapies prescribed to patients with severe disease. The difference could be
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related to improved access to care or a change in treatment paradigm due specifically to
the severity of metastatic colorectal cancer. Future studies aimed at understanding the
causes of this social change (i.e. reduced treatment disparities) are warranted.
Understanding the root cause of the reduced treatment disparities observed in this study
could potentially be used to reduce treatment disparities in other cancer populations.
I accepted the null hypothesis for all three research questions. However, two
covariates (reporting registry and age at diagnosis) did significantly predict adjunct
monoclonal antibody treatment rate. The age at diagnosis disparity in monoclonal
antibody treatment of metastatic colorectal cancer patients supports previous findings by
Fu et al. (2013) and Kozloff et al. (2010). In addition, two other findings were
uncovered. First, the number of Black American individuals in the cohort doubled from
2007 to 2011. The most likely cause, assuming insurance enrollment is stable in the
population, is an increase in first-line chemotherapy rate. This is encouraging and should
be explored further. Additionally, over the years of this study (2007 - 2011) there was an
8% decline in the overall rate of monoclonal antibody treatment. Monoclonal antibodies
have been shown to be safe and efficacious when added to chemotherapy. Given that all
the individuals in the cohort received chemotherapy (which has multiple side effects), the
low treatment rate and specifically the decline in adjunct monoclonal antibody treatment
(which has been shown to be safe and effective) was unexpected. Further research into
prescribing habits and who receives adjunct monoclonal antibody therapy is warranted.
One potential topic for further research is the perceived cost-effectiveness of monoclonal
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antibodies for metastatic colorectal cancer. This could be explored from both provider
and the patient angles. If an explanation for the low and declining rate of monoclonal
antibody treatment is found, policies or support systems could be put into place to
increase adjunct monoclonal treatment rates and possibly increase survival rates for
individuals with metastatic colorectal cancer.
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Appendix C: Power Analyses
Logistic regression – A priori: Compute required sample size – given α, power and effect
size: SES Input/Output Table

Input Parameters:
Tail(s) = Two
Odds ratio = 1.15
Pr(Y=1 I X = 1) H0 = 0.306
α err prob = 0.05
Power (1-β err prob) = 0.50
R2 other X = 0.09
X distribution = Normal
X parm υ = 0
X parm σ = 1

Output:
Critical z = 1.96
Total sample size = 1029
Actual power = 0.500

Logistic regression – A priori: Compute required sample size – given α, power and effect
size: Race
Input Parameters:
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Tail(s) = Two
Odds ratio = 0.85
Pr(Y=1 I X = 1) H0 = 0.306
α err prob = 0.05
Power (1-β err prob) = 0.50
R2 other X = 0.09
X distribution = Normal
X parm υ = 0
X parm σ = 1

Output:
Critical z = 1.96
Total sample size = 764
Actual power = 0.500

Logistic regression – A priori: Compute required sample size – given α, power and effect
size: Rural/Urban Neighborhood
Input Parameters:
Tail(s) = Two
Odds ratio = 0.84
Pr(Y=1 I X = 1) H0 = 0.306
α err prob = 0.05
Power (1-β err prob) = 0.50
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R2 other X = 0.09
X distribution = Normal
X parm υ = 0
X parm σ = 1

Output:
Critical z = 1.96
Total sample size = 666
Actual power = 0.500
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Appendix D: Database Generation and Cohort Selection Code (Organized by File
Generated)
Steps used to compile the study cohort:
1. Build the database (seer_create.sql; Appendix D): Script that creates the database
and tables for use on this project.
2. Import the PEDSF data (seer_load_pedsf.py; Appendix D): Python script that
connects to the database ‘seer_db’ created above and then runs sql insert queries
to load the data from the seer text files into the database.
a. This script loaded the data from the pedsf.cancer.file01.txt and
pedsf.cancer.file02.txt files into the PEDSF table.
3. Import the Claims File data (seer_load_other.py; Appendix D): Python script that
connects to the database ‘seer_db’ created above and then runs sql insert queries
to load the data from the seer text files into the database.
a. This script loaded the following datasets (each dataset has multiple files):
i. Durable Medical Equipment files to the seer_db.DME table (files
loaded: dme07.txt, dme08.txt, dme09.txt, dme10.txt, dme11.txt,
dme12.txt)
ii. Part D Event files to the seer_db.PDE table (files loaded:
pdesaf07.txt, pdesaf08.txt, pdesaf09.txt, pdesaf10.txt, pdesaf11.txt,
pdesaf12.txt)
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iii. Carrier Claims files to the seer_db.NCH table (files loaded:
nch07.file001.txt, nch07.file002.txt, nch07.file003.txt,
nch07.file004.txt, nch07.file005.txt, nch07.file006.txt,
nch07.file007.txt, nch08.file001.txt, nch08.file002.txt,
nch08.file003.txt, nch08.file004.txt, nch08.file005.txt,
nch08.file006.txt, nch08.file007.txt, nch08.file008.txt,
nch09.file001.txt, nch09.file002.txt, nch09.file003.txt,
nch09.file004.txt, nch09.file005.txt, nch09.file006.txt,
nch09.file007.txt, nch09.file008.txt, nch10.file001.txt,
nch10.file002.txt, nch10.file003.txt, nch10.file004.txt,
nch10.file005.txt, nch10.file006.txt, nch10.file007.txt,
nch10.file010.txt, nch11.file001.txt, nch11.file002.txt,
nch11.file003.txt, nch11.file004.txt, nch11.file005.txt,
nch11.file006.txt, nch11.file007.txt, nch11.file008.txt,
nch12.file001.txt, nch12.file002.txt, nch12.file003.txt,
nch12.file004.txt, nch12.file005.txt, nch12.file006.txt)
iv. Outpatient claims files to the seer_db.OUTPATIENT table (files
loaded: outsaf07.file001.txt, outsaf07.file002.txt,
outsaf07.file003.txt, outsaf07.file004.txt, outsaf07.file005.txt,
outsaf08.file001.txt, outsaf08.file002.txt, outsaf08.file003.txt,
outsaf08.file004.txt, outsaf08.file005.txt, outsaf08.file006.txt,
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outsaf09.file001.txt, outsaf09.file002.txt, outsaf09.file003.txt,
outsaf09.file004.txt, outsaf09.file005.txt, outsaf09.file006.txt,
outsaf10.file001.txt, outsaf10.file002.txt, outsaf10.file003.txt,
outsaf10.file004.txt, outsaf10.file005.txt, outsaf10.file006.txt,
outsaf10.file007.txt, outsaf11.file001.txt, outsaf11.file002.txt,
outsaf11.file003.txt, outsaf11.file004.txt,outsaf11.file005.txt,
outsaf11.file006.txt, outsaf11.file007.txt, outsaf12.file001.txt,
outsaf12.file002.txt, outsaf12.file003.txt, outsaf12.file004.txt,
outsaf12.file005.txt, outsaf12.file006.txt)
4. Execute SQL queries to select data based on inclusion and exclusion criteria
(seer_queries.sql; Appendix D): The selection process is described below.
a. Filters claim data to only those matching Chemotherapy or Monoclonal
antibody NDC or HCPCS codes needed for this research study.
b. Filters claim data to first claim after diagnosis.
c. Combines filtered claim data and pedsf data into one master table
d. Adds a ‘diagnosis_date’ column which is the last day of the month in
which the patient was diagnosed. This date is combination of
smPEDSF.date_yr and smPEDSF.date_mo.
5. Database export (export_master_view.sh; Appendix D): BASH script - runs a
simple SELECT query to export the seer_db.master_view to master_table.txt
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6. Pre-SPSS processing (update_master_table.py; Appendix D): Python script –
computes and adds five columns to the master_table.txt and saves it as
master_table_updated.txt. Columns added are below.
a. days – The number days between first chemotherapy treatment and first
monoclonal antibody treatment.
b. first_chemo – The date of the first chemotherapy treatment for that patient
c. chemo_type – The type (ex. hcpcs code) for the first chemotherapy
treatment
d. first_ma - The date of the first monoclonal antibody treatment for that
patient
e. ma_type – The type (ex. hcpcs code) for first monoclonal antibody
treatment
Code used to generate the study cohort:
seer_build.py
#
#
#
#
#
#
#

-*- coding: utf-8 -*seer_build.py
MySQL Workbench Python script
Written in MySQL Workbench 6.3.2
Author: Andrew Schroeder, May 2015
Description: Connects to MySQL server and executes 'seer_create.sql'
SQL script to create the seer_db

import mysql.connector
from mysql.connector import errorcode
import sys
import re
PATH_TO_FILE = "seer_create.sql"
try:
cnx = mysql.connector.connect(user='root',
password='', host='localhost')
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except mysql.connector.Error as err:
if err.errno == errorcode.ER_ACCESS_DENIED_ERROR:
print("Something is wrong with your user name or password")
elif err.errno == errorcode.ER_BAD_DB_ERROR:
print("Database does not exist")
else:
print(err)
sys.exit(1)
cursor = cnx.cursor()
sql = ""
for line in open(PATH_TO_FILE):
ln = line.rstrip()
if re.match("^--.*", ln):
pass
elif re.match("^\s*$", ln):
pass
else:
sql += " " + ln
for q in sql.split(";"):
if q == "":
pass
else:
print (q + ";")
cursor.execute(q + ";")
cnx.close()

seer_load_pedsf.py
#
#
#
#
#

-*- coding: utf-8 -*seer_load_pedsf.py
MySQL Workbench Python script
Written in MySQL Workbench 6.3.2
Author: Andrew Schroeder May 2nd 2015

import mysql.connector
from mysql.connector import errorcode
import sys
import re
class COLS:
patient_id = 0
registry = 1
race = 2
PEDSF_1_FILE = "/samba/seer/data/pedsf.cancer.file01.txt"
PEDSF_2_FILE = "/samba/seer/data/pedsf.cancer.file02.txt"
pedsf_tbl_cols = ['patient_id', 'reporting_id', 'rac_recb',
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'census_pov_ind', 'urbrur', 'm_sex', 'birthyr', 'age_dx',
'date_yr',
'date_mo', 'rsncd1', 'seq_num', 'ptbcnt_2007', 'ptbcnt_2008',
'ptbcnt_2009', 'ptbcnt_2010', 'ptbcnt_2011', 'ptbcnt_2012',
'hmocnt_2007', 'hmocnt_2008', 'hmocnt_2009',
'hmocnt_2010', 'hmocnt_2011', 'hmocnt_2012',
'ptd_2007', 'ptd_2008', 'ptd_2009', 'ptd_2010', 'ptd_2011',
'ptd_2012',
'cs_met_1', 'cs_met_2', 'cs_met_3', 'cs_met_4', 'cs_met_5',
'cs_met_6', 'cs_met_7', 'cs_met_8', 'cs_met_9', 'cs_met_10']
pedsf_txt_cols =
[
[1,10],[1,2],[101,2],[146,1],[97,1],[41,1],
[37,4],[1881,3],[1888,4],[1886,2],
#rsncd1
[43,1],[1884,2],
#ptbcnt 2007-2012
[1252,2],[1296,2],[1340,2],[1384,2],[1428,2],[1472,2],
#hmocnt 2007-2013
[1254,2],[1298,2],[1342,2],[1386,2],[1430,2],[1474,2],
#ptd 2007 - 2012
[261,2],[301,2],[341,2],[381,2],[421,2],[461,2],
# cs_mets
[1953,2],[2253,2],[2553,2],[2853,2],[3153,2],[3453,2],
[3753,2],[4053,2],[4353,2],[4653,2]
]
def slice(string, start, length):
s = start - 1 #adjust for zero based list
return string[s:s+length].strip()
def insert_table(cursor, table_name, line, table_cols, text_cols):
col_data = []
tbl_cols = []
count = 0
for tcol in text_cols:
data=slice(line,tcol[0],tcol[1])
if data != "":
tbl_cols.append(table_cols[count])
#print table_cols[count] +": " + data
col_data.append(data)
count +=1
table_string = ("INSERT INTO " +
table_name + " (" + ",".join(tbl_cols))
table_string += ") VALUES (" + ("%s," * (len(tbl_cols)-1)) +
"%s)"
cursor.execute((table_string), col_data)

def insert_pdesaf(cursor, line, year):
cols = []
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cols.append(slice(line,0,10))
cols.append(slice(line,0,2))
cols.append(slice(line,101,2))
cols.append(slice(line,146,1))
cols.append(slice(line,97,1))
cols.append(slice(line,41,1))
cols.append(slice(line,37,4))
cols.append(slice(line,1881,3))
cols.append(slice(line,1888,4))
cols.append(slice(line,1886,2))
#rsncd1
cols.append(slice(line,43,1))
cols.append(slice(line,1884,2))
#ptbcnt 2007-2013
cols.append(slice(line,1252,2))
cols.append(slice(line,1296,2))
cols.append(slice(line,1340,2))
cols.append(slice(line,1384,2))
cols.append(slice(line,1428,2))
cols.append(slice(line,1472,2))
#hmocnt 2007-2013
cols.append(slice(line,1254,2))
cols.append(slice(line,1298,2))
cols.append(slice(line,1342,2))
cols.append(slice(line,1386,2))
cols.append(slice(line,1430,2))
cols.append(slice(line,1474,2))
#ptd 2007 - 2013
cols.append(slice(line,261,2))
cols.append(slice(line,301,2))
cols.append(slice(line,341,2))
cols.append(slice(line,381,2))
cols.append(slice(line,421,2))
cols.append(slice(line,461,2))
# cs_mets
cols.append(slice(line,1953,2))
cols.append(slice(line,2253,2))
cols.append(slice(line,2553,2))
cols.append(slice(line,2853,2))
cols.append(slice(line,3153,2))
cols.append(slice(line,3453,2))
cols.append(slice(line,3753,2))
cols.append(slice(line,4053,2))
cols.append(slice(line,4353,2))
cols.append(slice(line,4653,2))
cursor.execute((pedsf_string), cols)

try:
cnx = mysql.connector.connect(
user='root', password='',
host='localhost',database='seer_db')
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except mysql.connector.Error as err:
if err.errno == errorcode.ER_ACCESS_DENIED_ERROR:
print("Something is wrong with your user name or password")
elif err.errno == errorcode.ER_BAD_DB_ERROR:
print("Database does not exist")
else:
print(err)
sys.exit(1)
cursor = cnx.cursor()
cursor.execute("truncate PEDSF;")
count = 0
with open(PEDSF_1_FILE) as infile:
for line in infile:
insert_table(cursor,"PEDSF",line,pedsf_tbl_cols,pedsf_txt_cols)
count +=1
if count % 500 == 0:
print count
with open(PEDSF_2_FILE) as infile:
for line in infile:
insert_table(cursor,"PEDSF",line,pedsf_tbl_cols,pedsf_txt_cols)
count +=1
if count % 500 == 0:
print count
cnx.commit()
cursor.close()
cnx.close()

seer_load_other.py
#
#
#
#
#

-*- coding: utf-8 -*seer_load_other.py
MySQL Workbench Python script
Written in MySQL Workbench 6.3.2
Author: Andrew Schroeder May 2nd 2015

import mysql.connector
from mysql.connector import errorcode
import sys
import re
import os
###########################################
# constants and data
###########################################
DATA_PATH = "/samba/seer/data"
DME_FILES = []
for i in range(7,13):
DME_FILES.append('dme{:02d}.txt'.format(i))
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dme_tbl_cols = ['patient_id', 'hcpcs', 'ndc_cd', 'claim_from_date']
dme_txt_cols = [[1,10],[93,5],[409,11],[32,8]]
PDE_FILES = []
for i in range(7,13):
PDE_FILES.append('pdesaf{:02d}.txt'.format(i))
pde_tbl_cols = ['patient_id', 'brand', 'prod_srvc_id', 'service_date']
pde_txt_cols = [[1,10],[90,30],[35,11],[27,8]]
nch_file_rages = [0,1,2,3,4,5,7,8,9,9,9,9,7]
NCH_FILES = []
for i in range(7,13):
for j in range(1,nch_file_rages[i]):
NCH_FILES.append('nch{:02d}.file{:03d}.txt'.format(i, j))
nch_tbl_cols = ['patient_id', 'hcpcs', 'claim_from_date']
nch_txt_cols = [[1,10],[93,5],[32,8]]
op_file_rages = [0,1,2,3,4,5,6,6,7,7,8,8,7]
OP_FILES = []
for i in range(7,13):
for j in range(1,op_file_rages[i]):
OP_FILES.append('outsaf{:02d}.file{:03d}.txt'.format(i, j))
op_tbl_cols = ['patient_id', 'hcpcs', 'claim_from_date']
op_txt_cols = [[1,10],[241,5],[32,8]]
progress_text = "Row Count: {:}\t\tTable: {:%}\t\tTotal: {:%}\r"
###########################################
#
functions
###########################################
def calc_num_records(FILES):
record_size = 0
records = 0
for file in FILES:
path = os.path.join(DATA_PATH,file)
if record_size == 0:
with open(path) as infile:
record_size = len(infile.readline())
if not os.path.isfile(path):
print "Error {0} does not exist!".format(path)
sys.exit(1)
if record_size != 0:
records += os.path.getsize(path) / record_size
return records
def slice(string, start, length):
s = start - 1 #adjust for zero based list
return string[s:s+length].strip()
def insert_table(cursor, table_name, line, table_cols, text_cols):
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col_data = []
tbl_cols = []
count = 0
for tcol in text_cols:
data=slice(line,tcol[0],tcol[1])
#convert from MMDDYYYY to YYYYMMDD
if table_cols[count] == 'claim_from_date' or
table_cols[count] == 'service_date':
date = data[4:] + "-" + data[:2] + "-" + data[2:4]
data = date
if data != "":
tbl_cols.append(table_cols[count])
col_data.append(data)
count +=1
table_string = "INSERT INTO " + table_name + " (" +
",".join(tbl_cols)
table_string += ") VALUES (" + ("%s," * (len(tbl_cols)-1)) + "%s)"
cursor.execute((table_string), col_data)
###########################################
# main script body
###########################################
# Connect to database
try:
cnx = mysql.connector.connect(user='root', password='',
host='localhost',database='seer_db')
except mysql.connector.Error as err:
if err.errno == errorcode.ER_ACCESS_DENIED_ERROR:
print("Something is wrong with your user name or password")
elif err.errno == errorcode.ER_BAD_DB_ERROR:
print("Database does not exist")
else:
print(err)
sys.exit(1)
# open data files and count the number of records
#
(used for progress reporting)
dme_records = calc_num_records(DME_FILES)
print "DME Records: {0}".format(dme_records)
pde_records = calc_num_records(PDE_FILES)
print "PDE Records: {0}".format(pde_records)
nch_records = calc_num_records(NCH_FILES)
print "NCH Records: {0}".format(nch_records)
op_records = calc_num_records(OP_FILES)
print "OP Records: {0}".format(op_records)
#import the DME data to the DME table
cursor = cnx.cursor()
cursor.execute("truncate DME;")
total_progress = 0
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total_records = dme_records + pde_records + nch_records + op_records
count = 0
for file in DME_FILES:
with open(os.path.join(DATA_PATH, file)) as infile:
for line in infile:
insert_table(cursor,"DME",line,dme_tbl_cols,dme_txt_cols)
count +=1
if count % 5000 == 0:
sys.stdout.write(
progress_text.format(
count, float(count)/float(dme_records),
float(total_progress + count)
/ float(total_records) ))
sys.stdout.flush()
cnx.commit()
print "DME table committed."
#import the PDE data to the PDE table
cursor.execute("truncate PDE;")
total_progress += count
count = 0
for file in PDE_FILES:
with open(os.path.join(DATA_PATH, file)) as infile:
for line in infile:
insert_table(cursor,"PDE",line, pde_tbl_cols,pde_txt_cols)
count +=1
if count % 5000 == 0:
sys.stdout.write(
progress_text.format(
count, float(count)/float(dme_records),
float(total_progress + count)
/ float(total_records) ))
sys.stdout.flush()
cnx.commit()
print "PDE table committed."
#import the NCH data to the NCH table
cursor.execute("truncate NCH;")
total_progress += count
count = 0
for file in NCH_FILES:
with open(os.path.join(DATA_PATH, file)) as infile:
for line in infile:
insert_table(cursor,"NCH",line,nch_tbl_cols,nch_txt_cols)
count +=1
if count % 5000 == 0:
sys.stdout.write(
progress_text.format(
count, float(count)/float(dme_records),
float(total_progress + count)
/ float(total_records) ))
sys.stdout.flush()
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cnx.commit()
print "NCH table committed."
#import the outpatient data into the OUTPATIENT database
cursor.execute("truncate OUTPATIENT;")
total_progress += count
count = 0
for file in OP_FILES:
with open(os.path.join(DATA_PATH, file)) as infile:
for line in infile:
insert_table(cursor,"OUTPATIENT",line,op_tbl_cols,op_txt_cols)
count +=1
if count % 5000 == 0:
sys.stdout.write(
progress_text.format(
count, float(count)/float(dme_records),
float(total_progress + count)
/ float(total_records) ))
sys.stdout.flush()
cnx.commit()
print "OUTPATIENT table committed."
cursor.close()
cnx.close()

update_master_table.py
# -*- coding: utf-8 -*# update_master_table.py
# author: Andrew Schroeder May, 2015
import sys
import re
from datetime import datetime
class COLS:
patient_id = 0
reporting_id = 1
rac_recb = 2
census_pov_ind = 3
urbrur = 4
m_sex = 5
date_yr = 6
date_mo = 7
birthyr = 8
age_dx = 9
rsncd1 = 10
cs_met_1 = 11
diagnosis_date = 12
ccDME_hcpcs = 13
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ccDME_claim_date = 14
ccDME_ndc_cd = 15
mmDME_hcpcs = 16
mmDME_claim_date = 17
mmDME_ndc_cd = 18
ccNCH_hcpcs = 19
ccNCH_claim_date = 20
mmNCH_hcpcs = 21
mmNCH_claim_date = 22
ccOP_hcpcs = 23
ccOP_claim_date = 24
mmOP_hcpcs = 25
mmOP_claim_date = 26
mmPDE_brand = 27
mmPDE_srvc_date = 28
mmPDE_prod_srvc_id = 29

MASTER_FILE_IN = "master_table.txt"
MASTER_FILE_OUT = "master_table_updated.txt"
future_date = datetime.strptime('2025-01-01', "%Y-%m-%d")
count = 0
with open(MASTER_FILE_OUT, 'w') as outfile:
with open(MASTER_FILE_IN) as infile:
outfile.write(
next(infile).rstrip() + "\t".join(
["","days","first_chemo","chemo_type", "first_ma",
"ma_type"])
+ "\n")
for line in infile:
cols = line.split()
print("{0}, {1}, {2}".format(
cols[COLS.ccDME_claim_date],
cols[COLS.ccNCH_claim_date],
cols[COLS.ccOP_claim_date]))
# chemo data
if cols[COLS.ccDME_claim_date] == 'NULL':
date1 = future_date
data = "NULL"
else:
date1 = datetime.strptime(
cols[COLS.ccDME_claim_date], "%Y-%m-%d")
if cols[COLS.ccNCH_claim_date] == 'NULL':
date2 = future_date
else:
date2 = datetime.strptime(
cols[COLS.ccNCH_claim_date], "%Y-%m-%d")
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if cols[COLS.ccOP_claim_date] == 'NULL':
date3 = future_date
else:
date3 = datetime.strptime(
cols[COLS.ccOP_claim_date], "%Y-%m-%d")

if

not (date1 > date2 or date1 > date3):
date_out = date1
if cols[COLS.ccDME_ndc_cd] != "NULL":
data_out = cols[COLS.ccDME_ndc_cd]
else:
data_out = cols[COLS.ccDME_hcpcs]
elif not (date2 > date1 or date2 > date3):
date_out = date2
data_out = cols[COLS.ccNCH_hcpcs]
elif not (date3 > date2 or date3 > date1):
date_out = date3
data_out = cols[COLS.ccOP_hcpcs]
# ma data
if cols[COLS.mmDME_claim_date] == 'NULL':
ma_date1 = future_date
ma_data = "NULL"
else:
ma_date1 = datetime.strptime(
cols[COLS.mmDME_claim_date], "%Y-%m-%d")
if cols[COLS.mmNCH_claim_date] == 'NULL':
ma_date2 = future_date
else:
ma_date2 = datetime.strptime(
cols[COLS.mmNCH_claim_date], "%Y-%m-%d")
if cols[COLS.mmOP_claim_date] == 'NULL':
ma_date3 = future_date
else:
ma_date3 = datetime.strptime(
cols[COLS.mmOP_claim_date], "%Y-%m-%d")
if cols[COLS.mmPDE_srvc_date] == 'NULL':
ma_date4 = future_date
else:
ma_date4 = datetime.strptime(
cols[COLS.mmPDE_srvc_date], "%Y-%m-%d")

if

not (ma_date1 > ma_date2 or
ma_date1 > ma_date3 or
ma_date1 > ma_date4):
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ma_date_out = ma_date1;
if cols[COLS.mmDME_ndc_cd] != "NULL":
ma_data_out = cols[COLS.mmDME_ndc_cd]
else:
ma_data_out = cols[COLS.mmDME_hcpcs]
elif not (ma_date2 > ma_date1 or
ma_date2 > ma_date3 or
ma_date2 > ma_date4):
ma_date_out = ma_date2;
ma_data_out = cols[COLS.mmNCH_hcpcs]
elif not (ma_date3 > ma_date1 or
ma_date3 > ma_date2 or
ma_date3 > ma_date4):
ma_date_out = ma_date3;
ma_data_out = cols[COLS.mmOP_hcpcs]
elif not (ma_date4 > ma_date1 or
ma_date4 > ma_date2 or
ma_date4 > ma_date3):
ma_date_out = ma_date4;
if cols[COLS.mmPDE_brand] != "NULL":
ma_data_out = cols[COLS.mmPDE_brand]
else:
ma_data_out = cols[COLS.mmPDE_prod_srvc_id]
else:
print ('This should not happen')
sys.exit(1)

if date_out == future_date or
cols[COLS.diagnosis_date] == "NULL":
days_out = "NULL"
date_out = "NULL"
else:
diagnosis_date = datetime.strptime(
cols[COLS.diagnosis_date], "%Y-%m-%d")
elapsed = date_out - diagnosis_date
days_out = elapsed.days
date_out = date_out.strftime("%Y-%m-%d")

if ma_date_out == future_date or
cols[COLS.diagnosis_date] == "NULL":
ma_days_out = "NULL"
ma_date_out = "NULL"
else:
diagnosis_date = datetime.strptime(
cols[COLS.diagnosis_date], "%Y-%m-%d")
ma_elapsed = ma_date_out - diagnosis_date
ma_days_out = ma_elapsed.days
ma_date_out = ma_date_out.strftime("%Y-%m-%d")
newline = line.rstrip() + "\t".join(
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['',str(days_out),
date_out,data_out,
ma_date_out,
ma_data_out])
print(newline)
outfile.write(newline + "\n")
count +=1

seer_create.sql
-----

MySQL Script generated by MySQL Workbench
seer_create.sql
05/01/15 17:33:43
MySQL Workbench Forward Engineering

SET @OLD_UNIQUE_CHECKS=@@UNIQUE_CHECKS, UNIQUE_CHECKS=0;
SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0;
SET @OLD_SQL_MODE=@@SQL_MODE,
SQL_MODE='TRADITIONAL,ALLOW_INVALID_DATES';
-- ------------------------------------------------------ Schema seer_db
-- ----------------------------------------------------DROP SCHEMA IF EXISTS `seer_db` ;
-- ------------------------------------------------------ Schema seer_db
-- ----------------------------------------------------CREATE SCHEMA IF NOT EXISTS `seer_db`
DEFAULT CHARACTER SET utf8 COLLATE utf8_general_ci ;
USE `seer_db` ;
-- ------------------------------------------------------ Table `seer_db`.`PEDSF`
-- ----------------------------------------------------DROP TABLE IF EXISTS `seer_db`.`PEDSF` ;
CREATE TABLE IF NOT EXISTS `seer_db`.`PEDSF` (
`idPEDSF` INT NOT NULL AUTO_INCREMENT,
`patient_id` VARCHAR(10) NULL,
`reporting_id` VARCHAR(2) NULL,
`rac_recb` TINYINT(2) UNSIGNED NULL,
`census_pov_ind` TINYINT(1) UNSIGNED NULL,
`urbrur` TINYINT(1) UNSIGNED NULL,
`m_sex` TINYINT(1) UNSIGNED NULL,
`birthyr` YEAR NULL,
`age_dx` TINYINT(3) UNSIGNED NULL,
`date_yr` YEAR NULL,
`date_mo` TINYINT(2) UNSIGNED NULL,
`rsncd1` TINYINT(1) UNSIGNED NULL,
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`seq_num` TINYINT(2) UNSIGNED NULL,
`year` YEAR NULL,
`ptbcnt_2007` TINYINT(2) NULL,
`ptbcnt_2008` TINYINT(2) NULL,
`ptbcnt_2009` TINYINT(2) NULL,
`ptbcnt_2010` TINYINT(2) NULL,
`ptbcnt_2011` TINYINT(2) NULL,
`ptbcnt_2012` TINYINT(2) NULL,
`hmocnt_2007` TINYINT(2) NULL,
`hmocnt_2008` TINYINT(2) NULL,
`hmocnt_2009` TINYINT(2) NULL,
`hmocnt_2010` TINYINT(2) NULL,
`hmocnt_2011` TINYINT(2) NULL,
`hmocnt_2012` TINYINT(2) NULL,
`ptd_2007` TINYINT(2) NULL,
`ptd_2008` TINYINT(2) NULL,
`ptd_2009` TINYINT(2) NULL,
`ptd_2010` TINYINT(2) NULL,
`ptd_2011` TINYINT(2) NULL,
`ptd_2012` TINYINT(2) NULL,
`cs_met_1` TINYINT(2) NULL,
`cs_met_2` TINYINT(2) NULL,
`cs_met_3` TINYINT(2) NULL,
`cs_met_4` TINYINT(2) NULL,
`cs_met_5` TINYINT(2) NULL,
`cs_met_6` TINYINT(2) NULL,
`cs_met_7` TINYINT(2) NULL,
`cs_met_8` TINYINT(2) NULL,
`cs_met_9` TINYINT(2) NULL,
`cs_met_10` TINYINT(2) NULL,
PRIMARY KEY (`idPEDSF`))
ENGINE = InnoDB;

-- ------------------------------------------------------ Table `seer_db`.`NCH`
-- ----------------------------------------------------DROP TABLE IF EXISTS `seer_db`.`NCH` ;
CREATE TABLE IF NOT EXISTS `seer_db`.`NCH` (
`idNCH` INT NOT NULL AUTO_INCREMENT,
`patient_id` VARCHAR(10) NOT NULL,
`hcpcs` VARCHAR(5) NULL,
`claim_from_date` DATE NOT NULL,
PRIMARY KEY (`idNCH`))
ENGINE = InnoDB;

-- ------------------------------------------------------ Table `seer_db`.`OUTPATIENT`
-- ----------------------------------------------------DROP TABLE IF EXISTS `seer_db`.`OUTPATIENT` ;
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CREATE TABLE IF NOT EXISTS `seer_db`.`OUTPATIENT` (
`idOUTPATIENT` INT NOT NULL AUTO_INCREMENT,
`patient_id` VARCHAR(10) NOT NULL,
`hcpcs` VARCHAR(5) NULL,
`claim_from_date` DATE NOT NULL,
PRIMARY KEY (`idOUTPATIENT`))
ENGINE = InnoDB;

-- ------------------------------------------------------ Table `seer_db`.`DME`
-- ----------------------------------------------------DROP TABLE IF EXISTS `seer_db`.`DME` ;
CREATE TABLE IF NOT EXISTS `seer_db`.`DME` (
`idDME` INT NOT NULL AUTO_INCREMENT,
`patient_id` VARCHAR(10) NOT NULL,
`hcpcs` VARCHAR(5) NULL,
`ndc_cd` VARCHAR(11) NULL,
`claim_from_date` DATE NOT NULL,
PRIMARY KEY (`idDME`))
ENGINE = InnoDB;

-- ------------------------------------------------------ Table `seer_db`.`PDE`
-- ----------------------------------------------------DROP TABLE IF EXISTS `seer_db`.`PDE` ;
CREATE TABLE IF NOT EXISTS `seer_db`.`PDE` (
`idPDE` INT NOT NULL AUTO_INCREMENT,
`patient_id` VARCHAR(10) NOT NULL,
`brand` VARCHAR(30) NULL,
`prod_srvc_id` VARCHAR(11) NULL,
`service_date` DATE NULL,
PRIMARY KEY (`idPDE`))
ENGINE = InnoDB;
SET SQL_MODE = '';
GRANT USAGE ON *.* TO krista;
DROP USER krista;
SET SQL_MODE='TRADITIONAL,ALLOW_INVALID_DATES';
CREATE USER 'krista' IDENTIFIED BY 'M#4806d#5656';
GRANT ALL ON `seer_db`.* TO 'krista';
GRANT SELECT ON TABLE `seer_db`.* TO 'krista';
GRANT SELECT, INSERT, TRIGGER ON TABLE `seer_db`.* TO 'krista';
GRANT SELECT, INSERT, TRIGGER, UPDATE,
DELETE ON TABLE `seer_db`.* TO 'krista';
SET SQL_MODE=@OLD_SQL_MODE;
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SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS;
SET UNIQUE_CHECKS=@OLD_UNIQUE_CHECKS;

seer_queries.sql
-- seer_queries.sql
-- author: Andrew Schroeder
-- May 5th, 2015
-- NCH, OUTPATIENT, PDE, DME tables are filtered for specific criteria
-- m, c, mm, cc prefixes are used to distinguish filtered results from
-- original table. New tables are generated for performance
enhancements
-- on final "master_view" queries
-------

c prefix indicates subset with matching chemotherapy code
cc prefix indicates subset of c with only first claim record
after diagnosis_date
m prefix indicated subset with matching monoclonal antibody code
mm prefix indicates subset of m with only first claim record
after diagnosis_date

-- create "c" and "m" tables
DROP TABLE IF EXISTS `seer_db`.`cNCH`;
CREATE TABLE cNCH AS
SELECT NCH.idNCH, NCH.patient_id, NCH.hcpcs, NCH.claim_from_date
FROM NCH
WHERE NCH.hcpcs IN ('J9190','J8520','J8521',
'J0640','J9200','J9263','J9206');
DROP TABLE IF EXISTS `seer_db`.`mNCH`;
CREATE TABLE mNCH AS
SELECT NCH.idNCH, NCH.patient_id, NCH.hcpcs, NCH.claim_from_date
FROM NCH
WHERE NCH.hcpcs IN ('J9035','J9055','J9303');
DROP TABLE IF EXISTS `seer_db`.`cOP`;
CREATE TABLE cOP AS
SELECT OUTPATIENT.idOUTPATIENT, OUTPATIENT.patient_id,
OUTPATIENT.hcpcs, OUTPATIENT.claim_from_date
FROM OUTPATIENT
WHERE OUTPATIENT.hcpcs IN ('J9190','J8520','J8521','J0640',
'J9200','J9263','J9206');
DROP TABLE IF EXISTS `seer_db`.`mOP`;
CREATE TABLE mOP AS
SELECT OUTPATIENT.idOUTPATIENT, OUTPATIENT.patient_id,
OUTPATIENT.hcpcs, OUTPATIENT.claim_from_date
FROM OUTPATIENT
WHERE OUTPATIENT.hcpcs IN ('J9035','J9055','J9303');
DROP TABLE IF EXISTS `seer_db`.`mPDE`;
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CREATE TABLE mPDE AS
SELECT PDE.idPDE, PDE.patient_id, PDE.brand, PDE.prod_srvc_id,
PDE.service_date
FROM PDE
WHERE brand IN ('AVASTIN','ERBITUX','VECTIBIX') OR
prod_srvc_id IN('5024206001','50242006101','66733094823',
'66733095823','55513095401','55513095601');
DROP TABLE IF EXISTS `seer_db`.`cDME`;
CREATE TABLE cDME AS
SELECT DME.idDME, DME.patient_id, DME.hcpcs, DME.ndc_cd,
DME.claim_from_date
FROM DME
WHERE DME.ndc_cd IN('00703301513', '00703301812', '00703301912',
'10139006301', '10139006310', '10139006311', '10139006312',
'10139006320', '10139006350', '63323011710', '63323011720',
'63323011751', '63323011761', '66758004401', '66758004403',
'00004110020', '54868414300', '54868414301', '54868414302',
'00004110150', '00004110175', '54868526000', '54868526001',
'54868526002', '54868526003', '54868526004', '54868526005',
'54868526006', '54868526007', '54868526008', '54868526009',
'00703279301', '00703279701', '00703514001', '00703514501',
'00703514591', '00904231560', '25021081310', '25021081430',
'25021081530', '25021081567', '25021081630', '25021081667',
'55390000901', '55390005110', '55390005210', '55390005301',
'55390005401', '55390081810', '55390082401', '55390082501',
'55390082601', '62701090030', '62701090099', '62701090125',
'63323071050', '63323071100', '55390013501', '63323014507',
'00024059010', '00024059120', '00024059240', '00069006701',
'00069007001', '00069007401', '00069101001', '00703398501',
'00703398601', '25021021120', '25021021250', '41616017640',
'41616017840', '47335017640', '47335017840', '61703036318',
'61703036322', '63323017530', '63323017650', '63323065010',
'63323065017', '63323065020', '63323065027', '00009111101',
'00009111102', '00009752901', '00009752902', '00009752903',
'00009752904', '00009752905', '00143970101', '00143970201',
'00703443211', '00703443411', '10019093401', '10019093402',
'10019093417', '10019093479', '10518010310', '18111000202',
'18111000203', '23155017931', '23155017932', '25021020002',
'25021020005', '25021021402', '25021021405', '55390029501',
'55390029601', '59762752902', '61703034909', '61703034916',
'61703034936', '63323019302', '63323019305', '66758004801',
'66758004802')
OR DME.hcpcs IN ('J9190','J8520','J8521','J0640',
'J9200','J9263','J9206');
DROP TABLE IF EXISTS `seer_db`.`mDME`;
CREATE TABLE mDME AS
SELECT DME.idDME, DME.patient_id, DME.hcpcs, DME.ndc_cd,
DME.claim_from_date
FROM DME
WHERE DME.ndc_cd IN( '50242006001', '50242006101', '66733094823',
'66733095823', '55513095401', '55513095601')
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OR DME.hcpcs IN ('J9035','J9055','J9303');

-- create "cc" and "mm" tables
-- create ccDME, uses cDME_temp for simpler SQL
DROP TABLE IF EXISTS `seer_db`.`cDME_temp`;
CREATE TABLE cDME_temp AS
SELECT cDME.*
FROM cDME
INNER JOIN (
SELECT cDME.patient_id,MIN(cDME.claim_from_date) as min_date
FROM cDME
GROUP BY cDME.patient_id) tmp
ON cDME.patient_id = tmp.patient_id
AND cDME.claim_from_date = tmp.min_date;
DROP TABLE IF EXISTS `seer_db`.`ccDME`;
CREATE TABLE ccDME AS
SELECT c.*
FROM cDME_temp c
INNER JOIN (
SELECT c.patient_id, MIN(c.idDME) as min_id
FROM cDME_temp c
GROUP BY c.patient_id) tmp
ON c.patient_id = tmp.patient_id AND c.idDME = tmp.min_id;
-- create mmDME, uses mDME_temp for simpler SQL
DROP TABLE IF EXISTS `seer_db`.`mDME_temp`;
CREATE TABLE mDME_temp AS
SELECT mDME.*
FROM mDME
INNER JOIN (
SELECT mDME.patient_id,MIN(mDME.claim_from_date) as min_date
FROM mDME
GROUP BY mDME.patient_id) tmp
ON mDME.patient_id = tmp.patient_id
AND mDME.claim_from_date = tmp.min_date;
DROP TABLE IF EXISTS `seer_db`.`mmDME`;
CREATE TABLE mmDME AS
SELECT m.*
FROM mDME_temp m
INNER JOIN (
SELECT m.patient_id, MIN(m.idDME) as min_id
FROM mDME_temp m
GROUP BY m.patient_id) tmp
ON m.patient_id = tmp.patient_id AND m.idDME = tmp.min_id;

-- create ccNCH, uses cNCH_temp for simpler SQL
DROP TABLE IF EXISTS `seer_db`.`cNCH_temp`;
CREATE TABLE cNCH_temp AS
SELECT cNCH.*
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FROM cNCH
INNER JOIN (
SELECT cNCH.patient_id,MIN(cNCH.claim_from_date) as min_date
FROM cNCH
GROUP BY cNCH.patient_id) tmp
ON cNCH.patient_id = tmp.patient_id
AND cNCH.claim_from_date = tmp.min_date;
DROP TABLE IF EXISTS `seer_db`.`ccNCH`;
CREATE TABLE ccNCH AS
SELECT c.*
FROM cNCH_temp c
INNER JOIN (
SELECT c.patient_id, MIN(c.idNCH) as min_id
FROM cNCH_temp c
GROUP BY c.patient_id) tmp
ON c.patient_id = tmp.patient_id AND c.idNCH = tmp.min_id;
-- create mmNCH, uses mNCH_temp for simpler SQL
DROP TABLE IF EXISTS `seer_db`.`mNCH_temp`;
CREATE TABLE mNCH_temp AS
SELECT mNCH.*
FROM mNCH
INNER JOIN (
SELECT mNCH.patient_id,MIN(mNCH.claim_from_date) as min_date
FROM mNCH
GROUP BY mNCH.patient_id) tmp
ON mNCH.patient_id = tmp.patient_id
AND mNCH.claim_from_date = tmp.min_date;
DROP TABLE IF EXISTS `seer_db`.`mmNCH`;
CREATE TABLE mmNCH AS
SELECT m.*
FROM mNCH_temp m
INNER JOIN (
SELECT m.patient_id, MIN(m.idNCH) as min_id
FROM mNCH_temp m
GROUP BY m.patient_id) tmp
ON m.patient_id = tmp.patient_id AND m.idNCH = tmp.min_id;
-- create ccOP, uses cOP_temp for simpler SQL
DROP TABLE IF EXISTS `seer_db`.`cOP_temp`;
CREATE TABLE cOP_temp AS
SELECT cOP.*
FROM cOP
INNER JOIN (
SELECT cOP.patient_id,MIN(cOP.claim_from_date) as min_date
FROM cOP
GROUP BY cOP.patient_id) tmp
ON cOP.patient_id = tmp.patient_id
AND cOP.claim_from_date = tmp.min_date;
DROP TABLE IF EXISTS `seer_db`.`ccOP`;
CREATE TABLE ccOP AS
SELECT c.*
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FROM cOP_temp c
INNER JOIN (
SELECT c.patient_id, MIN(c.idOUTPATIENT) as min_id
FROM cOP_temp c
GROUP BY c.patient_id) tmp
ON c.patient_id = tmp.patient_id AND c.idOUTPATIENT = tmp.min_id;
-- create mmOP, uses mOP_temp for simpler SQL
DROP TABLE IF EXISTS `seer_db`.`mOP_temp`;
CREATE TABLE mOP_temp AS
SELECT mOP.*
FROM mOP
INNER JOIN (
SELECT mOP.patient_id,MIN(mOP.claim_from_date) as min_date
FROM mOP
GROUP BY mOP.patient_id) tmp
ON mOP.patient_id = tmp.patient_id
AND mOP.claim_from_date = tmp.min_date;
DROP TABLE IF EXISTS `seer_db`.`mmOP`;
CREATE TABLE mmOP AS
SELECT m.*
FROM mOP_temp m
INNER JOIN (
SELECT m.patient_id, MIN(m.idOUTPATIENT) as min_id
FROM mOP_temp m
GROUP BY m.patient_id) tmp
ON m.patient_id = tmp.patient_id AND m.idOUTPATIENT = tmp.min_id;
-- create mmPDE, uses mPDE_temp for simpler SQL
DROP TABLE IF EXISTS `seer_db`.`mPDE_temp`;
CREATE TABLE mPDE_temp AS
SELECT mPDE.*
FROM mPDE
INNER JOIN (
SELECT mPDE.patient_id,MIN(mPDE.service_date) as min_date
FROM mPDE
GROUP BY mPDE.patient_id) tmp
ON mPDE.patient_id = tmp.patient_id
AND mPDE.service_date = tmp.min_date;
DROP TABLE IF EXISTS `seer_db`.`mmPDE`;
CREATE TABLE mmPDE AS
SELECT m.*
FROM mPDE_temp m
INNER JOIN (
SELECT m.patient_id, MIN(m.idPDE) as min_id
FROM mPDE_temp m
GROUP BY m.patient_id) tmp
ON m.patient_id = tmp.patient_id AND m.idPDE = tmp.min_id;
-- create the master_view
CREATE OR replace view master_view as
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select
smPEDSF.patient_id, smPEDSF.reporting_id, smPEDSF.rac_recb,
smPEDSF.census_pov_ind, smPEDSF.urbrur, smPEDSF.m_sex,
smPEDSF.date_yr, smPEDSF.date_mo, smPEDSF.birthyr, smPEDSF.age_dx,
smPEDSF.rsncd1, smPEDSF.cs_met_1,
LAST_DAY(CONCAT_WS('-',smPEDSF.date_yr,smPEDSF.date_mo,'1'))
as `diagnosis_date`,
ccDME.hcpcs as ccDME_hcpcs,
ccDME.claim_from_date as ccDME_claim_date,
ccDME.ndc_cd as ccDME_ndc_cd,
mmDME.hcpcs as mmDME_hcpcs,
mmDME.claim_from_date as mmDME_claim_date,
mmDME.ndc_cd as mmDME_ndc_cd,
ccNCH.hcpcs as ccNCH_hcpcs,
ccNCH.claim_from_date as ccNCH_claim_date,
mmNCH.hcpcs as mmNCH_hcpcs,
mmNCH.claim_from_date as mmNCH_claim_date,
ccOP.hcpcs as ccOP_hcpcs,
ccOP.claim_from_date as ccOP_claim_date,
mmOP.hcpcs as mmOP_hcpcs,
mmOP.claim_from_date as mmOP_claim_date,
mmPDE.brand as mmPDE_brand,
mmPDE.service_date as mmPDE_srvc_date,
mmPDE.prod_srvc_id as mmPDE_prod_srvc_id
FROM smPEDSF
LEFT OUTER JOIN ccDME
ON smPEDSF.patient_id = ccDME.patient_id
LEFT OUTER JOIN mmDME
ON smPEDSF.patient_id = mmDME.patient_id
LEFT OUTER JOIN ccNCH
ON smPEDSF.patient_id = ccNCH.patient_id
LEFT OUTER JOIN mmNCH
ON smPEDSF.patient_id = mmNCH.patient_id
LEFT OUTER JOIN ccOP
ON smPEDSF.patient_id = ccOP.patient_id
LEFT OUTER JOIN mmOP
ON smPEDSF.patient_id = mmOP.patient_id
LEFT OUTER JOIN mmPDE
ON smPEDSF.patient_id = mmPDE.patient_id;

export_master_view.sh
#!/usr/bin/bash
mysql -A seer_db -e "SELECT * FROM master_view ORDER BY patient_id;" >
master_table.txt
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Appendix E: Variables Transferred to SPSS for Analysis
•

Ten digit patient ID (column #1 in the PEDSF document; patient_id)

•

Registry reporting the data (The first 2 digits in the patient ID; PEDSF column #1)

•

Race (column #101 of the PEDSF document; rac_recb)

•

Census Tract Poverty Indicator, measure of SES (column #146 of the PEDSF
document; census_pov_ind)

•

PEDSF re-code of the 2003 Rural/Urban Continuum Codes (column #97 of the
PEDSF document; urbrur)

•

Gender (PEDSF column #41; m_sex)

•

Year of birth (PEDSF file column #37)

•

Age at diagnosis (PEDSF column #1881)

•

Year of diagnosis (PEDSF column #1888)

•

Month of diagnosis (PEDSF column #1886)

•

Reason for original Medicare entitlement (PEDSF column #43)

•

Cancer sequence number (PEDSF column #1884)

•

Medicare Part B coverage months 2007-2011 (PEDSF columns #548 and below)

•

Medicare Part D coverage months 2007-2011 (PEDSF columns #221 and below)

•

Medicare managed care plan (Medicare Part C) coverage months 2007-2011 (PEDSF
columns #550 and below; HMO Months).

•

Metastasis at Diagnosis (PEDSF column #1953; CS Mets at Dx)
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•

First Chemotherapy Claim and Date: These are two computed variables (first_chemo
and chemo_type) as in 6b and 6c in Appendix D above. The variable first_chemo is
the date of the first post diagnosis chemotherapy claim. The variable chemo_type is
the NDC or HCPCS code for the first post diagnosis appearance of any of the
following codes in any of the Part B files (Carrier Claims, DME or Outpatient
Claims): HCPCS codes: J9190, J8520, J8521, J0640, J9200, J9263, J9206; NDC
codes: 00703301513, 00703301812, 00703301912, 10139006301, 10139006310,
10139006311, 10139006312, 10139006320, 10139006350, 63323011710,
63323011720, 63323011751, 63323011761, 66758004401, 66758004403,
00004110020, 54868414300, 54868414301, 54868414302, 00004110150,
00004110175, 54868526000, 54868526001, 54868526002, 54868526003,
54868526004, 54868526005, 54868526006, 54868526007, 54868526008,
54868526009, 00703279301, 00703279701, 00703514001, 00703514501,
00703514591, 00904231560, 25021081310, 25021081430, 25021081530,
25021081567, 25021081630, 25021081667, 55390000901, 55390005110,
55390005210, 55390005301, 55390005401, 55390081810, 55390082401,
55390082501, 55390082601, 62701090030, 62701090099, 62701090125,
63323071050, 63323071100, 55390013501, 63323014507, 00024059010,
00024059120, 00024059240, 00069006701, 00069007001, 00069007401,
00069101001, 00703398501, 00703398601, 25021021120, 25021021250,
41616017640, 41616017840, 47335017640, 47335017840, 61703036318,

236
61703036322, 63323017530, 63323017650, 63323065010, 63323065017,
63323065020, 63323065027, 00009111101, 00009111102, 00009752901,
00009752902, 00009752903, 00009752904, 00009752905, 00143970101,
00143970201, 00703443211, 00703443411, 10019093401, 10019093402,
10019093417, 10019093479, 10518010310, 18111000202, 18111000203,
23155017931, 23155017932, 25021020002, 25021020005, 25021021402,
25021021405, 55390029501, 55390029601, 59762752902, 61703034909,
61703034916, 61703034936, 63323019302, 63323019305, 66758004801,
66758004802. The locations for these codes and dates in each of the files are
outlined below.
o Carrier Claims:
HCPCS codes (column #93)
Date of treatment for the previous code (column #32)
o Outpatient Claims:
HCPCS code (column #241)
Date of treatment for the previous code (column #32)
o DME:
HCPCS code (column #93)
NDC code (column #409)
Date of treatment for the previous code (column #32)
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•

First Monoclonal Antibody Claim and Date: These are two computed variables
(first_ma and ma_type) as in 6d and 6e in Appendix D above. The variable first_ma
is the date of the first post diagnosis monoclonal antibody claim. The variable
ma_type is the NDC, HCPCS code, or Brand Name code for the first post diagnosis
appearance of any of the following codes in any of the Part B files (Carrier Claims,
DME or Outpatient Claims): (Carrier Claims, Outpatient Claims, or PDE): HCPCS
codes: J9035, J9055, J9303; NDC codes: 50242006001, 50242006101, 66733094823,
66733095823, 55513095401, 55513095601; or Brand Name codes: Avastin, Erbitux,
Vectibix. The locations for these codes and dates in each of the files are outlined
below.
o Carrier Claims:
HCPCS code (column #93)
Date of treatment for the previous code (column #32)
o Outpatient Claims:
HCPCS code (column #241)
Date of treatment for the previous code (column #32)
o PDE:
Brand name code (column #90)
NDC code (column #35)
PDE drug dispense date (column #27)
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Appendix F: SEER-Medicare Data Approve to Use
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Appendix G: Logistic Regression Syntax; Monoclonal Antibody Disparities by Race

Monoclonal Antibody Treatment and Race Logistic Regression Syntax

DATASET ACTIVATE DataSet1.
USE ALL.
COMPUTE filter_$=(NOT rac_recb = 3 and NOT rac_recb = 9 and NOT rac_recb = 12).
VARIABLE LABELS filter_$ 'NOT rac_recb = 3 and NOT rac_recb = 9 and NOT
rac_recb = 12 (FILTER)'.
VALUE LABELS filter_$ 0 'Not Selected' 1 'Selected'.
FORMATS filter_$ (f1.0).
FILTER BY filter_$.
EXECUTE.

LOGISTIC REGRESSION VARIABLES MA_treatment
/METHOD=ENTER Race_new
/CONTRAST (Race_new)=Indicator(1)
/PRINT=CI(95)
/CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5).
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Appendix H: Logistic Regression Syntax; Monoclonal Antibody Disparities by SES
Monoclonal Antibody Treatment and SES Logistic Regression Syntax

DATASET ACTIVATE DataSet1.
USE ALL.
COMPUTE filter_$=(NOT census_pov_ind = 9 ).
VARIABLE LABELS filter_$ 'NOT census_pov_ind = 9 (FILTER)'.
VALUE LABELS filter_$ 0 'Not Selected' 1 'Selected'.
FORMATS filter_$ (f1.0).
FILTER BY filter_$.
EXECUTE.

LOGISTIC REGRESSION VARIABLES MA_treatment
/METHOD=ENTER census_pov_ind
/CONTRAST (census_pov_ind)=Indicator(1)
/PRINT=CI(95)
/CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5).
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Appendix I: Logistic Regression Syntax; Monoclonal Antibody Disparities by
Neighborhood Characteristics
Monoclonal Antibody Treatment and Neighborhood Characteristics Logistic Regression
Syntax

DATASET ACTIVATE DataSet1.
USE ALL.
COMPUTE filter_$=(NOT urbrur = 9 ).
VARIABLE LABELS filter_$ 'NOT urbrur = 9 (FILTER)'.
VALUE LABELS filter_$ 0 'Not Selected' 1 'Selected'.
FORMATS filter_$ (f1.0).
FILTER BY filter_$.
EXECUTE.

LOGISTIC REGRESSION VARIABLES MA_treatment
/METHOD=ENTER urbrur
/CONTRAST (urbrur)=Indicator(1)
/PRINT=CI(95)
/CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5).
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Appendix J. Logistic Regression Syntax; Model Including All Significant Independent
Variables and Covariates
Monoclonal Antibody Treatment and All Significant Variables Logistic Regression

DATASET ACTIVATE DataSet1.
FILTER OFF.
USE ALL.
EXECUTE.

LOGISTIC REGRESSION VARIABLES MA_treatment
/METHOD=ENTER reporting_id age_dx
/CONTRAST (reporting_id)=Indicator(1)
/PRINT=CI(95)
/CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5).

